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ABSTRACT 
Cornelia de Lange syndrome (CdLS) is a multiple malformation disorder 
characterized by peculiar facial features, growth and mental retardation, and a variety 
of other abnormalities affecting multiple organ systems. The molecular pathology 
underlying the disease phenotypes is not known. In the past, 3q26.3 was considered as 
a candidate region. However, no patient-specific mutations in the giant gene, 
NAALADL2, truncated by the 3q26.3 breakpoint were found. Thus, in this study, we 
tried to find the disease gene in loci other than 3q26.3 mainly by FISH mapping in 
patients with t(5; 13), t(14; 21) de novo balanced translocation. Of all the three regions 
(5p13,13g12,14q32) we studied, the novel gene that crosses the 5p translocation 
breakpoint was found to be the most likely candidate gene for CdIS. Subsequent finer 
FISH mapping using fosmid clones as probes confirmed the novel gene was truncated 
by the translocation breakpoint in intron 1. Standard point mutational screening of the 
newly found gene detected patient-specific mutations. The gene was named, NIPBL, 
which is the major determinant for this rare syndrome (Tonkin et al., 2004). Analysis 
of the NIPBL gene in further patients with CdIS revealed a wide variety of 
pathogenic mutations. More than half of the mutations resulted in premature 
termination. Loss of function causing haploinsufficiency is supported by patients with 
heterozygous deletion involving the whole NIPBL gene. No genotype-phenotype 
correlation was observed. The exact functions of delangin are not known. 
Tissue in situ studies of NIPBL, using riboprobes in early human embryos, 
showed expression in developing brain, limbs, muscle, bone, renal tubules and lung 
bronchioles. In our preliminary data, the expression of NIPBL is mainly in the active 
i 
proliferating tissue in early mammalian development. However, the tissue expression 
pattern in later mammalian development is not known. 
The predicted protein sequence of the NIPBL product, delangin, is 2804 amino 
acids for the long isoform and 2697 amino acids for the short isoform. In the 
carboxy-terminal region there is a clustering of HEAT repeats and these motifs (also 
called adherin) are highly conserved in the carboxy-terminal region of delangin 
homologues, Nipped-B of Drosophila, Scc2 of Saccharomyces cerevisiae and Mis4 of 
Schizosaccharomyces pombe, which are required for mitotic sister chromatid cohesion. 
Delangin is also related to Rad9 of Coprinus cinereus, which is required for DNA 
repair and meiotic chromosome paring. The Scc2 and Mis4 yeast, and Drosophila 
Nipped-B adherin homologues of human delangin are required for the Cohesin 
protein complex that mediates sister chromatid cohesin to associate with 
chromosomes. The major role in yeast and Xenopus Scc2 is to interact with Scc4 to 
help in loading the cohesin ring onto chromatin in the early S phase during cell 
replication. We also identified the sequence of the human Scc4 homologue, which we 
call human Mau-2. Tissue in situ hybridization data using a probe to dectect human 
Mau-2 showed a similar expression pattern to NIPBL in human embryos. However, 
no hMau-2 mutations were detected in CdLS patients in our mutation screen. 
In Drosophila, Nipped-B was also found to participate in remote activation of the 
cut and Ultrabithorax genes. Reducing the Nipped-B dosage reduces activation of the 
wild-type cut gene by the remote wing margin enhancer and causes the wing margin 
defect in Drosophila. Furthermore, Mau-2, the C. elegans homologue of yeast Scc4, 
which interacts with Scc2 to help in the establishment of the cohesion loading onto 
the chromatin, was found to guide axonal migrations in the CNS. However, the exact 
11 
functions of both NIPBL and hMau-2 need to be further elucidated. 
111 
TABLE OF CONTENTS 
Abstract ....................................................................................... i 
Table of Contents ......................................................................... iv 
Table of Figures .......................................................................... . xii 
Tables ............................................................................. . xv 
Acknowledgements 
..................................................................... xvi 
Common Abbreviations Used ...................................................... xvii 
CHAPTER 1: INTRODUCTION 
..................................................... 1 
1.1 CLINICAL FEATURES OF CORNELIA DE LANGE SYNDROME ........... 1 
1.1.1 Growth 4 ............................................................................... . 
1.1.2 Facial characteristics ............................................................... 4 
1.1.2.1 Head and Neck ............................................................... 4 
1.1.2.2 Face ............................................................................ 5 
1.1.3 Ears ................................................................................... 5 
1.1.4 Eyes .................................................................................. 6 
1.1.5 Mouth ............. 7 ................................................................... 
1.1.6 Cardiovascular System 
............................................................ 7 
1.1.7 Chest . 7 ................................................................................ 
1.1.8 Abdomen 
............................................................................. 8 
1.1.9 Genitourinary 
........................................................................ 8 
1.1.10 Skeletal 
............................................................................. 9 
1.1.11 Skin, Nails, Hair .................................................................. 9 
1.1.12 Neurological Anormalies ........................................................ 10 
1.1.13 Development and Behavior Phenotypes ....................................... 10 
1.1.14 Others .............................................................................. 11 
iv 
1.1.15 Mortality ........................................................................... 
11 
1.2 DIAGNOSIS ........................................................................... 14 
1.3 INHERITANCE ........................................................................ 
16 
1.4 STATUS OF GENE IDENTIFICATION IN OCTOBER 2002 .................. 18 
1.4.1 Background on the search for the CdlS genes ............................... 18 
1.4.1.1 Chromosome anomalies associated with CdLS ........................ 
18 
1.4.1.2 Linkage studies ............................................................. 
22 
1.4.1.3 Candidate gene approach .................................................. 
23 
1.4.1.3.1 Syndromes with phenotypes similar to CdIS ................. 24 
1.4.1.4.2 Other possible explanations for CdIS .......................... 
28 
1.4.1.4.3 Predicted expression patterns and functions of CdLS genes. 29 
1.4.2 Strategies of Gene Identification in Newcastle Group ........................ 31 
1.5 AIMS OF THE PROJECT .............................................................. 
33 
1.6 REFERENCES ........................................................................... 
34 
CHAPTER 2: FISH MAPPING OF CdLS PATIENTS WITH de novo 
BALANCED RECIPROCAL TRANSLOCATIONS and GENOMIC 
ORGANIZATION OF THE GENE TRUNCATED BY THE t(5; 13) 
TRANSLO CATI ON ........................................................................ 47 
2.1 INTRODUCTION 
........................................................................ 
47 
2.1.1 Standard FISH ........................................................................ 
48 
2.1.2 Array-CGH 
........................................................................... 
50 
2.2 AIMS OF THIS PROJECT ............................................................... 
52 
2.3 MATERIALS AND METHODS ........................................................ 53 
2.3.1 Data interpretation of FISH mapping in metaphase spreads ................... 53 
2.3.1.1 5p region ........................................................................ 53 
2.3.1.2 13q region ...................................................................... 54 
V 
2.3.1.3 14q region ...................................................................... 
55 
2.3.2 Preparation of metaphase slides ................................................. 
56 
2.3.3 Preparation of BAC/fosmid DNA ................................................ 
56 
2.3.3.1 Growth of bacteria ............................................................ 
56 
2.3.3.2 Preparation of DNA .......................................................... 
57 
2.3.4 DNA labeling with fluorochromes-Direct labeling ........................... 
58 
2.3.5 Purification of the labeled probe ................................................ 
59 
2.3.6 Competition of probe and resuspension in hybridization mix ............... 
59 
2.3.7 Commercial pre-labeled chromosome 5,13,14 marker probes ............. 
60 
2.3.8 In situ hybridization to chromosome spreads .................................. 
60 
2.3.9 Slide washing and detection of probe signal ................................... 
61 
2.3.10 Microscopic visualization of FISH signals .................................... 
62 
2.4 RESULTS ................................................................................. 
63 
2.4.1 Phenotypes and Giema chromosome banding of the patient with 
de novo t(5; 13)(p13.1; g12.1) translocation .................................... 
63 
2.4.2 Molecular definition of the t(5; 13) breakpoint by chromosome 
FISH ................................................................................. 
64 
2.4.3 Results of clones mapped to the 5p translocation breakpoint 
Region .............................................................................. 
65 
2.4.4 Hierarchy of the contig map in 5p13.1 .......................................... 
76 
2.4.5 Results of the clones mapped to the translocation breakpoint around 
the 13q12.1 area ................................................................... 
77 
2.4.6 Results of clones mapped to the translocation breakpoint around 
the 14q32 region ................................................................... 
80 
2.5 DISCUSSION ........................................................................... 
84 
2.5.1 Power of bioinfonmatics ........................................................... 84 
2.5.2 Assignment of clones relative to the chromosome breakpoints 
VI 
using standard chromosome FISH ................................................ 86 
2.5.3 Clues from the linkage studies ................................................... 86 
2.5.4 Data interpretations ............................................................... 89 
2.5.4.1 13g12.1 region .............................................................. 90 
2.5.4.1.1 Genes disrupted by the translocation ............................ 90 
2.5.4.1.2 Genes residing 1Mb on each side of the 13g12.1 
Breakpoint ........................................................... 92 
2.5.4.2 Genes residing 1Mb on each side of the 14g32 breakpoint .......... 97 
2.5.4.3 5p13 region ................................................................. 100 
2.6 CONCLUSION ........................................................................ 105 
2.7 REFERENCES 
........................................................................ 106 
CHAPTER 3: MUTATION SCREENING OF NIPBL GENE LOCATED 
WITHIN 5pl3.1 ........................................................................... 112 
3.1 INTRODUCTION -NIPBL AS CANDIDATE FOR CDLS ..................... 112 
3.2 APPROACHES TO MUTATION SCREENING .................................. 112 
3.2.1 SSCP ................................................................................ 113 
3.2.2 Heteroduplex Analysis (HET) ................................................... 114 
3.2.3 PCR Direct sequencing ............................................................ 115 
3.2.4 Cloning of PCR product into the pGem-T easy system ....................... 
115 
3.3 MATERIALS AND METHODS 
...................................................... 
118 
3.3.1 Materials ............................................................................. 118 
3.3.2 Amplification of exons from the NIPBL gene .................................. 118 
3.3.3 Single stranded conformation polymorphism (SSCP) and heteroduplex 
gel mobility shift analyses ......................................................... 119 
3.3.3.1 Preparation of the gel and electophoresis of the samples ............... 119 
3.3.3.2 Silver staining ................................................................ 120 
3.3.4 Direct sequencing of PCR products .............................................. 121 
3.3.4.1 Enzymatic purification of PCR products ................................. 121 
vu 
3.3.4.2 Cycle sequencing ............................................................ 
121 
3.3.5 Cloning of PCR product into pGem-T- Easy vector system ................. 122 
3.3.6 DNA preparation of the transformants by using QIAprep kit ............... 124 
3.3.7 Sequences of the cloned product ................................................ 
125 
3.3.8 Assessing the sequencing results ................................................ 
125 
3.4 RESULTS ................................................................................. 
126 
3.4.1 Study population .................................................................... 
126 
3.4.2 Mutation screening approach used in exons of different sizes ............... 
126 
3.4.3 Spectrum of NIPBL mutation detected .......................................... 
127 
3.4.4 Genotype-Phenotype correlation ................................................. 
129 
3.5 DISCUSSION ............................................................................ 
136 
3.6 REFERENCES 
........................................................................... 
148 
CHAPTER 4: EXPRESSION PATTERNS OF THE NIPBL GENE............ 153 
4.1 INTRODUCTION ........................................................................ 
153 
4.2 APPROACHES TO EXPRESSION STUDIES OF NIPBL ........................ 
153 
4.2.1 Northern blot analysis .............................................................. 
153 
4.2.2 Tissue in situ hybridization ........................................................ 
156 
4.2.3 Development of different organ systems during early human 
development 
........................................................................ 
158 
4.2.3.1 The developing nervous system ......................................... 
158 
4.2.3.2 The developing limbs ..................................................... 
162 
4.2.3.3 The developing craniofacial system .................................... 165 
4.2.3.4 The developing heart ...................................................... 167 
4.2.3.5 The developing lung, kidney and pancreas ............................ 170 
4.2.3.6 The developing gastrointestinal system ................................ 171 
VI" 
4.2.3.7 The developing germ cells ............................................... 172 
4.3 MATERIALAND METHODS ........................................................ 174 
4.3.1 Tissue in situ Hybridization ........................................................ 174 
4.3.1.1 Collection of human embryos ............................................... 174 
4.3.1.2 Tissue fixation and embedding ............................................. 174 
4.3.1.3 Tissue sectioning ............................................................. 
175 
4.3.1.4 Tissue pre-treatment .......................................................... 175 
4.3.1.5 Probes used for in situ hybridization ...................................... 176 
4.3.1.6 Probe labeling ................................................................ 178 
4.3.1.6.1 Temperate linearilisation ........................................... 178 
4.3.1.6.2 RNA transcription ................................................... 178 
4.3.1.6.3 Control Riboprobes .................................................. 179 
4.3.1.7 Probe hybridization ............................................................ 179 
4.3.1.8 Post-hybridisation washes .................................................... 
179 
4.3.1.9 Antibody Detection ............................................................ 
180 
4.3.2 Immunohistochemical (IHC) staining of the slides .............................. 
180 
4.3.2.1 Dewaxing and Antigen retrieval ............................................. 
181 
4.3.2.2 Staining of mouse monoclonal primary PCNA antibody ................. 182 
4.3.2.3 Secondary Antibody staining and antibody detection ..................... 182 
4.3.3 Image analysis ........................................................................ 183 
4.4 RESULTS ................................................................................. 184 
4.4.1 Expression of NIPBL in human embryonic nervous system .................... 184 
4.4.2 Expression of NIPBL in human embryonic limbs ............................... 189 
4.4.3 Craniofacial and ophthalmic expressions of NIPBL in human embryos ...... 193 
4.4.3.1 Craniofacial expression of NIPBL .......................................... 193 
4.4.3.2 Expression of NIPBL in developing eyes5.3.2.3.1 Craniofacial expression 
ix 
of NIPBL ....................................................................... 196 
4.4.3.3 Expression of NIPBL in developing ears5.3.2.3.3 Expression of NIPBL in 
developing ears ............................................................... 196 
4.4.4 Expression of NIPBL in developing heart ....................................... 198 
4.4.5 Expression of NIPBL in developing lung, kidney and pancreas .............. 201 
4.4.5.1 Expression of NIPBL in developing lung ................................... 201 
4.4.5.2 Expression of NIPBL in developing kidney ................................ 203 
4.4.5.3 Expression of NIPBL in developing pancreas ............... ............... 205 
4.4.6 Expression of NIPBL in developing gastrointestinal tract ..................... 205 
4.4.7 Expression of NIPBL in developing gonads ...................................... 207 
4.5 DISCUSSION ............................................................................ 209 
4.5.1 Expression of NIPBL in nervous system .......................................... 209 
4.5.2 Expression of NIPBL in developing limb ......................................... 210 
4.5.3 Expression of NIPBL in developing craniofacial skeletons, eye and ear ..... 212 
4.5.4 Expression of NIPBL in developing heart ................................... ..... 
214 
4.5.5 Expression of NIPBL in developing lung, kidney and pancreas .......... ..... 216 
4.5.6 Expression of NIPBL in developing gut ..................................... ..... 
218 
4.5.7 Expression of NIPBL in developing gonads ...................................... 
219 
4.6. CONCLUSION 
.......................................................................... 220 
4.7 REFERENCES 
...................................................................... ..... 223 
CHAPTER 5: THE EXPRESSION PATTERNS AND MUTATION 
SCREENING OF HUMAN MAU-2 ....................................... 234 
5.1 INTRODUCTION ....................................................................... 234 
5.2. MATERIALAND METHODS ........................................................ 242 
5.2.1. Northern blot analysis ............................................................. 242 
X 
5.2.1.1 Probe used for Northern blot analysis and Tissue in situ 
hybridization .................................................................. 
242 
5.2.2.2 Probe labelling-random priming ............................................. 
242 
5.2.2.3 Prehybridization of the RNA blots .......................................... 
243 
5.2.2.4 Hybridization ................................................................... 
243 
5.2.2.5 Post-hybridization wash and film development ........................... 
243 
5.2.2 Tissue in situ hybridization ........................................................ 
244 
5.3 RESULTS ................................................................................. 
245 
5.3.1 Northern blot analysis .............................................................. 
245 
5.3.2 Tissue in situ hybridization by using riboprobes ................................ 
246 
5.3.3 Mutation screening .................................................................. 
250 
5.4 GENERAL DISCUSSION .............................................................. 
252 
5.5 REFERENCES ............................................................................ 
254 
CHAPTER6: CONCLUSION .............................................. 
257 
APPENDIX A ................................................................................. 
260 
APPENDIX B ................................................................................. 262 
APPENDIX C ................................................................................. 264 
xi 
TABLE OF FIGURES 
Fig. 1.1 Phenotypes of patients with CdLS .............................................. 13 
Fig. 2.1 Illustration of the three types of chromosome FISH results expected 
after hybridizing 5p probes to the t(5; 13) metaphase chromosome 
preparation ......................................................................... 54 
Fig. 2.2 Illustration of the three types of chromosome FISH results expected 
after hybridizing 13q probes to the t(5; 13) metaphase chromosome 
preparation ........................................................................ 55 
Fig. 2.3 Phenotypes of the patient with t(5; 13)(p13.1; g12.1) de novo 
translocation ...................................................................... 63 
Fig 2.4 A BAC clone mapping telomeric to the 5p13.1 breakpoint 
(CID-2353F22) 
................................................................... 68 
Fig. 2.5 A BAC clone mapped centromeric to the 5p13.1 breakpoint 
(CTD-2249G23) 
................................................................. 69 
Fig. 2.6 A BAC clone mapped across the 5p13.1 breakpoint 
(CID-2653M23) 
................................................................ 70 
Fig 2.7 Results of FISH mapping. The colored 5p13 fosmid clones against 
DNA from the t(5; 13) (p13.1; g12.1) de novo translocation case......... 73 
Fig. 2.8 FISH mapping of clone G248P84262B4 .................................... 74 
Fig. 2.9 FISH mapping of clone G248P8840C10 .................................... 75 
Fig. 2.10 Genomic organization, FISH clones and expressed products of the gene 
located at the Sp13.1 breakpoint .............................................. 76 
Fig. 2.11 A BAC clone that spans the 13g12.1 breakpoint (RP11-172H24)........ 79 
Fig. 2.12 A BAC clone mapped centromeric to the 14q32 breakpoint 
(RP11-796G6) .................................................................. 82 
X11 
Fig. 2.13 A BAC clone mapped telomeric to the 14q32 breakpoint 
(RP 11-10e 13) ....................................................................... 
83 
Fig. 2.14 Genes located within 1Mb of each side of the 
13q12.1 breakpoint ..................................................................................... 
92 
Fig. 2.15 Genes residing within 1Mb of each side of the 14q32 
50Kb gap near the breakpoint ................................................... 
97 
Fig. 2.16 Genes residing within the 2Mb-region of the 5p13.1 breakpoint............ 101 
Fig. 3.1 Map of the pGem-T-Easy Vector ................................................ 
117 
Fig. 3.2 Examples of chromograms of patients with NIPBL mutations .............. 135 
Fig. 3.3 Missense mutations of the NIPBL. Most of the missense mutations were 
located within the highly conserved regions of NIPBL ...................... 140 
Fig. 3.4 Sequences conservation -2.5kb upstream of the NIPBL promoter and 2kb 
downstream of the exon 1 ........................................................ 
143 
Fig. 4.1 Results of NIPBL expression by Northern blot ................................. 
156 
Fig. 4.2 Elevator movement and the relationship with the cell-cycle of the by 
neuroepithelial cells .. ' .............................................................. 
161 
Fig. 4.3 Key stages in limb skeletal development ....................................... 
164 
Fig. 4.4 Expression pattern of NIPBL transcript on CS13 (A) and CS20 (B) embryo 
sections ............................................................................ 186 
Fig. 4.5 NIPBL expression in developing brain of CS20 embryo ..................... 187 
Fig. 4.6 NIPBL expression in developing brain of CS23 human embryonic 
section ............................................................................... 188 
Fig. 4.7 NIPBL expression in early limb bud ................................................ 190 
Fig. 4.8 NIPBL expression in hand plate of CS18 human embryo .................... 191 
Fig. 4.9 NIPBL expression in upper limb of CS23 human embryo ................... 192 
Fig. 4.10 NIPBL expression of in developing face ...................................... 194 
xl" 
Fig. 4.11 NIPBL expression of in developing pharynx and esophagus ............... 195 
Fig. 4.12 NIPBL expression in developing otic canal .................................. 197 
Fig. 4.13. NIPBL expression in developing heart ....................................... 200 
Fig. 4.14 NIPBL expression in developing lung ......................................... 202 
Fig. 4.15 NIPBL expression in developing embryonic kidney ......................... 204 
Fig. 4.16 NIPBL expression in developing stomach and pancreas ..................... 206 
Fig. 4.17 NIPBL expression in developing gonads ...................................... . 208 
Fig. 5.1 The cohesin cycles .................................................................. 237 
Fig. 5.2 Northern analysis of KIAA 0896 transcript ..................................... . 245 
Fig. 5.2 hMau-2 expression on CS23 embryo ............................................ . 247 
Fig. 5.3 hMau-2 expression on transverse section of CS18 embryo brain ............ . 248 
Fig. 5.4 hMau-2 expression on CS18 embryonic section ................................ 249 
xiv 
TABLES 
Table 1.1 Chromosome anomalies associated with CdIS .............................. 19 
Table 2.1 Results of mapping clones to the 5p13.1 breakpoint region by FISH..... 66 
Table 2.2 Results of mapping clones to the 13q12.1 breakpoint region by FISH.... 78 
Table 2.3 Results of mapping clones to the 14q32 breakpoint region by FISH...... 81 
Table 2.4 Linkage analysis of genome-scan data in 10 pedigrees ..................... 
88 
Table 2.5 Possible function of the genes residing within the 2 Mb candidate area ... 93 
Table 2.6 Possible function of the genes within the 2Mb candidate area (14g32).... 98 
Table 2.7 Genes located within the 2Mb candidate region (5p13.1) ................... 
102 
Table 3.1 Summery of CdLS patients with NIPBL mutations ........................... 
131 
Table 3.2 conservations of sequences at sites of NIPBL missense mutations and 
in-frame deletion between different species ............................................... 
133 
Table 3.3 Chromosomal location of the human cohesin complexes and associated 
proteins ........................................................................................ 146 
xv 
ACKNOWLEDGEMENTS 
Particular thanks are due of course to my supervision team, Prof. Tom Strachan 
and Dr Susan Lindsay of the Institute of Human Genetics at Newcastle University. 
Without their ideas, help and encouragement, this thesis would never have been 
possible. I would especially like to thank Prof. Tom Strachan for his extensive critical 
suggestions on most of my thesis. 
I would also like to thank, in particular, Dr. Emma Tonkin who taught me all the 
experiment procedures related to genomics and lots of associated knowledge 
including how to assess the internet information and experiment designs. 
I would also like to thank Steve Lisgo for teaching me the techniques involved in 
in situ hybridization and for his help in interpreting the data and solving the problems 
related to in situ hybridization. 
I would also like to thank Alexander Raymond for his thorough proof reading 
and moral support throughout the formation of the thesis. I also would like to thank 
John Fairlie, a former PhD student, who gave me lots of support for my dissertation 
writing. 
Most importantly, I would like to thank the Kaohsiung Medical Centre at 
Chang-Gung Memorial Hospital for. providing me with the grant to pay for the tuition 
fee and the expenses in the UK for at least 3 years. 
Finally I have to thank my parents for their warming and financial support during 
these 4 years. Without their support, I would never have had a chance to go to the UK 
to pursue my PhD. 
xvi 
COMMON ABBREVIATION USED: 
Ab antibody 
BAC bacterial artificial chromosome 
BCIP 5-bromo-4-chloro-3-indolyl-phosphate 
BMP bone morphogenetic protein 
bp base pair 
BSA bovine serum albumin 
CdIS Cornelia de Lange Syndrome 
cDNA copy or complementary DNA 
CGH comparative genomic hybridization 
CNS central nervous system 
CS Carnegie stage 
DAPI 4,6-diamino-2-phenyl-indole 
dATP deoxy adenosine triphosphate 
dCTP deoxy cytosine triphosphate 
ddNTP dedeoxy nucleotide triphosphate 
DEPC diethyl pyrocarbonate 
dGTP deoxy guanosine triphosphate 
DNA deoxyribonucleic acid 
dNTP deoxy nucleotide triphosphate 
DTT dithiothreitol 
dTTP deoxy thymidine triphosphate 
dUTP deoxy uridine triphophate 
EDTA ethylene diamine tetra acetic acid 
xvii 
FGF fibroblast growth factor 
FISH fluorescent in situ hybridization 
IPTG isopropyl-b-D-thiogalactoside 
ISH in situ hybridization 
kb kilo base pairs 
kD kilo Daltons 
m mili (10-3) 
M molar 
mg milligram 
mJ milliJoules 
ml milliliter 
mm millimolar 
mRNA messenger RNA 
u micro (10-6) 
99 microgram 
,u1 microliter 
uM micromolar 
n nano (10-9) 
NBT nitro blue tetrazolium 
779 nanogram 
MIN Mendelian Inheritance in Man 
ORF open reading frame 
p Pico (10"12) 
PAC Phagemid artificial chromosome 
PBS phosphate buffer saline 
PCNA proliferating cell nuclear antigen 
xviii 
PCR polymerase chain reaction 
PFA paraformaldehyde 
pg pictogram 
RNA ribonucleic acid 
SDS sodium dodecyl sulphate 
UTR untranslated region 
X-gal 5-bromo-4-chloro-3-indolyl-b-D-galactoside 
YAC yeast artificial chromosome 
xix 
CHAPTER 1 INTRODUCTION 
1.1 CLINICAL FEATURES OF CORNELIA DE LANGE SYNDROME 
The Cornelia de Lange syndrome (CdLS), also termed the Brachmann-de Lange 
syndrome (BDLS) (OMIM# 122470) is a congenital multiple malformation disorder. 
In 1916, Brachmann (Brachmann, 1916) reported on a foetus with severe ulnar 
defects and monodactylous hands resembling a very severe form of what is now 
known as the de Lange syndrome. In 1933, De Lange (deLange, 1933), a paediatrician 
in Amsterdam, described 2 infant girls with a mental deficiency and other features 
with a less severe form of the same syndrome. From that time, the term "Brachmann- 
de Lange syndrome" was used officially to describe patients with this congenital 
malformation condition. Over 300 patients with this syndrome have been reported in 
literature. 
The diagnosis of CdLS is mainly based on clinical observations. The key 
criteria for the diagnosis are (1) the phenotypic facial changes and other minor 
anomalies occurring with increased frequency in affected individuals (Leavitt et al., 
1985; Opitz, 1985; Preus and Rex, 1983); (2) pre- and postnatal growth deficiencies 
including (a) a feeding dysfunction (Cates et al., 1989; Kawai et al., 2004; Sommer, 
1993); (b) a psychomotor delay and (c) a distinctive behaviour profile (Berney et al., 
1999; Bryson et al., 1971; Johnson et al., 1976); and (3) associated major 
malformations most frequently developed in the musculoskeletal system (Filippi, 
1989; Lee and Kenny, 1967; Roposch et al., 2004), but also in other organ systems 
such as the cardiac and gastrointestinal systems (Braddock et al., 1993; Greenwood et 
al., 1977; Husain et al., 1994; Selicorni et al., 2005). 
1 
Although it is said that the diagnosis of CdLS is not a challenge to the 
experienced clinicians, controversy has continued over the minimal criteria for the 
diagnosis of CdLS. Uncertainty arises in physically less affected patients. In 1991, at 
the DW Smith Workshop on Malformation and Morphogenesis, consensus was 
reached amongst clinical geneticists on the existence of the "mild" CdLS phenotype. 
Based on the clinical variability in the de Lange syndrome, Van Allen et al. (Van 
Allen et al., 1993) proposed a classification system in which he subdivided CdLS into 
three types. These consist of Type I, or "classic" CdLS; Type II, or "mild" CdIS; 
and Type III, or "phenocopies" CdLS. 
The key criteria for Type I, or "classic" CdLS, are (1) growth retardation with a 
birth weight normally less than 2.5 std (standard deviation) below the mean for 
gestation, which becomes more severe postnatally (<3.5 std for the chronological age); 
(2) moderate to profound psychomotor retardation; (3) the presence of minor facial 
anomalies, skeletal and other components of the disorder giving a positive score using 
the diagnostic index of Preus and Rex(Preus and Rex, 1983); and (4) the presence of 
malformations, which are lethal or associated with severe disabilities. These criteria 
would place the patient into CdIS type I independent of the severity of psychomotor 
retardation or growth deficiency. 
Type II, or "mild" CdIS is characterised by the presence of typical facial 
changes and other distinct minor anomalies apparent in classic CdIS patients. The 
most significant distinctive findings of type II CdLS are: (1) less severe psychomotor 
retardation; (2) milder pre- and postnatal growth deficiencies; and (3) the absence of 
major malformations or - if present -a malformation that is surgically correctable or 
does not cause a severe disability. Patients with Type II CdLS have been reported to 
have three types of clinical presentations. These include (1) patients with the "classic" 
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CdIS facial features at birth who have had an unexpected positive outcome with mild 
psychomotor impairment (Gadoth et al., 1982; Hawley et al., 1985; Opitz, 1985); (2) a 
diagnostically difficult group of patients that develop the typical facial changes of 
"classic" CdLS during the first 2-4 years of life, and usually have less severe 
manifestations than those patients with "classic" CdLS (Greenberg and Robinson, 
1989); (3) a group consisting of the previously undiagnosed adults, usually with a low 
to normal range of performance, who have offspring with the "classic" CdLS 
phenotype (Leavitt et al., 1985; McConnell et al., 2003; Mosher et al., 1985). 
Behavioural problems may be significant in patients with Type II CdLS. However, as 
these patients are enduring a mild form of CdLS, better developmental skills permit 
more mobility and independence (Berney et al., 1999). 
A general consensus for the minimal criteria for the diagnosis of "mild" CdLS 
has not been reached. However, Allen et. al. recommend that at least 2 of the other 
major diagnostic criteria alongside the characteristic facial features be present (Filippi, 
1989; Van Allen et al., 1993). 
Type III CdIS, or phenocopies of CdIS, includes patients who have phenotypic 
manifestations of CdIS, which are causally related to chromosomal aneuploidies or 
teratogenic exposures, such as foetal alcohol sequences. Allanson et al. speculated 
that the "classic" and "mild" phenotype might be due to allele specificity or to 
modifying genes. Least likely, in their opinion, was the possibility that the mild de 
Lange syndrome might be a phenocopy of the classic phenotype (Allanson et al., 
1997). 
The clinical phenotypes of CdLS are described below 
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1.1.1 Growth: 
Growth retardation and short stature are seen in almost all the patients with CdLS. 
Growth retardation is prenatally onset and becomes more significant by the age of six 
months. In a study of 180 CdLS patients, Kline et. al. (Kline et al., 1993a) reported a 
mean height and weight below the 5th centile throughout life, with the mean head 
circumference below the 2°d centile. While the height velocity is comparable to that of 
unaffected children, it begins to slow once they reach adolescence. On the other hand, 
the weight velocity is below that of unaffected individuals until late adolescence. As 
is the case with normal spurts, maximum pubertal growth occurs at 15 years in males 
and 13 years in females. Kline et al. concluded that the patients with CdIS are of a 
proportionate small stature, with relatively normal or mild microcephaly. Thus, the 
diagnosis of failure to thrive would not be appropriate in these patients, since their 
small size is uniform and their weight gain is not unduly low for their height. On the 
other hand, the growth curves for many of the infants with the severe form of CdLS 
are far below the -2SD in comparison with normal children. 
1.1.2 Facial characteristics: 
1.1.2.1 Head and Neck: 
Almost all the patients with CdIS have microcephaly (a small head) and 
brachycephaly (a decreased anterior-posterior diameter of the head) (Hall, 1971; 
Jackson, 1993). Moreover, a short neck was another characteristic of patients with 
CdIS (Jackson et al., 1993). 
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1.1.2.2 Face: 
Facial features of patients include (1) "pencilled" eyebrows (98%), (2) long 
eyelashes (99%), (3) a long philtrum (94%), (4) a thin upper lip (94%), (5) a 
down-turned mouth (94%), (6) a broad and/or depressed bridge and anteverted 
nostrils (85%), (7) micrognathia and a high arched palate with or without a cleft 
palate/lips (84%). Widely spaced teeth and late eruption of the teeth were also 
observed in CdLS patients (Ireland and Bum, 1993; Ireland et al., 1993; Verloes et al., 
1996). The facial features combined with facial hypertrichosis are probably the most 
diagnostic of all the physical signs (Jackson et al., 1993, Bay et al., 1993). In a report 
by Ireland et. al. (1993), they found that the depressed nasal bridge, which is common 
in infants with CdIS, may disappear after the age of four. A finding that had not been 
highlighted in most literature was that underdeveloped orbital ridges and zygomatic 
arches were almost universal features in patients with CdLS. In that report, they also 
found that the crescent shaped mouth with down turned corners may disappear in 
male CdIS patients after puberty. This phenotypical change was not observed in 
postpubertal females. 
1.1.3 Ears: 
Low-set ears in patients with CdIS are not striking (Bay et al., 1993; Jackson et 
al., 1993), while disproportionately small auricles have been reported (Leroy et al., 
1993). Moreover, sensorineural hearing loss has been reported to be associated with 
CdLS. Sataloff et al. (Sataloff et al., 1990) studied the otolarngologic manifestation of 
CdLS in 45 patients and discovered that more than 90% of children with CdIS had a 
sensorineural hearing loss tested by audiometry. In 2002, Sakai et al. (2002) tested 13 
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children with CdIS by behavioral observation audiometry (BOA) and auditory 
brainstem evoked response (ABR). In the ABR examination, a delayed wave I peak 
latency was found in almost all the cases, and a prolonged peak interval of waves I-V 
was found in only one patient. 
Their results indicate a very high prevalence of hearing loss at the middle and 
inner ear levels in patients with CdLS. However, the finding in 2 patients without 
peaks after wave III in one ear suggested that they have brainstem impairment. Two 
patients who initially had no ABR in either ear, but later exhibited clear ABRs in one 
ear, were thought to have brainstem immaturity, such as delayed myelination. Further 
evidence of brainstem immaturity can be found in an earlier histopathological study 
performed in 1996. Sasaki et. al. ( 1996) conducted a histopathological study on the 
temporal bone and brainstem of a 9-month-old infant with CdLS. They located a 
malformation of the bony labyrinth, as no mesenchyme was seen in the perilymphatic 
space of cochlea. The size of the brain stem, particularly the pons, was below average. 
1.1.4 Eyes: 
Levin et al. (1990) examined 22 children with CdLS to ascertain the relative 
frequencies of ophthalmologic abnormalities. In addition to the frequent findings of 
brow hypertrichosis, synophrys (eyebrows growing across the base of the nose), and 
long arcuate eyelashes, they documented the association of CdIS with ptosis, 
nystagmus, and high myopia. Optic nerve pallor, poor macular reflex, chin lifts 
induced by ptosis, hypertropia, and nasolacrimal duct fistula were also described in 
their report. Moreover, hypertelorism and telecanthus were found amongst CdLS 
patients. However, contrary to previous reports, they did not find a link between 
6 
corneal, pupillary, or retinal disorders and this syndrome. Furthermore, they found no 
association between blue sclera and the syndrome. 
1.1.5 Mouth: 
Patients with CdIS are also characterized by a thin upper lip, down-turned 
corners of the mouth and a high arched palate with or without a cleft lip or palate. In 
contrast to the depressed nose, the crescent shaped mouth with down-turned corners 
may remain in the mild form of CdLS after puberty. 
1.1.6 Cardiovascular System: 
As a result of reviewing the literature on CdLS, Rao and Sissman (1971) could 
confirm that 15% of the affected individuals had a congenital heart defect. The 
cardiovascular diseases associated with CdLS patients are mainly ventricular septal 
defect and pulmonary stenosis. Other possible defects include tetralogy of Fallot, 
persistent arterial duct, coarctation, rudimentary left ventricle, anomalous systemic 
venous drainage, overriding aorta and ventricular fibro-elastosis (Mehta and 
Ambalavanan, 1997; Tsukahara et al., 1998). These may contribute to the early 
demise of patients with severe CdLS. 
1.1.7 Chest: 
Small nipples were noted in patients with CdIS, while congenital diaphragmatic 
hernia was reported by Pankau and Janig, (1993). The latter contributes to the high 
lethality caused by this syndrome more often seen in severe CdIS patients (Cunniff et 
al., 1993). 
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1.1.8 Abdomen: 
Gastroesophageal reflux (GER) is a frequent and severe medical complication of 
the Cornelia de Lange syndrome (Luzzani et al., 2003). The most severe 
complications of reflux include torticollis, opisthotonus, and paroxysmal dystonic 
posture (known as the Sandifer complex). Recently, Luzzani et al. (2003) evaluated a 
series of 43 patients and concluded that pathological GER was evident in 65% of 
CdIS patients. The incidence of the complication was not significantly different in 
patients with the classical (93.3%) versus the mild phenotype (82.3%). However, a 
strong correlation was present between the degree of the esophageal damage and the 
clinical phenotype. Hyperactivity was the most frequent sign associated with the 
condition (85%). Moreover, clinically significant feeding problems included tracheal 
aspiration, esophageal dysmotility, gastroesophageal reflux, hiatal hernia, and 
esophagitis. Adenocarcinoma following complicated GER was also reported (DuVall 
and Walden, 1996). Improved body weight gain was noted with early recognition of 
gastroesophageal reflux in these patients when medical treatment or surgical 
interventions were instituted appropriately. Another associated abdominal anomaly 
includes cecal volvulus (Husain et al., 1994; Masumoto et al., 2001). 
1.1.9 Genitourinary: 
Cryptochidism and hypoplastic genitals have been reported in more than 50% of 
males with CdLS, while renal abnormalities (primarily ureteral reflux) have been 
reported in 12% of males (Jackson et al., 1993). In a series reported by Selicorni et. al. 
(2005), structural anomalies of the kidney and urinary tract were detected either by 
sonography or voiding cystoureterography in 25 (41%) of the 61 patients. They 
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included absent or poor corticomedullary differentiation (13%), pelvic dilation (10%), 
small kidneys (5%), isolated renal cyst (5%), and renal ectopia (3%). Renal function 
was reduced in 15% of patients (Selicomi et al., 2005). 
1.1.10 Skeletal: 
Limb defects are noted in around 20% of patients with CdLS (Bozner et al., 1995; 
Jackson et at., 1993; Pashayan et at., 1975). The limb defects in patients with CdIS 
consist primarily of limited elbow extensions, dislocation of the radial head and 
phocomelia. Abnormalities developed on the hands and feet include single transverse 
palmar crease, proximally placed thumbs, fifth finger clinodactyly, oligodactyly and 
syndactyly of the 2°d and 3`d toes. Braddock et al. (1993) reviewed roentgenograms in 
21 cases of the Brachmann-de Lange syndrome and published descriptions of the 
radiological manifestations. They found that unusual radiologic manifestations were 
related mainly to the limb anomalies, and were often asymmetric. These 
manifestations included digital abnormalities, which ranged from acheiria to 
oligodactyly, hypoplasia of the thumb and first metacarpal, clinodactyly of the fifth 
finger, or ectrodactyly. Long bone abnormalities included ulnar aplasia/hypoplasia, 
and dysplasia of the radial head, or fusion of the elbow. Other radiological 
manifestations included 13 ribs with a precocious sternal fusion, and micrognathia. 
1.1.11 Skin, Nails, Hair: 
Cutis marmorata, hirsutism and a low posterior hair line are frequent findings in 
patients with CdIS (Jackson et al., 1993). 
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1.1.12 Neurological Anormalies: 
Yamaguchi and Ishitobi, (1999) described congenital dysgenesis of the brain 
including microbrachycephaly, immature or simple convolution pattern of the cerebral 
gyri, thickened leptomeninges, persistent subpial granule cells, hypoplasia of the 
anterior thalamic nuclei, neurohypophysis, lateral geniculate body, cerebral peduncle, 
ventral pons and cerebellar internal granular layers, and heterotopic cell nests in the 
cerebellar white matter. They concluded that congenital dysgenesis of the brain, 
especially that found in the diencephalon and the cortico-ponto-cerebellar system, 
may constitute morphologic evidence explaining the severe growth retardation and 
neurological abnormalities in CdIS. 
1.1.13 Development and Behavior Phenotypes: 
In a series conducted by Kline at al., most of the 122 patients with CdLS were 
found to be in the mild to moderate region of mental retardation, with I. Q. s ranging 
from 30 to 85. Moreover their average I. Q. level of 53 (Kline et al., 1993b) was higher 
than previously reported (Barr et al., 1971), while CdLS patients with normal IQ 
levels have also been reported (Saal et al., 1993). In a survey of speech and language 
skills in 116 patients with CdLS, Goodban (Goodban, 1993) discovered that 53% of 
the children who were four years or older combined two or more words into sentences, 
while 33% uttered no words or only 1-2 words. Meanwhile, 4% of the children in this 
range were judged to have language skills within normal to low normal limits. They 
suggested that the children who were not talking at all or who were severely delayed 
in their language skills had at least one of the following characteristics: (1) a birth 
weight under 5lbs; (2) a moderate to severe hearing impairment; (3) upper lim defects; 
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(4) poor abilities to relate socially; (5) severe motor delays. The behavioural 
phenotype of CdLS includes hyperactivity (40%), self-injury (44%), daily aggression 
(49%), and sleep disturbance (55%). The phenotypes correlate with the presence of 
autistic like behaviour and a degree of mental retardation (Berney et al., 1999). 
1.1.14 Others: 
In addition to the above mentioned clinical phenotypes, low-pitched, growling 
cries in the infancy stage (Jackson et al., 1993), panhypopituitarism (Kousseff et al., 
1993; Tonini and Marinoni, 1990) and dysfunctions of gonadotropin and prolactin 
secretion and of osmoregulatory mechanisms (Schwartz et al., 1990) have been 
described. In 1993, Froster and Gortner (Froster and Gortner, 1993) reported on a 
severely affected infant with an upper limb defect who also had thrombocytopenia. 
Furthermore, Fryns and Vinken, (1994) described thrombocytopenia in 2 out of 50 
patients with CdIS over a period of 25 years. 
1.1.15 Mortality: 
The mortality rate of de Lange patients was found to have slightly risen 
considering the expected number of deaths. However, no differences in the mortality 
rate were observed between the opposite genders. During their evaluation of the 
causes of death and pathological findings, Beck and Fenger, (1985) found pneumonia 
to be the most frequent cause of death. In some patients, congenital malformations 
seemed also to be contributory causes of death, the most frequent being congenital 
heart disease and gastro-intestinal malformations. Moreover, there is an increased 
incidence of aspiration related deaths among the CdLS population, which may be 
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related to the prevalence of GER in patients with CdLS. 
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Fig. L1 Phenotypes of patients with CdLS. (A) A newborn baby with severe prenatal onset growth 
deficiency of oriental origin. No severe limb reduction defect was noted (B) Typical facial 
characteristics of CdLS, note the synphorys, flat nasal root with anteverted nostrils and long philtrum. 
(C) A mild CdLS patient. (D, E, F) Severe limb reduction defects in patients with severe CdLS. (Q H) 
Minor upper limb abnormality in patients with CdLS, note the bilateral clinodactyly of the 5th fingers 
and short phanlanges of the 2" and 4"' fingers. 
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1.2 DIAGNOSIS 
The diagnosis of CdIS is mainly based on the recognition of the clinical features. 
The diagnosis for the severe form of CdIS is seldom in doubt. However, uncertainties 
may be raised in patients with mild phenotypes, in which the limb defects and growth 
deficiency are not prominent. The differential diagnosis of CdLS includes patients 
with the partial 3q duplication syndrome. Wilson et al. (1978) proposed clinical 
criteria for a distinction between these two syndromes. Intrauterine growth retardation, 
a prominent philtrum, proximally placed thumbs, and oligodactyly/phocomelia are 
more frequent in CdIS, while craniosynostosis, a cleft palate, and urinary tract 
anomalies are more characteristic of the dup (3q) syndrome. In most cases, CdLS 
patients have apparently normal chromosomes. Thin upper lips, a depressed nasal 
bridge, and hirsutism may also be frequent findings in patients with the fetal alcoholic 
syndrome or fetal teratogenic exposure. The differential diagnosis of CdLS with other 
syndromes also includes patients with the Rubinstein-Taybi syndrome (MIN 180846) 
(Partington, 1990) and the Ruvalcaba syndrome (MIN 180870). 
As for postnatal diagnosis, prenatal diagnosis also depends mainly on the 
phenotypic features such as the presence of nuchal fold by ultrasonography and also 
by certain serum markers such as PAPP-A and FßhCG (Bruner and Hsia, 1990). The 
pregnancy-associated plasma protein A (PAPP-A) is a large molecular-weight, 
placenta-derived glycoprotein. During pregnancy it is produced in high concentrations 
by the trophoblast and released into the maternal circulation. The functional 
significance of PAPP-A is unclear. The major clinical role of PAPP-A is as a marker 
of chromosomal aneuploidy (trisomies 21,18 and 13), complicated pregnancies and 
the Cornelia De Lange syndrome (Westergaard et al., 1983). The PAPP-A levels have 
14 
been reported to be decreased in first trimester (Arbuzova et al., 2003) and second 
trimester pregnancies (Aitken et al., 1999). In Aitken's series, they suggested that, in 
the second trimester, maternal serum PAPP-A levels are low but not deficient in 
pregnancies with the classical form of CdLS (Aitken et al., 1999). Although the 
median InhA level was significantly reduced in the CdLS cases, the magnitude of the 
reduction was less marked than for PAPP-A. FßhCG levels were also reduced but 
showed a wider range with several high values. They also pointed out that the cases in 
their study were biased towards the severe end of the phenotypic presentations. In 
other words, the rate of limb defects was higher than average. 
So it still remains to be established if similar reductions in PAPP-A levels are 
present in maternal serum when the fetus is only mildly affected. However, the 
recurrence rate for a couple with a previous affected CdLS pregnancy is 
approximately 1%. These are generally offered prenatal assessment with serial and 
detailed ultrasonography. The most common ultrasound abnormality associated with 
the syndrome is IUGR (Bruner and Hsia, 1990), but this is usually not identifiable 
until the third trimester. Abnormalities which may be detected at the 16-20 week scan 
include severe limb defects (14%), diaphragmatic hernias, structural heart 
abnormalities (18%), fixed flexion deformities of the elbows (84%) and characteristic 
facial profiles (Bruner and Hsia, 1990; Drolshagen et al., 1992) and increased nuchal 
thickness during first and second trimesters. Thus, the adjuvant use of PAPP-A 
maternal serum measurement during the first and second trimester of pregnancy with 
detailed ultrasonography may provide a useful tool to detect pregnancies at risk of 
CdIS. It is important for the counselor to consider the possibility of CdLS, especially 
in women with positive first-trimester screening results and a normal karyotype, in 
which case the PAPP-A level is very low. 
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1.3 INHERITANCE 
Despite the fact that the vast majority of CdIS cases are sporadic, multiple 
affected cases in the same families have been reported (Beck, 1974; Kumar et al., 
1985; Opitz, 1985; Robinson et al., 1985). In 1963, Ptacek et al., (1963) suggested a 
dominant mode of transmission of the mutation. In a recent review Russell et al., 
(2001) reported that 60% of the familial cases appear to demonstrate a dominant mode 
of transmission of the phenotype, while 40% may be consistent with recessive 
inheritance, or do not point directly to a dominant pattern of inheritance. In addition 
to these cases, another report by Krantz et al., (2001) described nine previously 
unreported families. He found that four families indicated dominant inheritance, four 
suggested recessive inheritance, and one family was inconclusive. However, it is 
difficult to decide whether the diagnosis of CdIS is correct or not simply based on the 
clinical descriptions and photographs provided in several of the familial cases. 
Although several ' reported familial cases suggested autosomal recessive 
inheritance (Naguib et al., 1987; Opitz, 1985), reasons exist against the assumption 
that CdLS is produced by the homozygous state of recessive mutation. These include 
the absence of consanguinity in the parents, and the high proportion of sporadic cases. 
It is possible that "gonadal mosaicism" is the mechanism in those families with 
recurrent affected siblings (de Die-Smulders et al., 1992; Ptacek et al., 1963). In 
addition, the preponderance of maternal transmission of the trait observed in the 
dominant inherited pedigrees may suggest a possible imprinting effect (de 
Die-Smulders et al., 1994). However, both paternal and maternal transmissions have 
been demonstrated and thus exclude the possibility of X-linked inheritance and 
imprinting (McKenney et al., 1996; Russell et al., 2001). Furthermore, Shaffer et al. 
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found in one study that uniparental disomy is not present in patients with CdIS 
(Kotzot, 2002; Shaffer et al., 1993). Similarly, mitochondrial inheritance seems 
unlikely, although there has been a CdLS case with multiple mitochondrial deletions 
(Melegh et al., 1996). 
Thus we can conclude from the literature that if CdIS were to be genetically 
homogeneous, most of the reported familial cases are consistent with a dominant 
transmission of the disease trait. However, recessive forms of inheritance still can not 
be excluded. With the recognition of the milder CdLS phenotype (Allanson et al., 
1997), it is possible that a greater number of familial cases will arise and will provide 
more information about the mode of inheritance. Thus, it is reasonable to speculate 
that heterogeneity exists in patients affected with de Lange syndrome. Hence, the 
definite diagnosis could not be established, especially for mild CdIS, until the 
molecular etiologies associated with the de Lange syndrome were found. 
The exact incidence of CdLS is unclear, but the rate amongst live births is 
thought to be between 1: 10,000 and 1: 30,000 (Opitz, 1985). The life expectancy of 
severe CdLS patients is shortened, while this reduction in the life span in less severe 
patients is not known. In the past, many children died of serious medical problems in 
the infancy stage because their needs were not anticipated. This is no longer the case, 
and it is expected that most CdIS patients will live into adulthood. 
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1.4 STATUS OF GENE IDENTIFICATION IN OCTOBER 2002 
1.4.1 Background on the search for the CdLS genes 
There are many ways of identifying disease genes. Most commonly, a candidate 
chromosome region is pinpointed, and then candidate genes can be identified within 
that region through the help of bioinformatics and data obtained. Strategies for this 
position dependent approach include positional cloning by use of chromosome 
abnormalities and linkage analysis. Alternatively, we also can use positional 
independent candidate gene approach to identify the disease genes. 
1.4.1.1 Chromosome anomalies associated with CdLS 
Chromosome abnormalities can provide clues to the localization of candidate 
genes. Balanced chromosome abnormalities (translocations or inversions) are of 
particular use. As no DNA materials are missing or added, a carrier is not expected to 
have any phenotypic effect. If a person has a balanced chromosomal abnormality with 
abnormal phenotypes, there are three possible explanations: (1) the finding is 
coincidental; (2) the rearrangement is not really balanced - there is unnoticed gain or 
loss of DNA material; (3) one of the breakpoints causes the disease. A chromosomal 
breakpoint can cause a loss-of-function phenotype by disrupting the coding sequence 
of the gene or separating it from nearby regulatory elements. On the other hand, it 
could cause a gain of function by bringing together exons from two genes to form a 
new chimeric gene, or cause inappropriate activation of a gene. Thus, the breakpoint 
provides a valuable information for the location of disease gene, especially in de novo 
balanced chromosome rearrangement. 
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A few individuals with CdLS have been reported to have chromosome 
abnormalities (Kousseff et al., 1994), but the gene responsible for the syndrome 
remains to be identified due to the lack of common breakpoints. However, 
chromosome abnormalities that rise de novo in sporadic CdLS patients may be 
specific and crucial. Review of the reported CdLS cases with chromosome 
derangement are as follows: 
Table 1.1 Chromosome anomalies associated with CdLS 
chromosome karyotype 
1 46, XX, del(1)(g44) 
2 46, XY, t(2; 12) de novo 
3 46, XY,? del(3q) 
3 46, XX, dup(3q)mat 
3 inv dup(3)(q29q25) 
3 dup(3)(q25q29) 
3 46, XX, dup(3)(q23q27) 
3 46, XY, r(3)de novo 
3 46, XX, t(3; 5)(g21; p13) 
3 46, XX, t(3; 17)(g26.3; q23.1)de novo 
3 46, XX, ins(10; 3)(g21.2; q25.1q26.2) 
3 46, XY, der(3)(3; 12)(p25.3; pl3.3)mat 
4 46, XY, t(4; 11)/46, XY mosaism, de 
novo 
4 46, XY, der(9)t(4; 9)mat 
5 46, XY, t(5; 12)/46, XY de novo 
5 46, XX, 
der(5)t(5; 9; 13)(g23; p24; q22)mat 
5 46, XX, del(5)(p 13) de novo 
5 46, XX, t(5; 13)(p 13.2; q 12.1) 
5 46, XX, der(5)t(1; 5)(q41; q35) 
reference 
Borck et al., (2004) 
Craig and Luzzatti, (1965) 
Szemere et al., (1972) 
Schwanitz et al., (1977) 
Wilson et al. (1978) 
Wilson et al. (1978) 
Sciorra et al. (1979) 
Lakshminarayana and 
Nallasivam, ( 1990) 
Price et al. (2005) 
Ireland et al. (1991) 
Holder et al. (1994) 
Descipio et al. (2005) 
Payne and Maeda (1965) 
Hersh et al. (1985) 
Geudeke et al. (1963) 
Eeg-Olofsson and Liedgren 
(1981) 
Taylor and Josifek (1981) 
Tonkin et al. (2004b) 
Telvi et al. (1999) 
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5 
7 
8 
8 
9 
9 
9 
11 
13 
14 
17 
18 
X 
X 
46, XY, del(5)(p13.1p14.2) de novo 
46, XY, der(7)t(7; 10)(g32; q24) pat 
46, XX, t(8;? ) de novo 
t (X; 8)(pll. 2; q24.3) de novo 
46, XY, 9qh+pat 
46, XX, r(9) de novo 
46, XY, 9qh+qh+patmat 
46, XY, del(11 q)/46, XY de novo 
46, XY, t(13q; 14q)mat 
46, XX, t(14; 21)(g32; q11.2) de novo 
46, XY,? del(17q) de novo 
47, XX, +i(18)(pl0) 
45, X/46, XX de novo 
45, X/46, XY de novo 
D group 45, XY, t(Dq; Dq)mat 
D group 46, XX, del(Dq)/46, XX de novo 
G Group 46, XY, Gp+ de novo 
Hulinsky et al. (2005) 
Randall-Pinto et al. (2000) 
D'Oelsnitz et al. (1971) 
Egemen et al. (2005) 
Berg et al. (1967) 
Mod and Opitz (1971) 
Babu et al. (1985) 
Payne and Maeda (1965) 
Beck and Mikkelsen (1981) 
Wilson et al. (1983) 
Gans and Thurston (1965) 
Borck et al. (2004) 
Klosovskii et al. (1968) 
Calo et al. (1968); Beck and 
Mikkelen (1981) 
Ott et al. (1968) 
Westermann et al. (1977) 
Hooft et al. (1965) 
The diversity of disease-associated chromosome abnormalities in patients with 
CdLS may suggest a variety of candidate chromosomal regions that could harbour the 
CdLS genes, and there are only very few consistently associated chromosome 
anomalies. It is difficult to determine if the chromosome rearrangements are causative 
of the CdLS phenotypes or just a coincidence. In cases where the chromosomal 
abnormalities have a well defined phenotype such as 45, X/46, XX or (XY), the CdLS 
phenotypes are likely to have no association with the chromosome anomalies. In 
many cases reported above, the phenotypes were not well described or the phenotypes 
were only partially overlapped with the de Lange syndrome. However, in the reported 
cases, three cases diagnosed as de Lange syndrome have rearrangements involving 
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5pl3. It should be noted, however, that two of these cases were reported only recently. 
Several cases with 3q rearrangement were also reported to have CdIS phenotypes. 
The regions involved in chromosome aberrations in CdIS patients with balanced 
reciprocal translocation are inconsistent and often, coincident. However, the 3q26.3 
breakpoint was initially considered to be particularly worthy of further investigation 
due to the perceived overlap in phenotype for the dup (3q) syndrome whose crticial 
region was mapped to 3q26.3-q27 (Aqua et al., 1995). Individuals who are not 
trisomic for this region, but are trisomic for regions immediately proximal or distal to 
it, do not show a phenotype resembling that of mild CdI. S (Aqua et al., 1995; Ireland 
et al., 1995). While some CdLS-associated features, notably prenatal growth 
retardation and severe limb abnormalities, are not seen in the dup 3q syndrome, 
phenotypic divergence between the two syndromes could be explained by differential 
dosage of active gene copies (given that the overexpression expected in trisomy 3q is 
unlikely to be consistently paralleled by heterozygous mutations in CdIS). Genes 
residing in other areas may also contribute to the CdLS phenotypes. 
A variety of different studies in distal 3q have been conducted in CdIS patients. 
Early in 1993, Shaffer et al., (1993) speculated that uniparental disomy (UPD) might 
be responsible for CdLS as seen in patients with Prader-Willi, Angelman, and 
Beckwith-Wiedemann syndromes based on the observation of more than one mode of 
inheritance and occasionally associated with a cytogenetic abnormality. However, 
none of the 16 probands studied had UPD using polymorphic markers in the distal 3q 
region and all demonstrated normal biparental inheritance for at least one locus. 
Mutation screening in SOX2, CHRD genes located within 3q26.3/q27 and the GSC 
gene located within 14q32 failed to identify any CdIS patient-specific mutations 
(Smith et al., 1999). 
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Nevertheless, the majority of the CdIS patients with chromosomal abnormalities 
showed no consistent regions involved. This may suggest that the multiple loci 
implicated in CdLS are just coincidental. Another possible explanation for the 
multiple chromosomal anomalies observed in CdLS cases is that the CdLS disease 
gene may play an important role in the repair of double strand DNA. An example of 
this possibility is Seckel syndrome type I. Mutations in the ATR gene cause increased 
chromosome breakage at fragile sites. The malformations seen in the affected 
individuals with Seckel syndrome may result from inappropriate checkpoint responses 
and chromosome breakage, thus resulting in cell death at time of replicative stress 
during development (Casper, 2004). 
1.4.1.2 Linkage studies 
Collecting familial cases for genetic mapping provides an alternative route to 
disease gene identification. However, for this approach, a large number of familial 
cases, clear diagnosis and the mode of Mendelian transmission are necessary. 
Even though the Cornelia de Lange syndrome was described 70 years ago, the 
exact molecular mechanisms that lead to CdIS had not been identified for the 
following three reasons: (1) lack of consistent chromosomal rearrangement; (2) 
paucity of familial cases; (3) small size and small affected cases in familial cases. 
In 2001, Krantz et al., (2001) performed a linkage analysis to the minimal critical 
region for the dup (3q) syndrome that encompasses the translocation breakpoint in 10 
rare familial cases with CdLS and excluded CDL1 region as the candidate region in 4 
out of 10 familial CdLS cases. However, due to the paucity of the familial cases, 
linkage analysis has not been an easy approach. 
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1.4.13 Candidate gene approach 
Another approach to identify disease genes is through positional independent 
strategies, especially for diseases without relevant mapping information. In this 
situation, the candidate must be suggested by the (1) gene products; (2) similar 
organism models; (3) comparison of phenotypic similarities with other related human 
diseases through possible expression array experiments. 
It was important to consider which developmental processes are involved with 
the CdLS phenotypes and how the roles of the processes are played in lower species. 
As CdIS affects many different organ systems and generalised and symmetrical 
growth deficiency is a hallmark of the disease, it is expected that the causative gene is 
likely to be expressed early in development and well conserved between divergent 
species and might be associated with the cell cycle. Genes, which have fundamental 
roles in development are subject to selective pressures to conserve the sequences of 
the gene product. Examples of such genes include cell regulators such as cyclins 
which have homologues conserved between Drosophila and humans. 
The most obvious phenotypes associated with CdLS are generalised growth 
deficiency and limb defects of variable severity. The microcephaly associated with 
CdI. S actually is not severe relative to the generalised growth deficiency they have. 
Microcephaly seen in patients with CdIS is due to generalised underdevelopment of 
the brain content. Other syndromes caused by defects in fibroblast growth factor 
receptors usually manifest normal brain development and most of them have a nearly 
normal mentality. Their impairment of brain development is a result of premature 
craniosynostosis rather than defect in the brain itself. Thus, genes that cause 
microcephaly due to primary craniosynostosis are not considered directly linked to 
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CdLS. Nevertheless, syndromes with resemblance to CdIS may be considered 
candidates for CdIS, as they involve genes with generalised growth deficiency and 
limb defects. 
1.4.1.4.1 Syndromes with phenotypes similar to CdIS 
The genetic basis of syndrome producing phenotypes similar to CdIS might give 
clues to the genetic connection with CdLS gene(s). There are some syndromes that 
share phenotypic overlap with CdIS. The most obvious is the 3q duplication 
syndrome, as described in section 1.2. Other syndromes characterised by growth 
deficiency with multiple malformations include (1) Coffin-Siris syndrome 
(MIN135900), which is characterised by growth retardation of prenatal onset, mental 
retardation, microcephaly, coarse faces, bushy eyebrows and long eyelashes, a flat 
nasal bridge, long philtrum and hypoplasia of the digits (especially 5th digits); (2) 
Scott Craniodigital syndrome with mental retardation (MIN 312860), which is 
characterised by mental retardation, brachycephaly, a small and narrow nose, a 
'startled' appearance, thick head hair extending unusually far on the temples and 
sideburn areas, long eyelashes, thick eyebrows, a short mandible, digital syndactyly 
and X-linked inheritance; (3) Ruvalcaba syndrome (MIN 180870), which is 
characterised by mental retardation, short stature, microcephaly, a peculiar face with a 
hooked nose and a small mouth, a narrow thoracic cage with pectus carinatum, 
hypoplastic genitalia, hypoplastic 'onion skin' cutaneous lesions, and skeletal 
deformities including short metatarsals and metacarpals and epiphysitis of the spine; 
(4) Fryns syndrome (MIN 229850), which is characterised by coarse faces with 
cloudy corneae, diaphragmatic defects, absence of lung lobulation, distal digital 
hypoplasia and early death; (5) Rubinstein-Taybi syndrome (MIN180849) (RSTS), 
which is characterised by growth deficiency of postnatal onset, broad thumbs and toes, 
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slanted palpabral fissure, microcephaly, hypoplastic maxilla and highly arched 
eyebrows; (6) Russell-Silver syndrome (MIN180860) (RSS), which is characterised 
by short stature of prenatal onset, skeletal asymmetry, small triangular face, and 
bilateral clinodactyly of bilateral 5`b fingers; (7) Seckel syndrome I (MIN 210600), 
which is characterised by growth retardation, microcephaly with mental retardation, 
and a characteristic 'bird-headed' facial appearance; (8) Roberts syndrome 
(MIN268300), which is characterised by hypomelia, midfacial defect, and severe 
growth retardation. The molecular defects associated with Coffin-Siris syndrome, 
Scott Craniodigital syndrome with mental retardation, Ruvalcaba syndrome and Fryns 
syndrome are still not recognised. 
Due to the presence of neat eyebrows in patients with Rubinstein-Taybi 
syndrome, the syndrome is frequently mis-diagnosed as a mild form of CdLS. 
Rubinstein-Taybi syndrome is caused by the heterozygous mutation in the 
CREB-binding protein (CBP) gene located on chromosome 16p13.3 and EP300 
(Roelfsema et at., 2005). CBP serves as a transcriptional coactivator and acts as an 
integrator of the signals from various pathways. Häploinsufficiency is the ultimate 
cause of the syndrome (Goodman and Smolik, 2000). Furthermore, the majority of the 
patients with mutations are located within the domain that would affect the intrinsic 
histone acetyl transferase activity (HAT) (Roelfsema et al., 2005), and the loss of 
HAT activity leads to the phenotypes of RSTS. This is an example for multiple 
congenital malformations with mental retardation caused by generalised dysregulation 
of gene expressions during early human development. An additional example would 
be the thalassemia/mental retardation syndrome (MIN301040), in which the mutation 
is located in the gene encoding X-linked helicase-2 (Gibbons et al., 1995). 
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In the Russell-silver syndrome (RSS), around 10% of RSS patients were found to 
have maternal uniparental disomy of chromosome 7, which indicated that an 
imprinted gene located on chromosome 7 may cause the disease phenotypes of RSS 
(Bernard et al., 1999; Yoshihashi et al., 2000). Moreover, the human growth factor 
receptor-bound protein 10/maternally expressed gene-1 (GRB10/MEG1) gene was 
found to be associated with RSS. Bilateral maternal expression of the imprinted GRB 
10 gene due to maternal uniparental disomy leads to RSS phenotypes in these patients. 
In vitro studies indicate that by interacting with either the insulin-like growth factor I 
(IGFI) receptor (Morrione et al., 1997) or the growth hormone receptor 
(Moutoussamy et at., 1998), GRB10 has a suppressive effect on growth. (Yoshihashi 
et at., 2000). Recently, hypomethylation of the H19 region in 11p15 was found to 
cause RSS and associated phenotypes (Gicquel et al., 2005). Hypermethylation of the 
H19 gene, on the contrary, causes the gigantism syndrome, Beckwith-Wiederman 
syndrome (MIN 130650). Due to the phenotypic overlap with the 3q duplication 
syndrome, the CdIS gene was once suspected to be an imprinted gene(s) located 
within the 3q region. However, no UPD in the 3q region was found in patients with 
CdIS (De Marchi et al., 1994). Nevertheless, genes that are regulated through 
epimutation are still strong candidates for causative CdLS gene(s). 
Seckel syndrome (type I) shares features in common with disorders involving 
impaired DNA-damage responses that lead to chromosome instability, such as 
Nijmegen breakage syndrome (OMIM 251260) and LIG4 syndrome (OMIM 606593) 
(Casper et al., 2004). To date, the only reported genetic defect identified in Seckel 
syndrome is a mutation in ataxia telangiectasia and Rad3-related protein 
(ATR)(O'Driscoll et al., 2003). ATR is a member of the P13K family, and is closely 
related to ATM. Moreover, it functions in the cell-cycle checkpoint and DNA repair 
26 
pathways. It is a key member of the intra-S and G2/M checkpoints and responds 
primarily to replication stress, such as that caused by hydroxyurea, aphidicolin, and 
hypoxia (Alderton et al., 2004). When activated, ATR stabilizes stalled replication 
forks, inhibits late origin firing, and blocks progression from G2 into mitosis (Cobb et 
al., 2005). Although lymphoma has been reported in some Seckel patients, they tend 
not to have ataxia or immunodeficiency. However, Seckel syndrome patients 
display features, including microcephaly and dysmorphic faces, commonly found in 
other syndromes associated with impaired responses to DNA damage(O'Driscoll et al., 
2004). Similar to the CREBBP gene that causes Rubinstein-Taybi syndrome and 
epimutation of H19 imprinted gene that causes Russell-Silver syndrome, it is possible 
that disease phenotypes caused by defects in essential genes involving basic cellular 
functions through interactions with multiple genes result in multiple malformations 
with generalised growth deficiency. 
Another example of this is Roberts syndrome which is also characterised by 
severe growth deficiency with meromelia (partial limb defects) in four limbs and a 
peculiar face with microcephaly. The causative gene has recently been recognised and 
named ESCO2. The ESCO2 protein product is a member of a conserved protein 
family that is required for the establishment of sister chromatid cohesion during S 
phase and has putative acetyltransferase activity. Defects in chromatid cohesion lead 
to mitotic spindle checkpoint activation and impaired cell growth. The mitotic spindle 
checkpoint may be activated by the defect, resulting in the mitotic delay and impaired 
cell proliferation observed in cell lines derived from patients with Roberts syndrome. 
During embryogenesis, the loss of progenitor cells could preclude a sufficient number 
of cells required for development of structures affected in Roberts syndrome (Vega et 
al., 2005). 
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1.4.1.4.2 Other possible explanations for CdLS 
Another fascinating mechanism that might be involved in CdLS is the 
non-coding MicroRNAs (miRNAs) pathway. MicroRNAs (miRNAs) are 
22-nucleotide, short, noncoding RNAs that are thought to regulate gene expression 
through sequence-specific base pairing with target mRNAs. MicroRNAs are 
transcribed as long RNA precursors (pri-miRNAs) that contain a stem loop structure 
of about 80 bases. Pri-miRNAs are processed in the nucleus by the RNase III enzyme 
Drosha and DGCR8/Pasha, which excises the stem-loop to form the pre-miRNA. 
Pre-miRNAs are then exported from the nucleus by Exportin-5. In the cytoplasm, 
another RNase III enzyme, Dicer, cuts the pre-miRNA to generate the mature 
microRNA as part of a short RNA duplex. The RNA is subsequently unwound by a 
helicase activity and incorporated into a RNA-induced silencing complex (RISC) 
(Alvarez-Garcia and Miska, 2005; Pasquinelli, 2006). Most microRNAs in animals 
are thought to be functioned through the inhibition of effective mRNA translation of 
target genes through imperfect base pairing with the 3'-untranslated region (3'UTR) 
of target mRNAs (Yekta et al., 2004). The underlying mechanism is still poorly 
understood. MicroRNA targets are largely unknown, but estimates range from one to 
hundreds of target genes for a given microRNA(Enright et al., 2003). Studies in 
model organisms have shown that miRNAs are involved in the control of 
developmental timing, cell proliferation, left-right patterning, neuronal cell fate, 
apoptosis and fat metabolism in invertebrates (Alvarez-Garcia and Miska, 2005; 
Mattick and Makunin, 2005). Therefore, it is reasonable to expect a similar range of 
functions in the developing vertebrate. Dicer defective ES cells exhibit severe defects 
in differentiation in vitro as well as in centromeric silencing (Kanellopoulou et al., 
2005). miRNAs embedded in Hox clusters exhibit expression patterns that are 
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comparable of Hox genes (Chopra and Mishra, 2006; Pearson et al., 2005). This 
suggests a miRNA-mediated mechanism for the post-transcriptional restriction of Hox 
gene expression during vertebrate development (Tanzer et al., 2005; Yekta et al., 
2004). Although no evidence suggests the association between miRNAs machinery 
and the CdIS, the regulatory role of miRNAs during early vertebrate development has 
gradually caught scientists' attention. Thus, we can not exclude the possibility that 
CdIS is caused by the defect in molecules such as dicer or helicase, which is involved 
in miRNAs biogenesis. The CdIS phenotype might also be caused by yet identified 
miRNAs that exert their effects through posttranscriptional modulation of a range of 
genes important to progenitor cells proliferation and differentiation. 
Another syndrome with phenotypic similarity to CdLS is fetal alcohol syndrome, 
which is caused by chronically maternal alcohol consumption. Babies affected with 
fetal alcohol syndrome are characterised by growth deficiency of prenatal onset, 
microcephaly, and short palpebral fissure. This syndrome is caused by the 
environmental factor rather than by the genetic factors. It is possible that teratogenic 
agents might also contribute to the generalised disregulation of certain important 
developmental steps associated with CdLS. 
1.4.1.4.3 Predicted expression patterns and functions of CdIS genes 
. The inheritance pattern in most of the familial cases suggested that CdIS 
appears to be a dominant disorder and it seems that in most cases the phenotype is 
expressed in the heterozygote. Dominantly inherited genes are likely to cause a 
phenotype through two actions. The first is haploinsufficiency, a defect in one of the 
alleles, which leads to the insufficient expression of the gene product that is required 
for the minimal function of the gene. Another possibility is a gain-of-function. Here, 
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mutations in the gene, especially missense mutations, may alter the properties of an 
important functional domain leading to altered gene function. The resulting product 
either functions in an inappropriate way or interferes with the functions of the normal 
gene product -a so called dominant-negative effect. As gradually more genes 
involved in early human developmental process are identified, the identification of the 
genes that might be involved with the CdLS becomes difficult. The predicted function 
of the putative CdLS gene is regulation of cell growth, since prenatal and postnatal 
growth retardation are the hallmarks of CdLS. Thus, a gene that is associated with cell 
proliferation is strongly considered as a candidate. Although severe limb reduction 
defects are reported in around 10-20% of CdLS patients (Jackson et al., 1993), severe 
limb reduction defects are very rare in CdLS patients of Taiwanese origin, even in 
patients with very severe phenotypes (personal communication in local meeting, 
unpublished data). Most of the patients in Taiwan have small hands and feet which are 
proportionate to their small build. Unless several different genes are involved in the 
pathogenesis of the CdLS phenotype from different ethnic backgrounds, we believe 
that the CdLS causing gene must play a role in basic cellular functions such as cell 
cycle regulators during early embryonic development that affect cell proliferation 
during organogenesis. Hence, genes that cause limb defects only are not considered 
likely candidates. The CdLS gene may exert its developmental regulatory effects 
through interaction with other molecules as seen in CREBBP gene in 
Rubinstein-Taybi syndrome. 
Unlike with diseases such as enzymopathies, it was impossible for us to use the 
gene product to map the gene, as this was not feasible in CdLS due to the lack of 
protein product information. Moreover, no known mouse models that are similar to 
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the phenotypes of CdIS had been reported. Thus, it was hard to find the CdLS disease 
gene through mouse models. 
However, due to the lack of some consistent clues such as some particular 
biological markers or animal models reminiscent of CdLS, gene mapping through a 
candidate gene approach is presently impractical. 
1.4.2 Strategies of Gene Identification in Newcastle Group 
Among these reported cases, only three patients with clinical features typical of 
severe CdIS who had a de novo balanced reciprocal translocation with blood samples 
were available to us. These include a female infant with a t(14; 21)(q32; qll) (Wilson 
et al., 1983), a female newborn with a t(3; 17)(q26.3; q23.1) (Ireland et al., 1991), and 
an unreported girl with a t(5; 13)(p13.1; q12.1) balanced translocation. All of them are 
sporadic cases. No familial inheritance was noted. 
Previously, a novel gene was found to be interrupted by the t (3; 17) (q26.3; 
q23.1) translocation breakpoint. However, patient-specific mutations were not found 
in this gene (Tonkin et al., 2004a). Linkage studies also exclude 3q26.3 as a candidate 
region (Krantz et al., 2001). Thus, we were prompted to investigate other 
chromosomal regions. Linkage studies using the rare familial cases are ideal for the 
purpose. Moreover, collection of the familial CdLS cases was extremely difficult for 
us. At that time, the Newcastle group only had two families affected by familial CdIS 
and a decision was taken to donate the blood samples from members of these two 
families to Drs. Krantz and Jackson who were committed to a global search for CdLS 
families that were suitable for linakge analysis. Meanwhile, the Newcastle group 
decided to continue the gene mapping by seeking to define, at the molecular level, the 
breakpoints in the t(5; 13) and t(14; 21) de novo balanced translocations, that would 
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then be expected to lead to candidate gene identification. A second approach 
undertaken by the Newcastle group in collaboration with Nigel Carter and co-workers 
at the Wellcome Trust Sanger Institute was to use microarray CGH to investigate the 
possibility that CdIS was due to a chromosomal microdeletion/microduplication that 
would involve deletion/duplication of multiple contiguous genes but that could not be 
detected by standard cytogenetic approaches. The initial approach was to use BAC 
clones selected from the candidate regions for the FISH mapping. The details for our 
positional mapping are described in chapter 2. 
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1.5 AIMS OF THE PROJECT 
The aims of this project were: 
1. To map the CdIS disease gene by using FISH mapping on three patients with de 
novo balanced translocation as described above. 
2. Patient-specific mutation screening of the most compelling candidate CdLS gene to 
determine if the mapped gene is the causative gene for CdIS 
3. Ongoing expression studies of the CdLS disease gene(s). 
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CHAPTER 2: FISH MAPPING OF CdLS PATIENTS WITH de 
novo BALANCED RECIPROCAL TRANSLOCATIONS and 
GENOMIC ORGANIZATION OF THE GENE TRUNCATED BY 
THE t(5; 13) TRANSLOCATION 
2.1 INTRODUCTION: 
Chromosome translocations can be extremely valuable for assessing the 
contributions of individual loci to the phenotype of certain syndromes, especially 
when occurring de novo. Compared with cytogenetically visible deletions or 
duplications, or unbalanced translocations which could leave tens or hundreds of 
genes to search through, the location of the de novo breakpoint within a balanced 
translocation should provide a quick entry into the gene which will most likely be 
severed by the translocation or immediately adjacent to it, since there is no apparent 
loss or gain of DNA. From the wide range of CdLS-associated chromosome 
abnormalities (Table 1.1), our Newcastle group were able to collect samples from 
three CdLS individuals with de novo balanced reciprocal translocations that had been 
reported before the onset of our study or had been referred as an unpublished case: a 
t(3; 17) (q26.3; q23.1) case (Ireland et al, 1990); a t(14; 21)(q32; qll. 2) case (Wilson et 
al., 1983) and a t(5; 13)(p13.1; q12.1) From the wide range of CdLS-associated 
chromosome abnormalities (Table 1.1), our Newcastle group were able to collect 
samples from three CdLS individuals with de novo balanced reciprocal translocations 
that had been reported before the onset of our study or had been referred as an 
unpublished case: a t(3; 17) (q26.3; q23.1) case (Ireland et al, 1990); a t(14; 
21)(q32; qll. 2) case (Wilson et al., 1983) and a t(5; 13)(p13.1; q12.1) case (M. 
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Bamshad, pers. comm). After initial prioritization of the 3q26.3 breakpoint (based on 
the perceived similarities in phenotype between CdLS and individuals that were 
trisomic for 3q26.3, as discussed in the previous chapter) the case for a CdIS gene at 
3q26 was weakened by the observation that in at least some multicase families linkage 
was excluded from the 3q26.2-q27 region ((Krantz et al., 2001). Accordingly, we also 
investigated the other breakpoints in the available translocation cases. - 
2.1.1 Standard FISH 
Fluorescent in situ Hybridization (FISH) is a relatively new and important 
technology utilizing fluorescently labeled DNA probes for identifying chromosomes 
and part of chromosomes, deciphering chromosome rearrangements and locating 
genes on chromosomes. By using a fluorophore, which absorbs energy of a specific 
wavelength and re-emits energy at a different (but equally specific) wavelength, as 
well as the techniques of in situ hybridization, this technique allows the use of 
non-radioactive DNA probes to be hybridized with the chromosomes, cells or tissue in 
place (in situ) on a microscope slide. 
FISH uses nucleic acid probes such as YACs, BACs, PACs, fosmids, cosmids, as 
well as cDNA sequences and Alu-PCR products. If the denatured probe and the target 
DNA sequences are complimentary to each other, fluorescent in situ hybridization will 
give a clear signal. With the completion of the human genome project and advances in 
bio-informatics technology, the information of the probes is easy to find and then 
information on the target DNA segments can be elucidated. 
Up to now, two kinds of FISH technologies have been commonly used - the 
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indirect and the direct method. The indirect FISH method involves probes pre-labeled 
with a hapten, most commonly digoxigenin. After hybridization, 
fluorochrome-labeled antibodies to the hapten are used for probe detection. The 
indirect FISH method requires additional blocking reagents and amplification steps. 
Furthermore, it has been reported to have a higher degree of background fluorescence 
problems. 
The direct FISH method involves directly labeled probes that have been 
pre-labeled with a specific fluorophore, allowing the fluorescent signal to be bound to 
the target in a single hybridization step. This method is more advanced, involves 
fewer steps, is easier to read and has a faster time-to-result. Therefore, direct label 
FISH represents a superior technology and offers many advantages. However, when 
analyzing very small probes, the indirect method is still preferred since the intensity 
of the fluorescence by using the direct method is not as strong as the intensity 
provided by the indirect method (Wiegant et al., 1991). 
FISH can be used to detect genetic abnormalities, providing valuable information 
about prenatal disorders, cancer, as well as other genetic diseases and chromosome 
derangements. Unlike other molecular DNA-based tests, which require cell lysis to 
free nucleic acids for analysis, FISH allows the analysis of DNA in situ, that is, in its 
native, chromosomal form within the cell nucleus. This attribute permits the analysis 
of chromosomes and genes of individual cells. 
Conventional chromosomal FISH uses metaphase spreads (metaphase FISH), 
with positive hybridization signals often showing double spots corresponding to 
probes hybridized to both sister chromatids. The maximum resolution for metaphase 
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FISH is around 2Mb. The use of interphase FISH can provide higher resolution 
analyses, since the chromosomes are extended longer. However, the problems with 
chromatin folding will make the signals from two different probes appear side-by-side 
and interfere with the data interpretation. Moreover, with the completion of the human 
genome draft, the relative positions of most BACs, PACs and fosmid clones are 
determined and can be viewed easily on most of the genome browsers. Therefore, the 
procedure to decide the relative positions of the two different probes becomes 
unnecessary. Thus, we employed the metaphase FISH as the main strategy for FISH 
mapping in our patients with balanced translocations. 
In the past, once a BAC clone had been shown to map near the breakpoint, a 
cosmid library would be screened for higher resolution mapping. However, there are 
some disadvantages associated with cosmid clones that use bacteria as hosts for 
propagation. The presence of repeated elements, palindromes, Z-DNA forming 
sequences and methylated bases in recombinant constructs can cause deletion or 
rearrangement of cloned DNA in bacterial hosts. This instability has also been 
observed for a subset of the human chromosome 19-specific cosmid library (Yokobata 
et al., 1991). Therefore Kim et. al. developed a new cosmid cloning system (referred 
to as the Fosmid system) that employs the use of a low copy number plasmid based on 
the F factor replication origin (Kim et al., 1992). The use of host strains with various 
deficiencies in the recombination system could improve the stability of mammalian 
genomic libraries. Moreover, with more and more fosmid libraries being constructed 
and reported, we decided to use fosmids for finer mapping once the BAC clone that 
crosses the breakpoints was found. 
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2.1.2 Array-CGH 
Another approach for gene mapping is to use comparative genome hybridization 
(CGH). CGH involves simultaneous painting of chromosomes in two different colors 
by using total DNA from two different sources as probes. CGH to metaphase 
chromosomes is a relatively rapid method for screening the entire genome. However, 
the resolution is limited to gains or losses of 2-10Mb, rendering it unsuitable in the 
analysis of small segmental deletions and duplications (Bentz et al., 1998). 
A more sensitive technique designed for this purpose is microarrays based CGH 
(array CGH), in which individual BAC/PAC clones are arranged in arrays, rather than 
whole genomes as metaphases. They are subsequently hybridized with genomic DNA 
to detect dosage changes with the resolution down to 0.2-0.4 Mb. The increased 
resolution of array-CGH allows detection of deletions and duplications of a single 
BAC/PAC clone (Cheung et al., 2005). However, in 2002, the resolution for BAC 
array-CGH was still low. High resolution of BAC (-3000) array-CGH only became 
available later in 2003 (Carter et al., 2002; Watson et al., 2004). 
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2.2 AIMS OF THIS PROJECT 
The linkage data performed by Krantz et al. suggested the exclusion of 3q26.3 as 
a candidate region for the CdIS gene (Krantz et al., 2001). Therefore, in this project, 
we focused on the translocation breakpoints on t(5; 13) and t(14; 21). FISH was first 
employed to map BAC clones relative to the chromosome 5p, 13q, 14q translocation 
breakpoints to narrow down the breakpoint regions because the breakpoint on 
chromosome 21 was expected to be in a region that had extremely few genes. The 
targets of the FISH analyses were metaphase chromosome spreads from blood 
lymphocytes collected from patients with translocations t(5; 13) and t(14; 21) 
respectively. Once the BAC clones that cross the respective translocation breakpoints 
were identified, the region was further narrowed down by FISH mapping using 
fosmid clones as probes to help with positional cloning. 
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23 MATERIALS AND METHODS 
2.3.1 Data interpretation of FISH mapping in metaphase spreads: 
23.1.15p region 
Clones that were mapped centromeric to the 5p translocation breakpoint gave 
two signals - one on normal chromosome 5 and one on translocated (derivative) 
chromosome 5. Clones that were mapped telomeric to the translocation breakpoint 
gave one signal on normal chromosome 5 and one on translocated chromosome 13. 
Clones, which spanned the translocation breakpoint, would give three signals - one on 
normal chromosome 5, one on translocated chromosome 5 and one on translocated 
chromosome 13. This is shown in the diagram below. 
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""- =Fluorescent probe 
Probe mapping centromeric 
to chromosome 5 
translocation breakpoint 
Normal D. -t- Normal Derivative 
Ch, 5 chr. 5 chr. 13 chr. 13 
" " - =Fluorescent probe 
Probe mapping telomeric 
- to chromosome 5 
translocation breakpoint 
Normal Derivative Normal Derivative 
ehr 5 Chr. 5 On, 11 crtr 13 
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Probe mapping across 
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Fig. 2.1 Illustration of the three types of chromosome FISH results expected after hybridizing 5p 
probes to the t(5; 13) metaphase chromosome preparation. 
2.3.1.2 13q region 
Clones that were centromeric to the 13q translocation breakpoint gave two 
signals - one on the normal chromosome 13 and one on the translocated (derivative) 
chromosome 13. Clones that were telomeric to the translocation breakpoint would 
Give one signal on normal chromosome 13 and one on translocated chromosome 5. 
Clones, which spanned the translocation breakpoint, would give three signals - one on 
normal chromosome 13, one on translocated chromosome 5 and one on translocated 
chromosome 13. This is shown in the diagram below. 
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Fig. 2.2 Illustration of the three types of chromosome FISH results expected after hybridizing 13q 
probes to the t(5,13) metaphase chromosome preparation 
2.3.1.3 14q region 
Clones that were mapped centromeric to the 14q translocation breakpoint gave 
two signals - one on normal chromosome 14 and one on translocated (derivative) 
chromosome 14. Clones that were mapped telomeric to the translocation breakpoint 
would give one signal on normal chromosome 14 and one on translocated 
chromosome 21. Clones that spanned the translocation breakpoint, would give three 
signals - one on normal chromosome 14, one on translocated chromosome 14 and one 
on translocated chromosome 21. 
9- =Fluorescent probe 
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2.3.2 Preparation of metaphase slides 
Slides containing metaphase spreads were prepared by staff from the NHS 
Cytogenetics Service within the Institute of Human Genetics the day before the FISH 
experiment and the remaining slides were stored at 41C. 
Cells stored in a fixative solution (methanol: acetic acid = 3: 1) at -20°C formed a 
pellet during storage. The fixative was discarded and the cell pellet was resuspended 
in 6ml of a fresh fixative solution. The cells were centrifuged at 1500rpm for 5 min 
and the supernatant was then discarded. This procedure was repeated 3 times. A small 
amount of fresh fixative was added to resuspend the cells. Approximately 25, u 1 of 
cell suspension was dropped onto a clean glass microscopic slide from a height of 3 
cm. The slides containing the metaphase spreads were then air-dried. The sum of cells 
on each slide amounted to approximately 2x105. 
2.33 Preparation of BAC/fosmid DNA 
The QIAGEN Plasmid Midi Kit was employed in the preparation of the BAC 
and fosmid DNA. 
2.3.3.1 Growth of bacteria 
Bacteria containing BAC DNA were grown on solid LB media containing 12.5 ,u 
g/ml chloramphenicol at 37°C overnight. A single colony was picked and inoculated 
into a starter culture of a 5m1 LB medium containing 12.5 g g/ml chloramphenicol and 
grown at 37°C for 8 hours by vigorous shaking (-250rpm). In addition, 0.5ml of 
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pre-culture was inoculated into a 100ml LB medium containing 12.5 ,u g/ml 
chloramphenicol and grown at 37°C for 14 hours by vigorous shaking. The cells were 
divided into two 50m1 tubes and harvested by centrifugation at 4500 xg for 20 min. 
2.3.3.2 Preparation of DNA 
Each bacterial pellet was resuspended in 20 ml of Buffer P1 (50mM Tris. HCl 
pH8,10mMEDTA, 100 µg/ml RNase A). Next, 20 ml of Buffer P2 (200mM NaOH, 
1%SDS) was added to each tube, followed by gentle inverting of the tube 4-6 times. 
The mixture was incubated at room temperature for 5 minutes, before 20 ml of chilled 
Buffer P3 (3M potassium acetate pH5.5) was added. Each tube was gently inverted 
4-6 times, and the mixture was incubated on ice for 15 minutes. After the mixture was 
centrifuged at =20,000 xg for 30 min at 4°C, the supernatant containing plasmid 
DNA was removed promptly and filtered through pre-wetted folded filter paper. 
A QIAGEN-tip 100 was equilibrated through the application of 4 ml of Buffer QBT 
(750mM NaCl, 50mM MOPS pH7,15% isopropanol, 0.15% Triton X-100) and 
allowed the column to empty by gravity flow. The filtered supernatant was applied to 
the QIAGEN-tip and allowed it to enter the resin by gravity flow. The QIAGEN-tip 
was washed with 2x 10 ml of Buffer QC (1M NaCl, 50mM MOPS pH7,15% 
isopropanol), and the DNA was eluted with 5x1 ml of Buffer QF (1.25M NaCl, 
50mM Tris. HCL pH8.5,15% isopropanol). To increase the yields, Buffer QF was 
pre-warmed to 65°C and applied to the column in 5 aliquots of 1 ml instead of 1 
aliquot of 5 ml to prevent cooling of the elution buffer. 
The DNA was precipitated by adding 3.5 ml of room-temperature isopropanol to 
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the eluted DNA. The precipitated DNA was centrifuged immediately at =15,000 xg 
for 30 min at 4°C, followed by careful decanting of the supernatant. The DNA pellet 
was washed with 2 ml of room-temperature 70% ethanol and centrifuged at =15,000 x 
g for 10 min. The supernatant was decanted carefully without disturbing the pellet. 
The pellet was air-dried for 5-10 min, and redissolved in a suitable volume of buffer 
(e. g., TE, pH 8.0, or 10 mM Tris-Cl, pH 8.5). The concentration and purification of 
the dissolved DNA was determined by using the ND-1000 Spectrophotometer 
(NanoDrop Technologies). 
2.3.4 DNA labeling with fluorochromes-Direct labeling 
The DNA used for FISH probes was labeled with either SpectrumGreen or 
SpectrumRed by Nick translation (Nick translation kit, Vysis). 1, u 1 of DNA was 
labeled in a 50 ju 1 reaction containing 5j1 of the 10x Nick translation buffer (500mM 
Tris-HCI, pH7.2,100mM MgSO4,1mM DTT ), 5 ,u 10.1mM 
dTTP, 10 u1 dNTP mix, 
10, u 1 of Nick translation enzyme (DNA polymerase I, DNase I in 50% glycerol, 
50mM Tris-HCI pH7.2,10mM MgS04i 0.1mM DTT, 0.5 mg/mL nuclease-free BSA), 
2.5 /t 1 of 0.2mM SpectrumGreen or SpectrumRed and sdH2O to a final volume of 50 
,u1. The reaction was incubated at 15°C for approximately 6 hours for BACs, and 
approximately 3 hours for fosmids. A3u1 of aliquot was then size fractionated on a 
1.5% agarose gel. For FISH assays, the goal is to produce labeled probe in a range of 
50-600bp, with an average size of 300 bp. If the fragments were still larger than this, 
the reaction was incubated further at 15°C until the desired fragments of the correct 
size had been produced. The reaction was stopped by allowing it to heat in a 70°C 
water bath for 10 minutes. 
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23.5 Purification of the labeled probe 
SpectrumGreen or SpectrumRed labeled DNA was purified in a NICK column 
containing Sephadex G-50 gel to separate the probe from unincorporated nucleotides. 
The column was washed twice with 3ml of sdH2O. The probe sample was added to 
the column and 400 ju 1 of sdH2O was supplied to allow the probe to enter the gel. 
Subsequently, the purified probe was eluted in a second fraction of 400 ,u1 sdH2O and 
the fraction was collected in a clean eppindorf. 
23.6 Competition of probe and resuspension in hybridization mix 
High copy repetitive sequences in the DNA probe were competed with human 
Cot-I DNA and salmon sperm DNA. 5, u 1 of sheared salmon sperm DNA (10mg/ml) 
and 10 ji 1 of Cot! DNA (GIBCO 1mg/ml) were added to each eluted 400, u 1 purified 
labeled probe. 1/10`1 volume of 3M sodium acetate (42, u 1, pH 4.8-7) and 2 volumes 
(915 j 1) of 100% ethanol were then added to the DNA, permitting it to precipate at 
-20°C overnight. 
The DNA was recovered by centrifugation at 13000rpm for 20 minutes in a 
microcentrifuge. The supernatant was subsequently removed and the DNA pellet was 
washed with 500 ,u1 of 70% ethanol. The sample was centrifuged at 13000rpm for 10 
minutes and the pellet was air-dried for 5 minutes. 16 g1 of the hybridization mix 
(50% deionised formamide, 2xSSC, 1% Tween-20,10% dextran sulfate, pH7-7.5) 
was thereafter added to the pellet, which was allowed to rehydrate at room 
temperature for 1 hour. The probe was either used immediately for FISH or stored at 
-20°C . If probes were stored, they were thawed at room temperature for 1 hour before 
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usage. 
23.7 Commercial pre-labeled chromosome 5,13,14 marker probes 
The majority of FISH experiments were carried out on metaphase spreads 
prepared from the blood lymphocytes of patients with t(5; 13) and t(14; 21) 
translocations. This allowed us to determine if the probes are mapped centromeric, 
telomeric or across the translocation breakpoint. Hence, it is very important to 
accurately determine the exact chromosome on the metaphase spreads. With the help 
of DAPI (1.5, i g/ml 4', 6-diamidino-2-phenylindole) counterstaining, it is easy to 
identify normal chromosomes 13,14 and 21 since they are acrocentric. It is also easy 
to identify derivative chromosome 13 and derivative chromosome 21 since they are 
very small in size (smaller than normal chromosome 21). However, chromosome 5, 
derivative chromosome 5, and derivative chromosome 14 are not so easily identifiable. 
To overcome this problem, direct labeled marker Sq, 13q telomeric probes and a 
chromosome 14,21 a -satellite direct labeled probes were added to the hybridization 
reactions. 
2.3.8 In situ hybridization to chromosome spreads 
Metaphase and prometaphase slides were provided by staff from the MHS 
Cytogenetics Service of the Institute of Human Genetics. 
Slides were incubated in a pre-warmed 2xSSC solution, which contained 100 ,u 
g/ml of ribonuclease A, for 1 hour at 371C. After being briefly dipped in a 2xSSC 
solution, the chromosomes were denatured by incubating slides in a 70 °C 
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pre-warmed 2xSSC solution containing 70% of formamide for 4 minutes in a 
waterbath in a fume hood. The chromosomes were dehydrated by washing the slides 
for 5 minutes each in a series of ice-cold 70%, 90%, and 100% ethanol solutions. The 
slides were dried at room temperature and warmed to 37°C on a hot plate. 20x40mm 
glass coverslips were cleaned with 100% ethanol and also warmed to 37°C . 
The competed probe that was previously dissolved in a hybridization mix was 
denatured at 75 °C for 5 minutes, snap cooled on ice for 2 minutes and then 
pre-annealed at 37°C for 30 minutes. Then, if applicable, 2, iI of the direct labeled 
marker probe was added to each probe. After brief centrifugation to collect the probe, 
15 ,u1 of the preannealed probe was applied to the centre of the 
denatured metaphase 
spreads. A glass coverslip was carefully lowered to the slide. The slides were placed 
in a plastic slide holder and put in a Tupperware box containing water-soaked towels. 
They were then hybridized in an oven at 37°C overnight. 
2.3.9 Slide washing and detection of probe signal 
After overnight hybridization, the slides were washed three times for 5 minutes 
in 50% formamide, 2xSSC at 45°C and then twice for 5 minutes in a 2xSSC solution 
at 45°C. The coverslips were removed from the slides by gentle shaking. The slides 
were then dehydrated in a series of room temperature 70%, 85%, and 100% ethanol 
solutions. Next, they were air-dried and mounted by applying one drop (40 g 1) of 
Vectashield antifadent containing DAPI (1.5, a g/ml 4', 6-diamidino-2-phenylindole). 
The chromosomes were stained blue. A clean glass coverslip was lowered to each 
slide, upon which the slides were stored in the dark at 4°C until visualization. 
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23.10 Microscopic visualization of FISH signals 
The slides were analysed using a Zeiss Axioskop epifluorescence microscope 
equipped with a cooled charge coupled device (CCD) camera. The filter sets within 
this microscope allow detection of specific fluorescent signals through color 
visualization. These signals include FITC (green signal), Rhodamine (red signal) and 
DAPI (blue signal). While FITC has an excitation minimum of 494nm and an 
emission maximum of 523nm, Rhodamine has an excitation maximum of 570nm and 
an emission maximum of 590nm. Meanwhile DAPI has an excitation maximum of 
345nm and an emission maximum of 425nm. Images were captured at 1000x 
magnification and analysed using AxioVision 4.1 image analysis software (Zeiss). 
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2.4 RESULTS 
2.4.1 Phenotypes and Giema chromosome banding of the patient with de novo 
t(5; 13)(pl3.1; g12. t) translocation. 
a b 
pl3. lw n l1 
44 i/ ' 
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5 der(5) 
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Fig 2.3 (a) Phenotypes of the patient with t(5; 13)(p13. l; gl2. l) de novo translocation. The index case 
showed typical characteristic facial features and severe limb defects with a generalized growth 
deficiency (provided with courtesy of Dr. M. Bamshad). (b) Giemsa chromosome banding showed a 
balanced de novo t(5; 13)(pl3. l; gl2. l) translocation (the karyotype was done by Mike Bamshad's 
team). The chromosome defect was not seen in either parent. 
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2.4.2 Molecular definition of the t(5; 13) breakpoint by chromosome FISH 
FISH was carried out using a single probe per slide on metaphase spreads from 
the t(5; 13) translocation fibroblasts. Chromosome 5q and 13q telomere marker probes 
were also used to allow accurate identification of the chromosomes of interest. 
For the initial mapping, the clones used as probes were BACs sourced from the 
RP-11, CTD libraries and selected using the UCSC Genome Browser, Assemblies: 
July 2003 and May 2004. The selected clones were directly labeled either with 
florochromes SpectrumRed or SpectrumGreen by NickTM translation. BACs have 
advantages over PACs in that they can have slightly larger inserts and are more stable. 
Therefore, they are significantly less likely to contain chiremic inserts, i. e. inserts 
from more than one region of the genome. 
The aim of the FISH experiments was to determine whether clones were mapped 
centromeric, telomeric or spanned across the breakpoints on the translocated 
chromosomes 5,13, and 14. A clone mapped centromeric or telomeric to the 
breakpoint will give two signals - one on the normal chromosome and one on the 
derivative chromosome. Thus, if a probe is mapped centromeric to the translocation 
breakpoint on chromosome 5, it will result in two signals - one on normal 
chromosome 5 and one on derivative chromosome 5. If a probe is mapped telomeric 
to the breakpoint on chromosome 5, it will also result in two signals - one on normal 
chromosome 5 and the other on derivative chromosome 13. On the other hand, if a 
probe is spanned across the breakpoint, it will give three signals - one on normal 
chromosome 5, one on derivative chromosome 5 and the other on derivative 
chromosome 13. The intensity of the signals on the derivative chromosomes of the 
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clone that crosses the breakpoint depends on the amounts of the corresponding DNA 
that are split by the translocation. 
2.4.3 Results of clones mapped to the 5p translocation breakpoint region 
Previous work done by E. Tonkins and M. Smith identified that on chromosome 
5p, BAC clones RP1I-29K6 and CTD-2039P12 are mapped telomeric to the 
translocation breakpoint. However, repeated FISH experiments showed that BAC 
clone RP II- 29K6 mapped centromeric to the translocation breakpoint on 5p l3. I. 
Based on the new results, I selected BAC clones that are located in the interval 
between RP I 1-29K6 and CTD-2039P 12 as probes to identify the clone that crosses 
the translocation breakpoint. For the selection of clones, we used the human BAC 
based physical map generated through the Human Genome Project. Information on 
BAC clones was obtained from both the ensembl and the NCBI genome browser web 
sites (http: //www. ensembl. org/Homo sapiens/index. html; 
http: //www. ncbi. nlm. nih. gov/end ome/guide/human/1). We restricted our clone 
selection to those that were readily available in the RPCI-11 and Caltech Dl/D2 
(informa. bio. caltech. edu/Bac info. html) libraries. 
The results of mapping BAC clones to the 5p13.1 breakpoint region by FISH on 
t(5; 13) metaphase chromosome spreads are shown in Table 2.1 See Figures 2.4,2.5 
and 2.6 for examples of clones mapped telomeric, centromeric and across the 
chromosome 5p breakpoint, respectively. 
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Table 2.1 Results of mapping clones to the 5p13.1 breakpoint region by FISH 
End(bp) ('lone name Position relative 
to the breakpoint 
31634946 31773870 CTD2039PI2 Telomeric 
33048353 33198517 CTD-2017D15 Telomeric 
34134813 34296260 RPI1-110H4 Telomeric 
33164437 35322042 CTD2258D22 Telomeric 
33322159 35472737 CTD-2562121 Telomeric 
3 36809 02 CTD-2353F22 Telomeric 
37002744 37106095 CTD-2249G23 Centromeric 
37183020 37333544 CTD-2124B8 Centromeric 
37755520 37985498 CTD-2194L12 Centromeric 
38535555 38685966 RPI 1-29K6 Centromeric 
Once the BAC clone that crosses the translocation breakpoint was determined, 
%%e queried the genes located within the area covered by the clone CTD-2653'x123 
through the databases from both the ensembl and the NCBI databases 
(http: //H, H, H. ensembl. or omo sapiens/index. html: 
http: //w, w-"-. ncbi. nlm. nih. gov/genome/guide/human/: ). 
Within this area. possible candidate genes in the regions were identified, 
including an uncharacterized gene that had been named as LOC345513. Hhich is 
similar to Keratin. t. pe I cvtoskeletal 18 (Cytokeratin 18) (K 18) (CK 18) and IDN3, a 
66 
sequence that corresponded to part of a previously uncharacterized gene . The exact 
function of these genes was unknown, but IDN3 was of interest because a predicted 
protein sequence that could be derived from it exhibits 37% sequence identity to the 
Nipped-B gene product of Drosophila, that facilitates enhancer-promoter 
communication of the remote wing margin enhancer in the cut and Ultrabithorax 
homeobox genes, both of which are important in limb development (Rollins et al., 
1999). The Drosophila Nipped-B protein is also homologous to a family of 
chromosomal adherins with broad roles in sister chromatid cohesion, chromosome 
condensation, and DNA repair. Transcript variants resulting from alternative splicing, 
and from use of alternative polyadenylation sites, have been reported for this gene; 
two of these encode different isofonms (Neuwald and Hirano, 2000; Rollins et al., 
1999). As growth deficiency exists among essentially all patients with CdIS, and limb 
defects were observed in around 10-25% of patients with CdIS, we recognized the 
human homologue of Drosophila Nipped-B as a potential candidate gene. The 
functions of the Drosophila Nipped-B gene product suggest that they are cell-cycle 
related and can also be developmentally regulated, and so the case for involvement of 
IDN3 in CdLS was considerable. 
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Fig 2.4 A BAC clone mapping telomeric to the 5pl3. I breakpoint (CTD-2353F22). FISH mapping of 
the chromosome breakpoint in the t(5; 13) metaphase spreads. The green signals are from the 
chromosome 5 telomere marker. The BAC clone CTD-2353F22 that was mapped telomeric to the 5p 
breakpoint shows red signals on normal chromosome 5 and derivative chromosome 13. 
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Fig 2.5 A BAC clone mapping centromeric to the Spill breakpoint (CTD-2249G23). FISH mapping 
of chromosome breakpoint in t(5; 13) metaphase spreads. The green signals are from the chromosome 5 
telomere marker. The BAC clone CTD-2249G23 that was mapped centromeric to the 3p breakpoint 
shows red signals on normal chromosome 5 and derivative chromosome 5. 
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Fig 2.6 A BAC clone spanning the 5p 13.1 breakpoint (CTD-2653\123). FISH mapping of chromosome 
breakpoint in t(5; 13) metaphase spreads. The green signals are from the chromosome 5 telomere 
marker. The BAC clone CTD-2653\. 123 mapped across the 5p breakpoint showed red signals on 
normal chromosome 5, derivative chromosome 5 and derivative chromosome 13. The red signal on 
derivative chromosome 5 is fainter than the one on derivative chromosome 13. 
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Due to the high probability of 5p13 as a candidate region harboring the CdIS 
disease gene (discussed in section 2.6), we decided to perform higher resolution 
mapping by using fosmids as probes. The results of FISH using the BAC clone as a 
probe highly suggested that the IDN3 sequence was disrupted by the 5p13 breakpoint 
in the t(5; 13) translocation patient. However, further investigation suggested that the 
IDN3 sequence was a gene fragment and that it was part of a larger gene that extended 
at least 100kb 5' upstream. The 3'end of a novel transcript, BX 
640644(DKFZp686J1O142), comprising 13 exons, overlapped with the 5' end (up to 
exon 5) of the original IDN3. Further data searches identified a cDNA clone, 
AJ627564, whose 3'end partially overlapped (by 743bp) with the gene fragment IDN3 
isoform A (AB019494,39 exons). In-house sequencing revealed sequence-identity 
over 743bp between AJ627564 and gene fragment ABO19494 suggesting that they 
both were part of a larger transcript, which we called NIPBL (Nipped-B like). The 
protein product of NIPBL was called delangin. Further analysis extended the previous 
IDN3 (39 exons) up to 47 exons as follows. BLAT analysis by using the UCSC 
genome browser (2003) (http: //genome. ucsc. edu/) suggested that the transcript of the 
cDNA clone AJ627564 consisted of 10 exons and overlapped with the original IDN3 
gene fragment at exon 9 of AJ627564 (IMAGE 5784375 as seen in Fig. 2.10). Thus, 
the total number of exons in NIPBL increased up to 47 exons. 
Subsequent mutation screening identified a patient-specific mutation in exon 4 of 
NIPBL and together with the previous FISH result suggested that the breakpoint of 
our patient with t(5: 13) was within intron 1 of NIPBL. Thus, the full exon-intron 
organization of the NIPBL gene was determined. 
To verify that the IDN3 sequence was a gene fragment, we decided to select 
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fosmids corresponding to this region (mainly located within intron 1 of the larger gene 
(now named NIPBL) for finer mapping. In this project, I initially selected 6 fosmid 
clones spanning intron 1 of this gene for FISH mapping. The results are shown in 
Figure 2.7,2.8 and 2.9. 
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Fig. 2.8 FISH mapping of clone G248P84262B4. FISH mapping of chromosome breakpoint in t(5; 13) 
metaphase spreads. The green signals are from the chromosome 5 telomere marker. Fosmid clone 
G248P84262B4, which was mapped telomeric to the 5p breakpoint showed red signals on normal 
chromosome 5 and derivative chromosome 13. 
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Fig 2.9 FISH mapping of clone G248P8840C10. FISH mapping of chromosome breakpoint in t(5: 13) 
metaphase spreads. The green signals are from the chromosome 5 telomere marker. Fosmid clone 
G248P8840C 10, which was mapped centromeric to the 5p breakpoint showed red signals on normal 
chromosome 5 and derivative chromosome 5. 
75 
2.4.4 Hierarchy of the contig map in 5p13.1 
Previous FISH mapping enabled us to pinpoint the possible candidates in this 
5p13 area to a number of limited genes. We then subsequently analyzed the 
expression patterns and phenotypes of mutants of other model organisms and 
sequence conservations to determine the priority gene for mutation screens. 
A 4-r_ 
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CTD-2653M23 
G248P88840C10 
G248P84262B4 
B IIu º! I LuI, 111 _ t11 L U111 
IDN3 AI Will III JI III li III I 
IDN3 Bf! I 
I III 1 II IMAGE 5784375 
IIII iI 1I DKFZp686JI0142 
t 
II 1I FLJ44854 
Fig. 2.10 Genomic organization, FISH clones and expressed products of the gene located at the 5p 13. 
breakpoint. (A) Ideogram of human chromosome 5 and FISH clones. Red vertical bars indicate the site 
of disruption at 5p13.1 by the t(5; 13) translocation. G248P88840C10 was mapped centromeric to the 
breakpoint and G248P84262B4 was mapped telomeric to the breakpoint. The breakpoint was located 
within intron I of NIPBL. (B) Genomic organization of NIPBL and the cognate cDNAs. The linked 
vertical bars illustrate the exon selection in representative cDNAs used to determine the full exon 
complement including the original ! L): ß'3 . -( and B clones. The start coding site of the NIPBL is located 
in exon 2 (adapted from E. T Tonkin, with permission). 
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NIPBL has two isoforms, of which the longer isoform A is 9717bp long and 
comprises of 47 exons. The protein product of NIPBL isoform A is 2804 a. a. The 
shorter isoform, NIPBL isoform B, is 8648bp long and comprises of 46 exons. The 
protein product of isoform B is 2697 a. a. The differences between isoform A and 
isoform B is their 3' end. NIPBL isoform B uses a different polyadenylation site from 
that located within intron 46 of NIBPL isoform A. The functional differences between 
these two isoforms are not known. 
2.4.5 Results of the clones mapped to the translocation breakpoint around the 
13q12.1 area 
Region 13g12.1, which was trancated by the de vono t(5; 13) translocation was 
also studies. Preliminary work done by E. T. Tonkin and M. Smith on haplotyping 
genetic markers around the breakpoint region showed that marker D13S175 mapped 
centromeric and D13S120 mapped telomeric to the breakpoint in the 13q12.1 region. 
The interval between these two markers is around 9.5Mb. Based on these results, we 
selected the BAC clones as the probes for FISH mapping through the information 
provided by MapViewer from NCBI (http: //www. ncbi. nlm. nih. gov/mapview/). 
The results of mapping clones to the 13q12.1 breakpoint region by FISH on 
t(5; 13) metaphase chromosome spreads are shown in Table 2.2. See Figures 2.8 for 
example of clones mapped across the chromosome 13q breakpoint. 
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Table 2.2 Results of mapping clones to the 13q12.1 breakpoint region by FISH 
Start (bp) End (bp) Clone name Position relative to 
the breakpoint 
19023711 19043428 RP11-76K19 Centromeric 
19 73840 19576369 RPI1-264J4 Centromeric 
20647784 20650871 RP11-101P17 Telomeric 
21099552 21102154 RP11-271B5 Telomeric 
24216405 24219032 RP11-534K14 Telomeric 
28478469 28671391 RP11-60N6 Telomeric 
34899905 335090902 RP11-98D3 Telomeric 
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Fig 2.11 A BAC clone that spans the 13g12.1 breakpoint (RPII-172H24). FISH mapping of 
chromosome breakpoint in t(5; 13) metaphase spreads. The green signals are from the chromosome 5 
telomere marker. BAC clone RPII-172H24 that was mapped crossing the 13q breakpoint gave red 
signals on normal chromosome 13, derivative chromosome 5 and derivative chromosome 13. The red 
signal on derivative chromosome 5 is fainter than the one on derivative chromosome 13. 
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2.4.6 Results of clones mapped to the translocation breakpoint around the 14q32 
region 
Preliminary work done by E. T. Tonkin and M. Smith found that the marker 
D14S865 mapped centromeric to the 14q breakpoint. By query on the MapViewer 
(http: //www. ncbi. nlm. nih. gov/mapview) the marker hit the BAC clone RP11-860p12 
on the 14q32 region. FISH mapping assigned the clone centromeric to the 
translocation breakpoint. Moreover, another marker, D14S1227, mapped telomeric to 
the breakpoint. An inquiry on the MapViewer arrived at the BAC clones RP11-894P9 
and RP11-600F2. FISH mapping showed that BAC clone RP11-600F24 is mapped 
telomeric to the breakpoint on 14q. Based on these results, we selected BAC clones 
located between these 2 BAC clones suggested by MapViewer as probes to narrow 
down the breakpoint. Through step-by-step FISH mapping, we showed that 
RP11-796G6 and RP11-1017G21 mapped most closely to the breakpoint, centromeric 
and telomeric, respectively. 
According to the results from the genome browser, CID-2017C7 should be 
crossing the translocation breakpoint in 14q. However, ongoing FISH mapping by 
using CTD-2017C7 as a probe showed that clone CTD-2017C7 is mapped outside of 
chromosome 14. It is more likely to be located in chromosome 19. Nevertheless, 
research on the human genome resource failed to find another BAC clone that 
encompasses the segment covered by CTD-2017C7. The only clone that we could 
find is RP11-10e13, which encompasses about 3/4 of the region covered by clone 
CTD-2017C7 and was mapped telomeric to the breakpoint. Nevertheless, there still 
existed a gap of 50kb between clones RP11-796G6 and RP11-10e13. To overcome 
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this problem, we considered to perform cosmid library screening to choose cosmid 
clones for mapping. At that time, we found a patient-specific mutation in the gene 
located in the 5p13 translocation breakpoint. Moreover, in this same patient with a 
t(14; 21) balanced translocation, a mutation was found in the NIPBL gene (Gillis et al., 
2004) and also in the patient with a t(3; 17) de novo translocation that we had studied 
for a long time (by TJ Wang and ET Tonkins). Thus, this region was not considered a 
potential candidate for the gene responsible for CdLS. 
The results of mapping clones to the 14q32 breakpoint region by FISH on t(14; 21) 
metaphase chromosome spreads are shown in Table 2.3. See Figures 2.11 and 2.12 for 
examples of clones mapped telomeric and centromeric to the chromosome 14q 
breakpoint, respectively. 
Table 2.3 Results of mapping clones to the 14q32 breakpoint region by FISH 
Start(bp) End(bp) Clone name Position relative 
to the breakpoint 
100980568 101190341 RP 11-1029J19 Centromeric 
101069362 101274469 RP11-796G6 Centromeric 
50kb gap 
101330K 101510K RP11-10E13 Telomeric 
101225028 101416143 CTD-2017C7 Telomeric 
101407260 101604130 RP11-1017G21 Telomeric 
101652975 101774270 CTD-2273N 11 Telomeric 
102583047 102777508 RP11-736N17 Telomeric 
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Red bars indicate the 
breakpoint on the 
corresponding 
14 21 
chromosomes 
Fig 2.12 A BAC clone mapped centromeric to the 14q32 breakpoint (RPII-796G6). FISH mapping of 
chromosome breakpoint in the t(14; 21) metaphase spreads. BAC clone RP I 1-796G6 that was mapped 
centromeric to the 14q breakpoint gave red signals on normal chromosome 14 and derivative 
chromosome 14, respectively. 
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Fig 2.13 A BAC clone mapped telomeric to the 14q32 breakpoint (RPII-10e13). FISH mapping of 
chromosome breakpoint in t(14: 21) metaphase spreads. BAC clone RP II -10e l3 that was mapped 
telomeric to the 14q breakpoint gave red signals on normal chromosome 14 and derivative 
chromosome 21, respectively. 
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2.5 DISCUSSION 
In the beginning, the CdLS phenotypes involving multiple organ systems enabled 
us to consider it as a microduplication or microdeletion syndrome affecting several 
genes. However, a whole genome high-density BAC microarray comparative genomic 
hybridization screen found no evidence for a consistent pattern of microdeletion or 
micropuplication in a panel of 11 classical CdLS patients (H. Fiegler and N. Carter, 
personal communication; subsequently published in Tonkin et al., 2004b). Thus, we 
considered microdeletion or microduplication an unlikely cause of CdIS. After the 3q 
breakpoint had been exhaustively analysed, other lab members also defined the 17q 
breakpoint, but no obvious candidate genes mapped in the vicinity of this breakpoint 
(Tonkin et al, 2004b). These conclusions prompted investigation of the other two de 
novo balanced translocation cases. The 21q breakpoint was expected to map to a gene 
desert and most attention was based on progressive FISH mapping to identify clones 
that spanned the 5p, 13q and 14q breakpoints. 
2.5.1 Power of bioinformatics 
With the completion of the Human Genome draft, the choice for the BAC clone 
used for high-resolution FISH mapping has become more straightforward. Scientists 
can now save lots of time by spending hours in front of the computer and querying the 
necessary information through the Internet. (Tilghman, 1996). Once a candidate 
chromosome region has been pinpointed, candidate genes can be identified from 
within that region. As the more novel human genes have been identified, the task of 
identifying candidates has become easier. Once the contig across the candidate region 
has been established, the next step is to catalog the genes within. Genome browsers 
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such as Ensembl (http: //www. ensembl. org) and the UCSC. genome browser 
(http: //genome. cse. ucsc. edu) are frequently used to display and analyze all the definite 
and possible genes in the candidate region. From the lists of genes that have been 
mapped to the candidate region, it is possible to look for a gene that has the 
appropriate expression and/or appropriate function. Furthermore, one can investigate 
the possibility of significant sequence homology to some other human or nonhuman 
genes that have similar expressions or functions, and to identify other animal models 
related to the gene of interest and see if there are mutants with related phenotypes. 
After gaining a greater understanding of the structural and functional homologies 
extending across different species, even distantly related species like Drosophila or 
yeast, the top candidates can be shortlisted from multiple candidate genes. 
Nevertheless, the data needs to be interpreted with great caution. In general, the 
genomic DNA sequence is very accurate, but the exons of a gene can be dispersed, 
complicating the identification of transcripts. Although the cDNA sequence is a good 
source of transcript information, cDNAs are often incomplete and seldom extend to 
the 5'end. Expressed sequence tags (ESTs) are single-pass sequencing reads generated 
from either the 5' or 3' end of a cDNA clone. Due to the paucity of full length cDNA 
sequences and the abundance of ESTs, several groups have used these sequences to 
assemble electronic transcripts such as Unigene, STACK and HGI data sets. However, 
the relative abundance of various types of data varies greatly. The amount of genomic 
DNA identified as a coding region is limited as is the number of full length cDNA 
insert sequences. The most abundant source of gene information is the ESTs data. The 
advantage of using ESTs is that a large number of ESTs derive from different tissue 
and different developmental and disease states. The disadvantage of using ESTs is that 
many of them have low-quality sequencing reads. Efforts made by most of the groups 
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working on the electronic assembly of the ESTs into transcripts are trying to prevent 
the incorporation of very low quality ESTs and non-gene sequences (Bouck et al., 
1999; Miller et al., 1999). However, not all the clustering databases contain the same 
information and consensus sequences. So in our project, we consulted many database 
providers and found that the original IDN3 was a gene fragment, as the first 9 exons 
are missing in the transcript described both in Ensembl and the NCBI genome 
browsers. However, with the help of the ESTs databases, we identified at least two 
clones (AJ627564 and BX640644) that were partially overlapping with the original 
IDN3 at their 3'end. Also with the in-house sequences of the clones, this allowed us to 
extend the gene from the original IDN3A to 47 exons (46 exons for IDN3 B). 
2.5.2 Assignment of clones relative to the chromosome breakpoints using 
standard chromosome FISH 
Standard color FISH on metaphase chromosomes from the t(5; 13) metaphase 
spreads was successful in mapping clones relative to the chromosome 5 and 
chromosome 13 breakpoints. Unfortunately, no BAC clone that spanned the 
breakpoint in t(14; 21) metaphase spreads was identified, but the data suggest that the 
gap around the translocation breakpoint in the 14q region was narrowed down to 
50kb. 
2.53 Clues from the linkage studies 
In December 2002 the Krantz group informally communicated the results of their 
genome wide linkage studies (which had included families supplied by the Newcastle 
group). Their data indicated that five regions of the genome could not be excluded and 
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so were candidate CdLS gene regions: 3q13; 8p21.3-p23.1; 10pll. 23-pl2.31; 14q21.2; 
and 17p13.2-13.3 (see Table 2.4). However, in July 2003, a member of the this group 
showed a summary slide of their linkage data at the world CdIS meeting in Sydney, 
Australia where it was revealed, unexpectedly, that 5p13 was now considered to be 
one of five likely locations for a CdIS gene. At the same time, FISH mapping of the 
metaphase spreads in a patient with the t(5; 13) translocation showed that a novel gene, 
at that time named IDN3, was likely to be disrupted by the translocation in that patient. 
Also in 2003 ,a CdLS case with deletion involving 5p13.1 was reported at the 
American Human Genetics Society annual meeting (Hulinsky et al., 2005). The 
surprising revelation from the linkage data that 5p13 could now be considered a 
possibility, but especially the report of a fetus resembling CdLS with interstitial 
del(5)(p13.1p14.2) chromosome derangement prompted targeting of the 5p13.1 area 
as a top priority. The gene fragment, IDN3, which mapped just proximal to the 5p13 
breakpoint in the t(5; 13) translocation was of particular interest since it is involved in 
long distance regulation of the cut phenotype in Drosophila and is evolutionally well 
conserved. 
87 
Table 2.4 Linkage analysis of genome-scan data In 10 pedigrees (data provided by Dr. 
Ian Krantz, pers. Comm. ) 
Marker cM Lods alpha HLods NPL p-val Information 
d3s1271 117 -0.96 0.71 0.93 1.33 0.09 0.90 
118 0.59 0.75 0.97 1.31 0.09 0.87 
119 1.01 0.85 1.08 1.33 0.09 0.79 
120 1.22 0.96 1.22 1.35 0.09 0.75 
121 1.35 1.00 1.35 1.37 0.09 0.72 
122 1.45 1.00 1.45 1.40 0.09 0.70 
123 1.51 1.00 1.51 1.42 0.08 0.70 
124 1.55 1.00 1.55 1.45 0.07 0.70 
125 1.54 1.00 1.54 1.47 0.07 0.73 
126 1.49 1.00 1.49 1.50 0.07 0.76 
127 1.35 0.97 1.34 1.53 0.07 0.82 
d3s1278 128 0.88 0.78 1.15 1.57 0.06 0.90 
Marker cM Lods alpha HLods NPL p-val Information 
d8s550 16 -2.22 0.72 1.23 1.68 0.05 0.90 
17 1.30 0.85 1.39 1.69 0.05 0.78 
18 1.57 0.99 1.57 1.69 0.05 0.70 
19 1.72 1.00 1.71 1.69 0.05 0.64 
20 1.80 1.00 1.80 1.70 0.05 0.60 
21 1.85 1.00 1.84 1.71 0.04 0.58 
22 1.86 1.00 1.86 1.72 0.04 0.56 
23 1.85 1.00 1.85 1.73 0.04 0.56 
24 1.79 1.00 1.79 1.74 0.04 0.58 
25 1.68 1.00 1.68 1.76 0.04 0.60 
26 1.45 0.93 1.46 1.77 0.04 0.65 
d8s549 27 -1.99 0.75 1.23 1.79 0.04 0.74 
Marker cM Lods alpha HLods NPL -val Information 
d10s548 46 -0.65 0.72 0.99 1.74 0.04 0.85 
47 1.55 1.00 1.54 1.75 0.04 0.82 
48 1.86 1.00 1.86 1.79 0.04 0.79 
49 1.99 1.00 1.99 1.83 0.04 0.78 
50 2.06 1.00 2.06 1.87 0.03 0.78 
51 2.09 1.00 2.09 1.92 0.03 0.81 
d10s197 52 2.10 1.00 2.10 1.98 0.03 0.86 
53 2.06 1.00 2.06 1.94 0.03 0.82 
54 1.98 1.00 1.98 1.86 0.03 0.77 
55 1.91 1.00 1.91 1.78 0.04 0.73 
56 1.82 1.00 1.82 1.70 0.05 0.72 
57 1.73 1.00 1.72 1.63 0.05 0.71 
58 1.61 1.00 1.61 1.56 0.07 0.72 
59 1.47 1.00 1.47 1.49 0.07 0.75 
60 1.28 0.95 1.28 1.43 0.07 0.79 
61 0.96 0.80 1.08 1.37 0.09 0.85 
d10s208 62 -2.40 0.68 0.93 1.32 0.09 0.96 
Marker cM Lods alpha HLods NPL p-val Information 
d14s288 40 -3.87 0.33 0.13 0.61 0.27 0.88 
41 -0.29 0.51 0.30 0.76 0.23 0.84 
42 0.45 0.75 0.57 0.91 0.19 0.79 
43 0.87 0.93 0.87 1.06 0.15 0.76 
44 1.17 1.00 1.17 1.21 0.12 0.75 
45 1.40 1.00 1.40 1.37 0.09 0.74 
46 1.59 1.00 1.59 1.52 0.07 0.75 
47 1.76 1.00 1.76 1.68 0.05 0.77 
d14s276 48 1.90 1.00 1.90 1.84 0.04 0.81 
49 1.91 1.00 1.91 1.80 0.04 0.75 
50 1.91 1.00 1.91 1.76 0.04 0.71 
51 1.90 1.00 1.90 1.72 0.04 0.68 
52 1.89 1.00 1.89 1.68 0.05 0.66 
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53 1.87 1.00 1.87 1.64 0.05 0.65 
54 1.84 1.00 1.84 1.61 0.05 0.64 
55 1.81 1.00 1.81 1.57 0.06 0.64 
56 1.77 1.00 1.77 1.54 0.07 0.65 
57 1.71 1.00 1.71 1.50 0.07 0.66 
58 1.63 1.00 1.63 1.47 0.07 0.68 
59 1.54 1.00 1.53 1.44 0.07 0.71 
60 1.39 1.00 1.39 1.40 0.08 0.74 
61 1.16 0.88 1.19 1.37 0.09 0.79 
d14s63 62 0.53 0.73 1.03 1.34 0.09 0.86 
Marker cm Lods alpha HLods NPL -val Information 
d17s831 6 -1.63 0.79 1.67 2.73 0.00 0.97 
7 1.90 0.96 1.90 2.67 0.00 0.90 
8 2.08 1.00 2.08 2.60 0.00 0.86 
9 2.14 1.00 2.14 2.55 0.01 0.84 
10 2.12 1.00 2.12 2.49 0.01 0.82 
11 2.07 1.00 2.07 2.45 0.01 0.82 
12 1.96 1.00 1.96 2.40 0.01 0.82 
13 1.79 1.00 1.79 2.36 0.01 0.83 
14 1.48 0.97 1.48 2.33 0.01 0.86 
d17s938 15 -1.65 0.74 1.15 2.30 0.01 0.92 
The size of the candidate regions listed above are as follows: 
Region Distance sp anned Approximate number of genes contained 
3q13 -10 Mb over 30 genes, 
17 13.2-13.3 -6Mb over 53 genes 
8 21.3- 23.1 --10Mb over 40 genes 
10 11.23- 12.31 -13Mb over 50 genes 
14 21.2 -20Mb over 100 genes. 
2.5.4 Data interpretation 
As discussed in chapter 1, chromosomal rearrangements can facilitate positional 
cloning of human disease genes. However, in some instances, the translocation 
breakpoint occurs outside of the putative gene. In these cases, the malfunction of the 
gene can be caused by a `position effect', a deleterious change in the level of gene 
expression brought about by a change in the position of the gene relative to its normal 
chromosomal environment, but not associated with an intragenic mutation or deletion. 
Thus, the transcription unit and minimal promoter of the rearranged gene are expected 
to remain intact (Kleinjan and van Heyningen, 1998). It is well known that the local 
megabase-scale chromatin organization can affect gene expression, particularly for 
genes that are located within or near the heterochromatin (Cook and Karpen, 1994). 
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Chromosomal rearrangements frequently lead to alteration of the gene's environment 
and this may be reflected in a change of expression, referred to as a position effect. A 
number of factors can affect the level of gene expression: (1) the chromosomal 
rearrangement that separates the promoter/transcription unit from a distant regulatory 
element, (2) a rearrangement may bring together the gene with an enhancer element 
from another gene, (3) the translocation can place the gene and its regulatory elements 
next to a gene located near the translocation. Competition between the disease gene 
and the second gene for the regulatory elements may result in reduction of the level of 
gene expression, (4) the rearrangement could give rise to classical position effect 
variegation (PETS) - that is, the rearrangement bring together of an euchromatic gene 
to a heterochromatic region (Cook and Karpen, 1994; Kleinjan and van Heyningen, 
1998). The position effect can stretch as far as 900Kb, as observed in POU3F4, a gene 
involved in X-linked deafness (de Kok et al., 1996). Thus, it is rational for us to 
examine genes residing within 1Mb on each side of the translocation of the 
breakpoint. 
2.5.4.1 13g12.1 region: 
2.5.4.1.1 Genes disrupted by the translocation 
As shown in the results, RP11-172H24 was mapped across the 13q12.1 
breakpoint. Human DNA sequence from clone RP11-172H24 on chromosome 13 
Contains the 3' end of the gene for polycystic kidney disease, autosomal 
recessive TG737, now termed IFT88 (intraflagellar transport 88 homolog, TTC10 in 
Fig. 2.14) and the 5' end of the IL17D gene for interleukin 17D. Mutations in mouse 
Tg737 cause random left-right axis specification, polycystic kidney disease, liver and 
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pancreatic defects, hydrocephalus and skeletal patterning abnormalities such as 
polydactyly (Taulman et al., 2001). However, the abnormal phenotypes observed in 
Tg737 are not observed in CdLS patients and together with the recessive mode of 
inheritance in Tg737, rendering Tg737 an unlikely candidate gene for de Lange 
phenotypes. Another gene, IL-17D, a member of the interleukin 17 family, is 
associated with rheumatoid arthritis, lupus, asthma and allograft rejection (Starnes et 
al., 2002). As the defects of the immune system in CdIS patients are not apparent, the 
phenotypes associated with the IL-17D mutants render this gene an unlikely candidate 
for de Lange phenotypes. 
91 
2.5.4.1.2 Genes residing 1Mb on each side of the 13gl2.1 breakpoint 
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Table 2.5 Possible function of the genes residing within a2 Mb candidate area spanning 
a translocation breakpoint at 13g12.1 
Gene Function/phenotypes References 
FGF9 Male-to-female sex Colvin et al. (Colvin et al., 
reversal in mouse model 2001) 
GRK6PS G protein-coupled 
receptor kinase 6 
pseudogene 
ESTRRA estrogen-related receptor 
alpha pseudogene 
MRP63 Helps in protein synthesis 
within the mitochondria, 
function not known 
SAP18 mediated repression of Zhang et al. (Zhang et at., 
transcription involves the 1997) 
modification of histone 
polypeptides 
LATS2 encodes a putative Yabuta et al. (Yabuta et 
serine/threonine kinase in al., 2000); McPhenrson et 
Drosophila, essential role al. (McPherson et al., 
in the integrity of 2004) 
processes that govern 
centrosome duplication, 
maintenance of mitotic 
fidelity and genomic 
stability 
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XPO4 exportin 4, function not 
known 
IL-17D As previously described 
Tg737 As previously described 
CRYL1 crystallin, lambda 1, 
function not known 
GJB6 CONNEXIN 30, codes for Dahl et al. (Dahl et al., 
the protein subunits of gap 1996) 
junction channels that 
mediate direct diffusion of 
ions and metabolites 
between the cytoplasm of 
adjacent cells 
GJB2 associated with autosomal Mese et al. (Mese et al., 
recessive neurosensory 2004) 
deafness 
GJA3 Maintains normal lens Gong et al. (Gong et al., 
transparency by providing 1997) 
a cell-cell signaling 
pathway or structural 
component for the proper 
organization of lens 
membrane and 
cytoplasmic proteins. 
ZNF198 stem cell Abruzzo et al. (Abruzzo et 
94 
leukemia/lymphoma at., 1992) 
(SCLL) syndrome 
ZMYM5 zinc finger, MYM-type 5, 
function not known 
PSPC1 paraspeckle component 1, 
function not known 
HSMPP8 M-phase phosphoprotein, 
mpp8, function not known 
ESRRAP estrogen-related receptor 
alpha pseudogene 
TPIP as a phosphatidylinositol Walker et al. (Walker et 
3-phosphatase with no al., 2001) 
activity against the soluble 
inositol phosphate 
Two CdLS patients have been described with sex reversal. One was an XX male 
with the presence of an SRY gene, which suggested X-Y interchange, indicating that 
the sex reversal and the CdLS phenotypes were co-incidental (Chen, 1994). The other 
case was an XY female without mutations in the HMG box of the SRY gene (N. 
Affara, per. comm. ). Thus we cannot exclude the FGF 9 gene as a candidate, which 
might have genetic interaction with the CdLS disease gene. 
Other adjacent genes, SAP18, LATS2, TPIP, which are associated with the basic 
chromosome functions, could not be excluded as candidates and may be considered 
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affected by the "position effect" brought by the de novo translocation in our patient 
with a t(5; 13) translocation. As described previously, the major characteristic of CdLS 
phenotypes is general growth deficiency. And the growth deficiency is profound in 
CdLS with a t(5; 13) translocation. Thus, the genes described here might be affected 
through the "position effect" in this patient. However, this requires further 
experiments in order to be proven, which can only be undertaken if further patient 
samples are available. 
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2.5.4.2 Genes residing 1Mb on each side of the 14q32 breakpoint 
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Table 2.6 Possible function of the genes within the 2Mb candidate area (14g32) 
Gene Function/phenotype References 
CDC42BPB CDC42 binding protein 
kinase beta (DMPK-like), 
function not known 
AMN Autosomal recessive Aminoff et al. (Aminoff 
hereditary megaloblastic et al., 1999) 
anemia 
TRAF3 a member of the tumor Hu et al. (Hu et al., 1994) 
necrosis factor receptor 
(TNFR) family 
RPL23AP11 ribosomal protein L23a 
pseudogene 11 , 
function 
not known 
RCORI encodes a functional Lunyak et al. (Lunyak et 
corepressor required for al., 2002) 
regulation of 
neural-specific gene 
expression 
ANKRD9 ankyrin repeat domain 9, 
function not known 
CINP cyclin-dependent kinase 
2-interacting protein, 
function not known 
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RAGE Renal tumor antigen Gaugler et al. (Gaugler et 
al., 1996) 
WDR20 WD repeat domain 20, 
function not known 
HSPCA reduced activity of Hsp90 Sollars et al. (Sollars et 
induces a heritably altered al., 2003) 
chromatin state in 
Drosophila 
DNCH] transmitted as autosomal Hafezparast et al. 
dominant traits and give (Hafezparast et al., 2003) 
rise to age-related 
progressive loss of muscle 
tone and locomotor ability 
in heterozygous mice 
without a major reduction 
in life span in mouse 
PPP2R5C Protein phosphatase 2A McCright et al. (McCright 
(PP2A), a heterotrimeric and Virshup, 1995) 
serine/threonine 
phosphatase, has been 
implicated in a variety of 
regulatory processes 
including cell growth and 
division, muscle 
contraction, and gene 
99 
transcription 
NPMJP20 nucleophosmin 1 
(nucleolar phosphoprotein 
B23, numatrin) 
pseudogene 20 
RPL26P4 ribosomal protein L26 
pseudogene 4 
DI03 Thyroxine Deiodinase, Huang et al. (Huang et al., 
Type 111, congenital 2000) 
hypothyroidism 
MEG3 Maternally expressed Miyoshi et al. (Miyoshi et 
gene 3 al., 2000) 
DLK1 inhibition of adipogenesis Smas et al. (Smas and Sul, 
1993) 
PPP2R5C can be considered as a potential candidate as it is involved in the cell 
growth and division. However, (Gillis et al., 2004) found a nonsense mutation in the 
CdLS patient with t(14,21) balanced translocation. Thus, the 14q32 qnd 21g11 regions 
did not have any strong case to be included as regions containing candidate CdLS 
genes. 
2.5.4.3 5p 13 region: 
For all the candidate regions, we found that the 5p breakpoint had top priority for 
harboring the CdLS disease gene after report of a CdLS fetus with interstitial 
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deletion involving 5p13.1 (Hulinsky et al., 2005). The genes residing within 1Mb of 
the 5 p13.1 translocation break-point are summarized below: 
I IL7R 
4GC26610 
FLJ34658 
LOC167127 
OKF2º434.. 
J LKP2 
FLJ30596 
FLJ25422 
I SLC1R3 
N PDL 
L0C391777 
FLJ13231 
. OfDIP1 L0C441468 
rw iss 
FL310233 
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Table 2.7 Genes located within the 2Mb candidate region (5p13.1) 
Gene Function/phenotype References 
GDNF promoted the survival and 
differentiation of 
dopaminergic neurons in 
rat embryonic midbrain 
cell cultures, rescued 
avian motor neurons from 
programmed cell death, 
Lin et al. (Lin et al., 
1993); Oppenheim et al. 
(Oppenheim et al., 1995); 
Boucher et al. (Boucher et 
al., 2000); Eketjall et al. 
(Eketjall and Ibanez, 
2002). 
reduced ectopic 
discharges within sensory 
neurons after nerve injury 
in mouse model, 
promoted the migration of 
neural crest stem cells, is 
associated with human 
Hirschsprung disease 
NUPJ55 involved in bidirectional Gorlich et al. (Gorlich and 
trafficking of molecules, Mattaj, 1996) 
especially mRNAs and 
proteins, through the 
nuclear pores between the 
nucleus and the cytoplasm 
in eukaryotic cells 
OFDJP1 OFD1 pseudogene 1 
NIPBL Described in the text 
SLC1A3 reuptake of secreted 
amino acid 
neurotransmitter, possibly 
maintaining extracellular 
amino acid concentrations 
at nontoxic and 
nonepileptogenic levels; 
related to the syndrome of 
microcephaly and mental 
retardation observed in 
association with 
interstitial deletion of 
Keppen et at. (Keppen et 
al., 1992); (Shashidharan 
et al., 1994) 
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distal band 5p13 
SKP2 CDK2/cyclin A associated Bai et at. (Bai et at., 1996) 
protein 45, binds to cyclin 
F and potentially to other 
regulatory proteins that 
may be involved in 
ubiquitin proteolysis 
through its F box 
CAPSL calcyphosine-like , 
function not known 
IL 7R encoded a secreted form Goodwin et al. (Goodwin 
of the receptor capable of et al., 1990) 
binding IL7 in solution 
Of all the genes listed above, IL7R and GDNF were not considered potential 
candidates since immunodeficiency and the Hirschsprung disease (MIN 142623) are 
improbable major characteristics for CdLS phenotypes. However, we could not 
exclude NUP155, SLCIA3, SKP2 as potential candidates, that could be 
inappropriately expressed in the t(5; 13) translocation case through a "position effect". 
As described in chapter 1, most of the CdLS patients have phenotypes of growth 
retardation, microcephaly and mental retardation. As most of the genes listed above 
are expected to have either associated cell-cycle functions or related to neuronal 
function, it was reasonable to consider them as potential candidates. However, it was 
impossible for us to test such assumptions because we had limited material to study, 
because the cell line established from the t(5; 13) translocation case was a fibroblast 
cell line. 
As the NIPBL gene was disrupted by the translocation, we considered it the most 
compelling CdLS candidate gene within the 5p13.1 2Mb candidate region. This 
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reasoning was based on: (1) The NIPBL gene encodes the homolog of the Drosophila 
melanogaster Nipped-B gene product that is known to be important in regulating 
various developmentally significant genes, including genes such as cut and 
Ultrabithorax that are involved in limb development, and fungal Scc2-type sister 
chromatid cohesion proteins, The CdLS phenotypes involve multiple organs and 
systems and are assumed to be a result of defect occurring during early human 
development. The severe growth retardation and limb defects observed in classic 
patients with CdIS suggest that the disease gene might have functions related to cell 
proliferations and wide-range developmental regulation. (2) The protein sequences of 
the NIPBL gene product, delangin, are well conserved among different species. The 
possible association of the CdLS phenotype with the Drosophila mutants prompted us 
to perform mutation screening in the NIPBL gene. 
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2.6 CONCLUSION 
Through sequential rounds of chromosome FISH mapping, genes spanning the 
various breakpoints of the three translocation cases were identified. Of all of these, the 
gene severed by the 5p13 translocation breakpoint, appeared the strongest CdIS gene 
candidate. 
We considered NIPBL the top priority for ongoing mutation due to (1) evidence 
of linkage to the 5p13.1 region (Krantz et al. world CdLS meeting in Australia, per. 
comm. ); (2) report of the CdIS case with interstitial deletion involving 5p13.1 
(ASHG annual meeting, 2003); (3) NIPBL being found to be disrupted in our patient 
with de novo balanced t(5; 13) translocation; (4) potential phenotype overlap in 
Drosophila model with CdLS (Rollins et al., 1999); (5) the sequences of the NIPBL 
gene product, delangin, being well conserved among different species (see chapter 3). 
Due to the large number of coding exons and the large size of some of the exons 
(notably exons 9 and 10), mutation screening posed a considerable challenge both in 
terms of time and expense. As mutation screening in large genes is time consuming 
and the cost is high, a detailed and thoughtful investigation of the information that 
databases provide is very important nowadays. We therefore had to select the ideal 
mutation screening method for our giant NIPBL gene, which initiated our mutation 
screening sessions discussed in further detail in Chapter 3. 
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CHAPTER 3: MUTATION SCREENING OF THE NIPBL GENE 
LOCATED WITHIN 5pl3.1 
3.1 INTRODUCTION 1VIPBL AS CANDIDATE FOR CDLS 
As described in Chapter 2, we considered NIPBL as the top priority for mutation 
screening. NIPBL has two isoforms; the longer isoform A consists of 47 exons that 
specify a 2804 a. a. polypeptide; and the shorter isoform B consists of 46 exons that 
encode a 2697 a. a. polypeptide. The predicted A and B polypeptide isoforms have a 
common sequence from a. a. 1 to a. a. 2683 but differ at the extreme C-terminus ends. 
The transcription start site is in Exon 2. Because of the large number of coding exons 
and the large size of some of the exons (notably exons 9 and 10), mutation screening 
posed a considerable challenge both in terms of time and expense. 
3.2 APPROACHES TO MUTATION SCREENING 
The ideal mutation screen method should consist'of the following features: (1) 
ability to scan kilobase lengths (2) a 100% detection rate (3) no false positives or 
negatives (4) usage of a single step (5) no complex equipment or facilities (6) no 
harmful reagents (7) no electrophoresis (8) high throughput (9) low elapse and little 
bench time (10) mutation identification (11) low cost (Cotton, 1997). Hence, we 
considered DHLPC a very promising method for mutation screening. However, due to 
the cost and facilities available then, our initial screening method consisted of single 
strand conformation polymorphism and gel-based heteroduplex analyses for 
fragments of less than 400bp. Also, direct sequencing was employed for apparent 
shifts and larger fragments (Petersen et al., 1994). Primers were designed to span the 
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exon-intron boundary to detect the splice site mutations. Every time a sample 
demonstrated the presence of a deletion or insertion by the reading of the chromogram 
from the sequencing results, the PCR product was cloned into vector pGem-T easy 
vector systems (Promega) and a number of transformants were sequenced to confirm 
the change. All mutations were re-amplified and re-sequenced to confirm that the 
change observed was not the result of base mis-incorporation by the Taq polymerase. 
Parental DNA, where available, was analyzed to confirm that the observed mutation 
had occurred de novo in sporadic cases or in familial cases if the mutation was 
inherited. For each of the mutations, 200 normal chromosomes were also screened. 
3.2.1 Single strand conformation polymorphism (SSCP) 
Orita et al. (Orita et al., 1989) developed the PCR-SSCP method as a rapid and 
sensitive method to detect mutations or polymorphisms in DNA. PCR is used to 
amplify the region of interest. The resultant PCR product is heat denatured and 
separated as single-stranded molecules by electrophoresis in a non-denaturing 
polyacrylamide gel. The mutations or polymorphisms can be detected 
electrophoretically as mobility shifts in non-denaturing gel resulting from a change in 
the conformation of single stranded DNA. The change in the mobility shift depends 
on the secondary structure that may be altered by a single nucleotide substitution. The 
mutations are detected as the appearance of new bands on autoradiograms (radioactive 
detection), by silver staining of bands or the use of fluorescent PCR primers. These 
are subsequently detected by an automated DNA sequencer (non-radioactive 
detection). 
Mutation detection for PCR-SSCP is around >80% in a single run for fragments 
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shorter than 300bp (Hayashi and Yandell, 1993). However, the sensitility for 
fragments larger than 400bp is decreased. There are two major structural factors 
responsible for the reduced mutation detection rate in long amplicons. The first is 
increased contribution from other secondary structure modules and domains in longer 
fragments, which mask the structural change induced by the mutation. The second is 
higher frequency of single-nucleotide polymorphisms (SNPs) including common 
polymorphisms in longer fragments. Since the sensitility for mutation detection is not 
100%, the nonappearance of a new band does not prove the absence of a mutation in 
the analyzed fragments. 
3.2.2 Heteroduplex Analysis (HET). 
Heteroduplexes are generated by heat denaturation and reannealing of a mixture 
of wild type and mutant DNA molecules. In nondenaturing polyacrylamide gels, 
homoduplexes and heteroduplexes exhibit distinct electrophoretic mobilities. They are 
detected by ethidium bromide or silver staining. The optimal fragment length for 
heteroduplex analyses is between 200 and 600 bps. The detection of mutations mainly 
depends on the position and type of mismatch. The sensitivity of HET analyses is 
around 80%. However, through the combination of SSCP, HET, running on the same 
gel, and adjustments of the temperature, gel composition, ionic strength and additives, 
the mutation detection rate can be as high as 97.5% (Liechti-Gallati et al., 1999). 
3.2.3 PCR Direct sequencing 
PCR direct sequencing is an efficient method providing more sequence data in 
limited lab time. Indeed, there are some distinct advantages to this approach. However, 
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some drawbacks of direct sequencing have to be recognized. They include (1) 
amplification of the wrong fragments (2) unclear removal of residual PCR primers 
and unincorporated nucleotides (3) inadequate design of primers for automated 
sequencing (4) excessively high concentration of DNA. However, direct sequencing 
is quicker and more accurate and has much less PCR mutations by cloning artifacts 
compared with the cloned based sequencing methods. Moreover, the cost for the 
sequencing kits has recently decreased considerably. Thus, direct sequencing has 
become a mainstream for large scale mutation screens (Rao, 1994). 
3.2.4 Cloning of PCR product into the pGem-T easy system 
We employed the pGEM®-T Easy Vector System as the RCP product cloning 
system, which is a convenient system for cloning PCR products. The vectors are 
prepared by adding a 3' terminal thymidine to both ends. These single 3'-T overhangs 
at the insertion site greatly improve the efficiency of ligation of a PCR product into 
the plasmids by preventing recircularization of the vector and providing a compatible 
overhang for PCR products generated by certain thermostable polymerases (supplier's 
manual). 
The high copy number pGEM®-T Easy Vectors contain T7 and SP6 RNA 
polymerase promoters flanking a multiple cloning region within the a-peptide coding 
region of the enzyme ß-galactosidase. Insertional inactivation of the a-peptide allows 
recombinant clones to be directly identified by color screening on indicator plates 
(supplier's manual). Thus, the recombinants will appear as white colonies and the 
non-recombinants will appeared as blue colonies. This enabled us to select clones for 
further sequencing. The pGEM-T Easy vector also contains the origin of replication of 
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the filamentous phage fl for the preparation of single-stranded DNA. We presumed 
that the changes observed in NIPBL gene in CdIS patients would be heterozygous as 
most of the familial cases suggested an autosomal mode of inheritance. Particularly 
when a deletion or insertion is observed, confirmation of the clones with 
single-stranded DNA product is very important for interpreting the data. 
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Xmn 12009 
N I ae Sca 11890 2707 T7 
I start 
fl orl Apa 1 14 
Aat II 20 
Sph1 26 
BstZ1 31 
Ampr Nco1 37 
PGEM`-T Easy lacZ BstZ 1 43 
Vector T7 Not 1 43 
(3015bp) Sac II 49 EcoR 1 52 
Spe1 64 
EcoR 1 70 
Not 1 77 
BstZ 1 77 
Pst1 88 
on &111 90 
Nde 1 97 
Sac1 109 
BstX I 118 
Nsi I 127 
141 
SP6 
Fig 3.1 Map of the pGem-T-Easy Vector. The pGEM®-T Easy Vector contain multiple restriction sites 
within the multiple cloning region. These restriction sites allow for the release of insert by digestion 
with a single restriction enzyme. The pGEM®-T Easy Vector multiple cloning region is flanked by 
recognition sites for the restriction enzymes EcoR BstZ I and Not I, thus providing three single-enzyme 
digestions for release of the insert. 
117 
33 MATERIALS AND METHODS 
3.3.1 Materials 
The sample of CdIS patients selected for the screening consisted of 68 patients 
that were divided into three groups. These included 63 sporadic and 2 familial cases. 
The study population also included 2 previously reported, unrelated cases with de 
novo balanced translocation cases involving t(3; 17) and t(14; 21) respectively. Most of 
the cases are of Caucasian ethnic origin except for two that were of Arabic origin. All 
the DNA samples were extracted from blood lymphocytes from the referring centres. 
3.3.2Amplification of exons from the NIPBL gene 
PCR primers were designed from the intronic regions flanking the exon-intron 
boundaries by using the primer designing program Primer 3 
(http: //frodo. wi. mit. edu/cgi-bin/primer3/primer3). The amplification reactions were 
carried out on DNA attained from 45 patients diagnosed with CdLS. We first analyzed 
exons from the 3' end, since its sequences were more conserved among different 
species. PCR amplifications for each exon were carried out in a 204a I reaction for 
short exons that allow a single reaction to amplify them. For long exons, sets of 
primers were designed and amplified in several reactions. For every amplification, a3 
,u1 aliquot of each PCR product was analyzed on 1% agarose gel to ensure a single 
band before being used for SSCP, heteroduplex, or direct sequencing analyses. 
However, amplification was hindered by the high quanidine/cytosine content of some 
exons. To overcome this problem, DMSO (dimethyl sulphoxide) was added to the 
reaction in the concentration of 7.5%. This helps to maintain the single stranded state 
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during the elongation reaction and thereby allows the use of more stringent 
amplification conditions to produce specific products. The sequences of PCR primers 
for the NIPBL gene mutation detection were listed in Appendix A. 
3.3.3 Single stranded conformation polymorphism (SSCP) and heteroduplex gel 
mobility shift analyses 
3.3.3.1 Preparation of the gel and electophoresis of the samples 
SSCP and heteroduplex analyses were carried out simultaneously on a single 
non-denaturizing polyacryamide gel using the PROTEAN II xi system and PowerPac 
3000 power supply. Polyacryamide gels are formed by co-polymerization of 
polyacryamide and bis-acryamide (N. N'-methylene-bis-acryamide), initiated by 
TEMED (tetramethylethylenediamine) and APS (ammonium persulphate). Gels used 
in our experiments contained 1x MDE (Mutation detection enhancement) gel solution 
and 5% glycerol. 
To make two 2x MDE gel for 40 samples per gel tank, 80 ml of gel mixture was 
prepared by mixing 40m1 2x MDE gel solution, 8m1 of 50% glycerol, 4.8ml 1OxTBE 
buffer (0.89M Tris base, 0.89M orthoboric acid, 0.02M EDTA p'1 8), 27.2m1 dH2O, 
480't 1 10% (w/v) APS and 4.8 ,u1 TEMED. A 200x200x1.5mm gel was then poured 
quickly and a comb was inserted to produce the wells. The gel was allowed to set for 
at least 1 hour before being assembled into clamps for running. Prior to loading the 
samples, the combs were removed from the gel and rinsed with 0.6xTBE buffer by 
using a small plastic pastette. 
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A5u1 aliquot of each PCR product was mixed with 5, u I denaturing buffer (95% 
formamide, 20mMEDTA, 20mM NaOH, 0.025% bromophenol blue, 0.025% xylene 
cyanol) in a 96 wee microtiter plate. The DNA was denatured by heating at 95°C for 
5 minutes and snap cooled on ice. Each sample was loaded into a separate well of the 
gel using a long gel-loading pipette tip. The gel plates were sealed onto the gel 
cooling core and placed in the lower buffer chamber containing approximately 1.2 
litres 0.6xTBE buffer. The upper buffer reservoir was filled with 0.6xTBE buffer, the 
lid attached to the apparatus and then connected to the power supply. The gels were 
run at 250W, 140V for 1 hour, then at 250W, 300V at 4°C for more than 16 hours. 
The duration for the gel running depends on the size of the amplified PCR products 
and until denaturing loading dye runs to the bottom of the gel plates. 
3.3.3.2 Silver staining 
After electrophoresis, DNA was visualized on the gel by silver staining. The gel 
apparatus was dissembled and the gel was carefully transferred to a plastic tray. The 
gel was fixed by incubating in solution I (10% ethanol, 0.5% acetic acid) twice for 3 
minutes each, upon which the solution was discarded. Next, the gel was immersed in 
solution II (0.1% aqueous silver nitrate) for 15 minutes and rinsed quickly in two 
changes of distilled water. Solution II can be collected and stored in the dark at 4 °C, 
and can also be re-used up to 8 times. After the meticulous rinsing, the gel was then 
incubated in solution III (aqueous solution of 1.5% sodium hydroxide, 0.15% 
formaldehyde, freshly prepared before use) for 20 minutes. Solution III was 
subsequently discarded. Finally, the gel was incubated with solution 1V (0.75% 
aqueous solution of sodium carbonate), upon which solution IV was also discarded. 
During all the steps, the gel was shaken gently and kept submerged. For long term 
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storage, each gel was sealed in BIORAD GelAir cellophane support membrane and 
dried. 
3.3.4 Direct sequencing of PCR products 
3.3.4.1 Enzymatic purification of PCR products 
The amplified PCR products for cycle sequencing were purified by enzymatic 
clean-up method to remove residual oligonucleotides and dNTP's (Kim JB, 2001). For 
each of 3, u I aliquot of PCR product, a2uI aliquot of the enzyme mixture containing 
0.1µl of Exonuclease I (20u/, u1, NEB), 0.1, u1 of Shrimp Alkaline Phosphatase (lu/µl, 
Promega) and l. 8µ1 of buffer (50mM Tris-Cl Buffer, pH 8.0) was added. The mixture 
was incubated at 37°C for 20 minutes and then heat inactivated at 80°C for a further 
20 minutes. 
3.3.4.2 Cycle sequencing 
The system we used for sequences analyses was the MegaBACE 1000 DNA 
Analysis System. It is a high-throughput, fluorescence-based DNA system utilizing 
capillary electrophoresis with up to 96 capillaries operating in a parallel manner. The 
system performs sample injection, gel matrix replacement, DNA separation, detection, 
and data analysis, offering unparalleled flexibility. The sequencing kit used in our 
experiments was DYEnamic ET Terminator Kits for MegaBACE. 
For direct PCR sequencing, once treated with Exonuclease I and Shrimp Alkaline 
Phosphoptase, 3-5 ,i1 of the purified PCR product was mixed with 8 ,u1 of 
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DYEnamic ET Terminators, 5 pmol of primer previously used for PCR amplification 
and distilled water to a total of 20 a1 sequencing reactions in a 96-well plate and 
mixed thoroughly by gentle vortexing. Then the plate was sealed and placed into the 
thermal cycler for 35 sequencing cycles. Terminator clean up was performed by 
propanolol precipitation. The samples were injected into MegaBACE at 2 kV for 80 
sec, and separation was carried out at 9 kV for 130 min by the in-house sequencing 
services in the Institute of Human Genetics. 
3.3.5 Cloning of PCR product into pGem-T Easy vector system: 
The pGem-T-Easy vector and the control DNA were provided by the supplier and 
the cloning procedures were under the manufacturer's instructions. Briefly, the 
ligation reaction mixtures were set up in a 0.5m1 tube as described below: 
Standard Positive Background 
reaction control control 
T4 DNA ligase (3u/ul) 1, u 11 /2 l 1, u 1 
10x ligation buffer (300mM Tris-HC1 l ,u1l 121 l 121 
pH7.8,100mM MgCl2,100mMDTT, 10mM ATP, 
10% polyethylene glycol) 
pGEM-T Easy Vector (SOng) l ,u1l ,u11 ýu 1 
PCR product X, u 1-- 
Control insert DNA - 2g l 
Deionized water 7-X ,u1 5g l 7g l 
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The amount of insert used was following the formula described below: 
ng of vector x kb size of insert x insert: vector molar ratio = ng of insert 
kb size of vector 
Most of our PCR product size is around 500bp, so the amount of PCR we used was: 
50ng vector x 0.5kb insert x3= 25ng insert 
3.0kb vector 1 
The mixtures were mixed by pipetting and were then incubated at 4°C for 
overnight. 
Meanwhile, the LB plates containing ampicillin (100 ,u g/ml), IPTG(0.5mM) and 
X-Gal (80, t g/ul) were prepared for plating the transformants. Briefly, 15g of agar 
was added to 1L of LB medium (10gm trypton, 5gm yeast extract, 5gmNaC1) and 
autoclaved. The LB medium was then allowed to cool to 50°C before adding 
ampicillin, IPTG and X-Gal. 30-35 ml of medium was pour into 85mm petridishes 
and allowed to set. The plates can be stored at 4°C to up to one month. 
Two LB/ampicillin/IPTG/X-Gal plates were prepared for each ligation reaction. 
The plates were equilibrated to room temperature before plating. The tubes containing 
the ligation reaction were centrifuged and 2u1 of the ligation reaction was added to a 
1.5ml eppendorf on ice. Frozen JM109 High Efficiency Competent Cells were 
removed from - 80°C storage and placed in an ice bath for about 5 minutes until just 
thawed. The cells were mixed by gently flicking the tube. 50µl of cells were carefully 
transferred into each tube containing the ligation reaction mixtures and mixed gently. 
The mixtures were then placed on ice for 20 minutes. Next, the cells were 
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heat-shocked for 45-50 seconds in a water bath at exactly 42°C (do not shake), upon 
which the tubes were immediately returned to ice for 2 minutes. 950µ1 of room 
temperature SOC medium (2. Og Bacto®-tryptone, 0.5g Bacto®-yeast extract, 1ml 1M 
NaCl, 0.25m1 1M KCl lml, 2M Mg2+ stock, and filtersterilized lml 2M 
glucose/100ml) was added to the tubes containing cells transformed with ligation 
reactions and 900µl to the tube containing cells transformed with uncut plasmid. The 
cells were then incubated for 1.5 hours at 37°C by shaking (-200rpm). 1O0µ1 of each 
transformation culture was plated onto duplicate LB/ampicillin/IPTG/X-Gal plates. A 
1: 10 dilution with SOC medium was also plated for the transformation control. To 
obtain a higher number of colonies, the cells were pelleted by centrifugation at 1,000 
xg for 10 minutes and resuspended in 200µ1 of SOC medium. 100µl of the 
resuspended cells were plated on each of the two plates. The plates were incubated 
overnight (16-24 hours) at 37°C. 
White colonies were picked up and inoculated into 5m1 of LB medium containing 
ampicillin and incubated overnight at 37°C . 
3.3.6 DNA preparation of the transformants by using QlAprep hit 
The overnight cultures were centrifuged at 1000rpm for 15 minutes. The pelelted 
bacterial cells was resuspended in 250 ul Buffer P1 (50mM Tris. IIC1 p118, 
1OmMEDTA, 100 pg/ml RNase A) and transferred to a microcentrifuge tube. 250µl 
Buffer P2 (200mM NaOH, 1%SDS) was then added and mixed thoroughly by 
inverting the tube 4-6 times. 350 pl Buffer N3 (3M potassium acetate p115.5) was 
added and mixed immediately and thoroughly by inverting the tube 4-6 times. The 
suspension was subsequently centrifuge for 10 min at 13,000 rpm (-. 17,900 x g) in a 
table-top microcentrifuge. The supernatants were applied to the QlAprep spin column 
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by decanting or pipetting and then centrifuged for 30-60 seconds. The flow-through 
was discarded. The QIA prep spin column was washed by adding 0.75m1 buffer PE 
and centrifuged for 60 seconds. The flow-through was discarded and the spin column 
was again centrifuged for an additional 60 seconds to remove residual wash buffer. 
The QlAprep column was placed in a clean 1.5m1 microcentrifuge tube. 50 µl Buffer 
EB (10 mM Tris"Cl, pH 8.5) was added to the centre of each QIAprep column to elute 
the DNA. The column was allowed to stand for 60 seconds and was then centrifuged 
for 60 seconds. The miniprepped DNA was then electrophresed on the 1.5% agarose 
gel to determine the presence of insert. 
3.3.7 Sequences of the cloned product 
The pGEM-T Easy vector contains M13 site. M13 forward primer was used as a 
sequencing primer for sequencing reaction. The procedures for the sequencing were 
similar to that of direct sequencing. However, the primer used was M13 forward 
primer and the amount of DNA was around 350, u g (according to the instructions 
from the supplier). 
3.3.8 Assessing the sequencing results 
The software we used for the sequences analysis is sequencer, version 4.1 
(Genecodes). 
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3.4 RESULTS 
3.4.1 Study population 
A total of 68 CdIS patient DNA samples were screened. They are divided into 
three groups. The first group consisted of 45 patient DNA samples for initial 
screening, while the second group included the previously reported two de novo 
translocated cases of CdLS involving t(3; 17) and t(14; 21) respectively to exclude the 
regions disrupted by the 3q, 17q, 14q and 21q breakpoints as the candidate regions for 
CdLS. The third group comprised of 20 patient DNA samples from Denmark and the 
UK, which were screened for the confirmation of the diagnosis. Of the third group, 17 
samples were from Denmark and 3 samples were from the UK and Ireland. One 
familial case (mother and daughter both affected) from Ireland and a sporadic case of 
Arabic origin were included in the third group. A small number of patients' DNA 
failed to amplify with any primers, so the actual number of patients tested was less 
than sixty eight due to the poor quality of the DNA samples. 
3.4.2 Mutation screening approach used in exons of different sizes 
Fragments flanking the exon-intron boundaries of Exons 2-8 were screened by 
using SSCP and heterduplex analysis due to the smaller fragment size. If a shifted 
band was found, subsequent direct sequencing was performed. Due to the large 
fragment size (most of them are more then 400bp), we employed direct PCR 
sequencing for exons 15-47. The PCR products were sequenced bidirectionally for a 
better confirmation. 
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3.4.3 Spectrum of NIPBL mutations detected 
The complete list of mutations identified is shown in Table 3.1. For the first 
group, a total of 35 exons were screened. The coding sequence sampled in these 35 
exons corresponds to around 40% of the total. 2/3 of exon-intron junctions were 
screened for a splice site mutation. NIPBL mutations were identified in 11 patients 
with CdIS (1 familial and 9 sporadic). A total of 10 different mutations were 
identified and comprised 2 frameshift, 1 nonsense, 3 missense, 1 non-frame shifting 
deletion and 3 splice site mutations. All identified mutations were unique. 
In the second group, a total of 39 exons were screened. A NIPBL mutation was 
found in the patient with a de novo t(3; 17) (Ireland et al., 1991), where the 4bps 
(TTTG) deletion in exon 23 that led to premature truncation of NIPBL was identified. 
In the other CdLS patient with de novo t(14; 21) translocation (Wilson et al., 1983), 
the nonsense mutation S1459X in exon 20 of NIPBL was identified by Gillis et. al. 
(Gillis et al., 2004) and confirmed in the present study. Neither of the mutations was 
present in either of the respective parents, which suggested that the de novo balanced 
translocation may represent events that were not directly related to the pathogenesis, 
but possibly could be downstream consequences of the NIPBL mutations. The sample 
of the index case with the de novo t(5; 13) translocation we used for FISH mapping in 
this study was found to have disruption in intron 1 (see Chapter 2) 
In the third group, a total of 41 exons were screened. The coding sequence 
sampled in these 41 exons corresponds to around 84% of the total. 41 of the 
exon-intron juctions were screened for splice-site mutation. NIPBL mutations were 
identified in 4 patients with CdLS (1 familial and 2 sporadic). A total of three different 
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mutations were identified and comprised a 3bp non-shift deletion, 1 nonsense 
mutation and 1 missense mutation. 
In 14 of the 63 individuals with sporadic CdIS, 13 different mutations were 
identified. Of these, 2 were small deletions, which resulted in a deletion of 1 amino 
acid. They included I1206del (exon 14) and N2217de1, which are evolutionally well 
conserved. One small deletion which led to a4 bp deletion in exon 23 was found in 
the patient with a t(3; 17) balanced translocation and resulted in a prematurely 
truncated protein product. Two were small insertions which resulted in a prematurely 
truncated protein product. Three of the mutations had a single-base-pair change that 
led to immediate stop codons. One mutation contained a major translocation that 
disrupted the gene in intron 1. 
Two patients with sporadic CdLS had different mutations that affect the splice 
sites and were predicted to lead to alterations in splicing. The splice-site alterations 
were not found in their parental samples and in the 200 normal chromosomes. 
Of the 13 mutations identified in patients with sporadic CdLS, three were single 
base change that resulted in substitution of a single amino acid. The missense 
mutations identified included C1311R (exon 17), L1348R (exon 17) and Y2430C 
(exon 43). These amino acids were highly conserved throughout evolution and such 
changes were not found in the parental samples and the normal chromosomes. Thus, 
we considered the changes as pathogenic. 
Mutations were identified in 2 of 3 familial cases of CdIS. In the first family 
(from Poland), a splice site mutation in exon 38 (donor site) was observed both in the 
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affected son and daughter. No mutation was observed in their parents. Thus, germline 
mosaism is the most likely mechanism in this family. The second CdIS familial case 
was an Irish family involving three generation with an affected daughter, an affected 
mother and probably affected maternal grandmother (McConnell et al., 2003). 
Q2280K (exon 40) missense mutation was observed in both the affected daughter and 
mother. Hence, autosomal dominant inheritance is the most likely mode of 
transmission in this family. 
No particular mutational hot spots were observed. All the mutations detected in 
our patients with CdLS are heterozygous. As the inheritance of CdLS from many 
familial cases suggested autosomal dominant, and the changes in NIPBL in CdLS 
patients were heterozygous, this confirms that autosomal dominant inheritance is the 
major mode of transmission in de Lange syndrome. 
3.4.4 Genotype-Phenotype correlation 
Because of the clinical heterogeneity observed in patients with CdIS and the 
lack of patient's information from certain referring samples, genotype-phenotype 
correlation in our study cohort is not easy. However, we tried to analyze the possible 
correlations in patients with available phenotypic information. In our series, patients 
found to have mutations in NIPBL that led to truncation of the gene product had more 
severe phenotypes. Patients with splice site mutation also had severe phenotypes. 
Patients with in-frame deletion of one amino acid tend to have milder phenotypes. As 
for patients with missense mutations, both severe and mild phenotypes can be seen. 
Moreover, in one of our familial cases that was referred from Poland 
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(Krajewska-Walasek et al., 1995), phenotypes discrepancy was found between the two 
affected sibs. However, they both shared the same splice site mutation in intron 38. 
The variation in the phenotypic severity was also observed in different sporadic CdLS 
patients, who share the same mutation (Gillis et al., 2004). Thus, no clear 
phenotype-genotype correlation was observed in patients affected with CdLS. 
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Table 3.1 Summery of CdLS patients with N/PBL mutations 
Panel Nature of mutation Location of Altered amino Phenotype 
identif mutation acid/premature stop 
ier colon 
Group I and II patients 
P2 lbp insertion Exon 43 S2462X 
7306 7307insG 
P3 Missense Exon 43 Y2430C 
7289A>G 
PH Splice acceptor AG Intron 30 undertermined 
dinucleotide 5575-2A>G 
P13 3bp deletion Exon 14 11206del 
3616_3618deIATA 
1116 Missense Exon 17 L1348R 
4043T- G 
P18 Missense Exon 17 C131 IR 
3931 T>G 
P27 Nonsense Exon 46 E2635X 
79036>T 
P28 Splice donor GT Intron 38 undertermined 
dinucleotide 6589+5G>C 
P29 1 hp insertion Exon 4 YI 16X 
355356 insA 
P37 Splice acceptor AG Intron 44 undcricrmined 
dinuclcotide 7686-2A>G 
P46 t(5; 13) Intron 1 N/A 
P47 t(3; 17) Exon 23 F562X 
4bp deletion 5152_5155 del 
'rrfG 
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Classical 
Classical 
Classical 
Mild 
Classical 
Mild 
Classical 
('lassical 
The mildly 
affected 
sister also 
has the 
same 
change 
Classical 
Classical 
Classical 
('Iassical 
P48 t(14; 21) Exon20 S1459X(Gillis ct al., Classical 
2004) 
Group III patients 
D6 Nonsense Exon20 Y 1445X N/A 
D18 Missense Exon40 Q2280K Mild 
Affected 
mother has 
same 
mutation 
P20 3bp deletion Exon 39 N2217de1 N/A 
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Table 3.2 conservations of sequences at sites of NIPBL missense mutations and in-frame 
deletion between different species 
Q2280K 
Human NIPBL VSSGMSS:; QVLEAFFHTQSSV 
Mouse 
Chick 
Xenopus 
Zebrafish 
Drosophila 
C. eieg nts 
N2217de1 
VSSGMSSY -QVLEAFFHTQSSV 
ISSGMSS' : QVLEAFFHTQSNV 
ISSGMSS: ' QVLESFFSTQSSV 
ISSGMSS: ' QVLESFFHAQSSV 
VSSGMAS: 7-ILECFLNRDDTV 
SGSGLGS: '. --ýi" --'\VLESYVDADIQL 
Human NIPBL QE, 
I 
'-'j KNSSVNLKIQVLKNL 
Mouse QE' DKNSSVNLKIQVLKNL 
chick QE' : KNCSVNLKIQVLKNL 
Xenopus VE` 
, 
. DKNSSVNLKIQVLKNL 
Zebrafish ::; DKRSSITLKIQVLKNL 
Drosophila SEL: "; "r : ýSIANDAGFKIICMRNI 
Y2430C 
Sp ie s Amino acii 
Human NIPBL DTA---KTDVTMLIJIADNLACFPYQTQEEPLF 
Mouse DTA---KTEVTMLL, IADNLACFPYQTQEEPLF 
Chick DTA---KTEVNMLLJIADNLACFPYQTQEEPLF 
Xenopus DAA---KTEVNMLIJIADNLACFPYQTQEEPLF 
Zebrafish DSS---KMEVNMLLEIADNLAYFPYQSQEEPLF 
Drosophila DQ---- KTSLQQMI., IADNLAYFPYWQDEPLY 
C. elegann EEF---SHDKPQLMEYIFIADNLAMFPYQMI DE 
0. Sativa NRS---YPTISFLICAEVLASLPFTSPDEPLY 
11206 del 
Human NILBL EMMDSSTFKRF-AASIFNILDN 
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Muse 
Chick 
Xenopus 
Zebrafish 
Drosophila 
C. elegans 
CI31IR 
LN1ti. DSSTFKRFTAS'F cILEN 
EMMDSSTFKRFIASIENILEN 
EiMMDSSTFKRFSSAVENILEN 
ELMDSSTFKRFLTSIDNILEN 
EVTRSQTYQQFIRNMDHIIEI 
ELKMPKNKKRRSGGDHHHKGD 
Lýlpeý-ies rirTl - Cic dý, __, ., '. -i a_F_', 5 
Human NIPBL MERVTKSA: _`, 
t 
" -NIMTSPNMPKAV 
Mouse MERVTKSA. 
J 
.: ' LNIMTSPNMPKAV 
Chic MERVTKSA '' , I- NIMTSPNMPKAV 
Xenopus MERVTKSA_, NIMTSPSMPKAV 
Zbrafish MERVTKSAiI :., -NIMTSAHMPKAV 
Drosophila IEKLLNAM', -I : _. 
'NIYSTVSDLQFL 
C. eIegans EERVKRA` ::, 'V'V -'; '. ýNIMSSHRMHKQV 
L 1348R 
Human NIPBL 
Mouse 
Chick 
Xenopus 
Zebrafish 
Drosophila 
C. elegans 
QNTI! PQYDPVYR---LDPH 
1tiI -QYDPVYR---LDPH 
LQN-Q`, -DPVYR---VDPL 
I 
iQN"'IYPQYDPVYR---LDPH 
LQNNTIiPQYDPVYRVDPHGGG 
LRETIFPLHDPVYT---AKSI 
LIHLIYPASDSIYKSVNSKKK 
134 
a P29 - Exon 4 
355 356insA 
Y1 16X 
NRX 
NRYVQ 
IJ, 
C 
P18 - Exon 17 
3932T> C 
c131 1R 
r., A -:. R .T 
lw 
DACLTI 
b 
P13-Exon14 
3617 3619deLATA 
11206dol 
A. 'EN 
ýtlI ýiýt'. 
i1ýý ' 
A5ICN 
d 
PI6- Exon 17 
4044T>>G 
Ll 3482 
NI L', -'R YP 
V 
iI 
II 
II IIý 
ýI 
1 
NTLYP 
rrr.. r---, 
ýýýý ýý, ý. 
`, ý'' ýi1'ý' `'aß, 1 
Fig. 3.2 Examples of chromograms of patients with NIPHl. nititations 
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3.5 DISCUSSION: 
Up to now, over 50 causative mutations have been reported that include missense 
(-22%), frameshift (-43%), nonsense (-20%), and splice-site mutations (-15%) 
(Borck et al., 2004; Gillis et al., 2004; Krantz et al., 2004; Tonkin et al., 2004). The 
majority of identified mutations have been private; however, several mutations have 
been seen in two or three unrelated probands (Gillis et al., 2004). It has been 
suggested that milder forms of CdLS are more likely to be caused by missense 
mutations and more severe forms by truncating mutations (Bhuiyan et al., 2006a; 
Gillis et al., 2004). Mutations in NIPBL either lead to haploinsufficiency (frameshift, 
nonsense, and possibly splice-site mutations) or to altered proteins (missense 
mutations) whose function and viability is unknown at this time. Ilaploinsufficiency 
of the NIPBL protein results in CdLS as demonstrated by two reports of CdLS in 
infants with deletions of the entire gene (Hulinsky et al., 2005; Taylor and Josifek, 
1981). 
Missense mutations that impair protein function may result in disease. The 
disease severity caused by such deleterious mutations is dependent on when and 
where the protein's function is required by the organism. The disease phenotype is 
likely determined by three parameters: (1) the degree to which the function of the 
protein is impaired by the missense mutation; (2) variants of other genes that 
modulate the effect of the major locus, also referred to as genetic background; and (3) 
the environment. Several studies suggest that mutations in evolutionary conserved 
sites tend to impair protein function and lead to disease. The disease severity is also 
somewhat correlated with the physicochemical difference between the original amino 
acid and the missense variant (Miller and Kumar, 2001; Sunyacv et al., 2001a; 
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Sunyaev et at., 2001b; Williams et at., 2003). Residues that are conserved completely 
in the protein family are expected to be important for function, and even a 
conservative substitution at one of these residues may affect protein function. At some 
positions, any amino acid change can be tolerated in the protein if these positions are 
not involved in protein function or structure. Because these are expected to be neutral 
substitutions, one might expect amino acids in these positions of the protein aligment 
to be diverse. 
An analysis of the frequency matrix for disease-associated missense mutations 
reveals some differences from amino acid substitution rates seen in wild-type proteins. 
There are eight mutations that occur significantly more frequent in disease-associated 
than in wild-type proteins. Seven of them involve two amino acid types, that is, 
cysteine (C->R, C4Y and C-G) and arginine (R->Q C411, H411, W->R and 
R-)L). Other substitutions commonly found in wild-type proteins such as L4M, 
L-I, A-S and F-*Y are relatively rare causes of disease. Presumably, this is because 
similarities in physicochemical properties between these amino acids and thus ensure 
conservation of protein function despite their substitution (Goodstadt and Ponting, 
2001). Cysteine and arginine are both more highly substituted and more highly 
substituting in disease-associated variations. For cysteine, this is likely to arise from 
its unusual chemical properties, in particular gain or loss of disulphide-bridges or free 
thiols. The dominance of arginine in disease-associated missense variants may be due, 
in part, to its participation in salt bridges and its prevalence in solvent-accessible 
peripheries rather than the hydrophobic interiors of proteins and is important for 
molecular stability and function (Goodstadt and Ponting, 2001). Protein 
phosphorylation is a key mechanism for intracellular signal transduction in both 
prokaryotic and eukaryotic cells. Vertebrate proteins are prevalently phosphorylatcd 
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on side chains that contain a hydroxyl group, such as serine, threonine and tyrosine 
residues. Phosphorylation of serine, threonine or tyrosine results in the formation of a 
phosphoester linkage. Phosphorylation of histidine residues occurs on nitrogen atoms, 
producing a phosphoramidate bond. Phosphohistidines have a large standard free 
energy of hydrolysis making them the most unstable of any known phosphoamino 
acid (Matthews, 1995). Thus, missense mutation that substitutes these phosphrylation 
associated amino acids is expected to result in disease phenotypes. 
Missense mutations in NIPBL that cause substitution of the "wild-type" amino 
acid to a variant amino acid are also observed in CdLS patients from several research 
groups (Ben-Asher and Lancet, 2004; Bhuiyan et al., 2005; Bhuiyan et al., 2006b; 
Borck et al., 2004; Borck et al., 2006; Gillis et al., 2004; Krantz et al., 2004; Tonkin et 
al., 2004)(see Fig. 3.2 as a summary). Most of the missense mutations arc located 
within the highly conserved region of NIPBL. 
Of the 32 missense mutations (29 different locations) shown below (Fig. 3.3), 28 
mutations are located within the highly conserved region, especially clustered within 
the HEAT repeat region. Mutations involving the wild-type amino acid into arginine 
occurred in 4 of the 29 different mutations. Arginine substituted by other amino acids 
was found in 6 of the 29 different mutations, especially clustered in the HEAT repeat 
region. Amino acid substitution involving arginine might influence the stability of the 
protein molecules and result in disease phenotype. Mutation involving substitution of 
cysteine was found in 3 of the 29 types of mutations. Change in the cysteinc amino 
acid might lead to gain or loss of the disulfide bridges or free thiols. Mutation 
involving serine, threonine and histidine was found in 6 of the 29 different mutations. 
Most of such mutations were located within the highly conserved region, especially 
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near the phophrylated end of NIPBL protein. Mutation involving thrconine and 
histidine might alter the state of phosphrylation and affect the signaling pathway. 
Aspartic acid (D) change to glycine (G) was observed in 2 of the 29 different 
mutations. A study to evaluate the exchangiabilty of amino acids in protein showed 
that the exchangeability from aspartic acid to glycine is low (Yampolsky and Stoltzfus, 
2005). Thus, it is reasonable for a substitution from aspartic acid to glycine to alter the 
protein function. 
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In our series, the overall mutation detection rate in patients with CdLS is 
relatively low compared with the series reported by (Gillis et al., 2004). In our series, 
the mutation detection rate was around 40% in group I (when account is taken of the 
number of exons screened), 100% in group II, but only 18% in group III. The 
mutation detection rate in the first 2 groups is similar to other series reported 
(Ben-Asher and Lancet, 2004; Bhuiyan et al., 2005; Borck et al., 2004; Gillis et at., 
2004) with the exception of the Japanese group. They reported a mutation detection 
rate of 26% (Miyake et at., 2005). However, in the third group, the mutation detection 
rate is relatively low compared to all the other series reported. It should be noted that 
most of the samples were referred from Denmark, and most of the patients' 
information was not clear to us in the third group. In this group, 4 patients were 
referred from Britain and Ireland. Mutations were found in three (1 sporadic, two 
familial) out of four patients. Only one sample in the remaining 17 samples referred 
from Denmark was found to have a nonsense mutation. In contrast to the US group's 
report (Gillis et at., 2004), most of the patients in our cohort studies were sporadic. 
Only two families had more then one affected member in their families. The low 
mutation rate in the cohort studies may be due to the following reasons: (1) The 
uncertainty of the diagnosis in certain cases; (2) large deletion or duplication 
involving several exons; (3) variation in sequences beyond cxon/intron boundaries 
such as regulatory elements or intronic sequences; (4) difficulty in amplifying certain 
NIPJ3L exons such as exon 33 and 37; (5) the existence of mosaicism in tissues other 
than blood cells; (6) other genes involved in the pathogenesis of CdLS. There arc 
several inherited genetic syndromes that have some phenotypic overlap with CdLS 
and thus might make the diagnosis confusing, particularly with mild CdLS. One of the 
examples is Rubinstein-Tabi syndrome (MIN 180849). The neat arched eyebrow, 
mental retardation and growth deficiency seen in Rubinstein-Tabi syndrome (Francois, 
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1981; Partin-ton, 1990) sometimes will be mistaken ti)r the mild de Lange syndrome. 
Thus, further clinical reevaluation in the patients without . 
VIPBL mutations is 
important. Deletions/insertions of the entire exon(s) were also considered as a 
possibility for the low mutation detection rate in our study. However, to find out it the 
low mutation detection rate is partly due to rearrangements resulting in deletion or 
duplication of one or more exons, Lott et al. (reported in annual meeting of European 
Society of Human Genetics, 2006) tested the : ViPBL gene for copy number changes 
with the MLPA (multiplex ligation dependent probe amplification) technique. No 
exon deletions in the I8 CdLS patients without point mutations were detected. Thus, 
deletions/insertions involving the whole exon(s) seem unlikely. Recently, the mutation 
5'tJ R region was found to be associated with the CdLS phenotype. The mutation 
occurred in exon I of the ; VIPBL gene, 32 1 bps upstream of' the translation start site 
(-321_-320 delCCinsA) (Borck et al., 2006). The mutation was located within the 
highly conservative region of exon l (as illustrated in Fig. 3.3). It is quite possible this 
area might contain certain important cis regulatory elements. Moreover, in our patient 
with t(5,1 3) balanced translocation, the breakpoint vas in intron I ol'the . 
V/Pill, gene. 
Due to the location of the transcription start site of' . 
V/Pill. in I: xon 2, disruption of 
intron I in the t(5,13) CdI. S patient %Nith severe phenotypes suggests that the well 
conserved untranslated regions might contain certain important c"is regulatory 
elements. Disruption ofthis cis-elenment might reduce the level of gene transcription. 
Sequences analysis of' -2kb 5' of' promoter and 2. Okb Vol' ßexon I 
by using VIS FA 
genome broý%scr (http: //pipeline ibl gov/cgi-bin/gatewati2'! b phrl&sclc; ctot=vista) 
(Brudno et al., 2003; Couronne et al.. 2003) suggested that the first 2kb sequence t' 
intron I as well as exon I are highly conserved (see Fig. 3.4). 
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Fig 3.4 sequences conservation -2.5kb upstream of the A'IPBL promoter and 2kb downstream of the 
exon l 
For many genes, the region immediately upstream of the minimal promoter 
contains sufficient transcription factor binding sites to direct correct expression of the 
gene - these are termed "regulatory promoters. " However, many genes also require 
multiple cis-acting distant genomic elements for spatiotemporally correct expression 
(I loward and Davidson, 2004). These are often defined as enhancers, although some 
will be repressors or insulators, they can be located upstream, mthin introns, or 
downstream of' the "transcription unit, " which comprises the transcribed exons and 
introns from the promoter to the polyadenylation site. 
Additional complexities include the possible presence of multiple alternative 
promoters and cxons. The genomic regions harboring regulatory elements can stretch 
as much as I Mb in either direction from the transcription unit (Pfeiler et al.. Io)99). 
Also, in one ol'our familial cases, both the allected brother and sister harbor the same 
splice site mutation in intros 38. I Ionwevcr, the phenotypes in the brother were milder 
than his atlccted sister. There have been reports on phenotypic variations in the 
afflected individuals in the same family (Feingold and Lin, I993i Gardner, 2003). In 
1 4.1 
today's studies, the use of molecular genetic analysis to interpret and predict the 
phenotype in genetic disease initially appeared promising. However, for many human 
diseases, including malformation syndromes, no clear phenotype-genotype 
relationship has been demonstrated. For some phenotypes it is becoming clear that 
mutations in a single gene are not sufficient to cause a phenotype without sequence 
alterations in another gene. Further variations in phenotype or pcnctrance can be 
caused by loss or alteration of contiguous genes, transporter proteins and activator 
proteins, and other classes of molecules. Modifier genes have become increasingly 
recognized as an important source of phenotypic variation that may explain the 
relation of phenotype to genotype. Thus, it is reasonable to speculate the existence of 
another gene or modifier gene for the phenotypes variation seen in some of our family 
members with the same mutation in NIPBL. Therefore, we still need to try to find 
other possible genes that cause or modulate the CdLS phenotypes. Thus, it is also 
important to check for the possible mutation occurred within. Recently, germline 
mosaism has also been reported in familial cases with D2433G misscnse mutation. 
Mutation was found in the father's sperm but not in the blood lymphocytes, and the 
phenotype tend to be milder (Niu et al., 2006). It is possible that the mutation-negative 
mild CdIS patients might have somatic mutations other than blood lymphocytes. 
Recently, mutations in SMC1L1 (also known as SMCI), which encodes a 
different subunit of the cohesin complex, have been reported to be responsible for 
X-linkcd variant of CdLS (Musio ct al., 2006). Krantz ct al. screened a cohort of 95 
NIPIIL mutation-negative patients with CdLS and identified SMC1LI mutations in 8 
of them, which are phenotypically milder (abstract from annual meeting in American 
Society of Human Genetics, 2006). Furthermore, the 20-50% NIPiL mutation 
detection rate in patients with CdLS suggests the existence of heterogeneity of CdLS. 
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By using karyotyping, FISH and Array-CGH techniques, de novo chromosome 
imbalances include tctrasomy of the entire chromosome 18p and terminal deletion of 
lq spanning 6.5Mb was found in two patients out of 14 CdLS patients. Mutation in 
NIPBL was only detected in 5 of the 14 patients (Borck et al., 2004) Thus, it is quite 
reasonable that genetic heterogeneity existing in CdLS and mutations in other genes 
involved in the sister chromatic cohesion complex may cause the CdLS phenotypes. 
The cohcsin complexes consist of SMC1, SMC3, Sccl, and Scc3. The human 
homologues of these are hSMC1L1, hSMC3, hRAD21 and hSA1/hSA2 respectively. 
Scc2 (hNIPBL)/Sc 4(hMau"2) complexes help in the establishment and loading of 
cohesin ring (Gruber et at., 2003). Recently, another study in Hela cells reported that a 
subfraction of SNF2h/ISWI, the ATPase subunit of many remodeling complexes, is 
co-purified with cohesin. hSccl/hRAD21 subunit of the cohesin complex directly 
interacts with the ATPase subunit SNF2h. SNF2h can help in the loading of hSccl on 
chromatin (Hakimi ct al., 2002). Table 3.3 summarizes the chromosomal locations of 
the subunits of cohesin complexes and associated proteins. 
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Table 3.3 chromosomal location of the human cohesin complexes and associated 
proteins. 
Cohcin Gene location in Homo sapiens Possible roles 
hSMCl(SMC1LI) Xp11.22 One of the disease causing 
gene for CdIS (Musio et 
at., 2006) 
hSMC3 10q25 Structural maintenance 
protein of cohesin 
hSc cl(RAD21) 8q24 Part of the cohesin ring 
complexes 
SAl(STAG1) 3q22.3 assembles with the cohesin 
proteins (Prieto et al., 
2002) 
SA2(STAG2) Xq25 assembles with the cohesin 
proteins (Prieto et at., 
2002) 
hScc2JNIPBL 5p13.2 Major CdIS causing 
gene(Krantz et al., 2004; 
Tonkin et at., 2004) 
hScc4/hMau-2 19p13.11 Help in loading of 
cohesin onto chromatin 
(Gruber et at., 2003) 
hPdsS/APRIN 13g12.3 inducing cell cycle arrest 
in the G0/G1 phase (Geck 
et at., 2000) 
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Of the above gene locations described, hSccl/RAD21(8g24) is located near de 
now t (X; 8)(p11.2; g24.3) translocation breakpoint affected with CdLS (Egemen et al., 
2005). The location of the APRIN (13g123) is near the CdLS patient with de novo 
t(5; 13)(p13.2; q12.1). The translocation in 13g12.1 might interrupt the normal 
functions of the APRIN. As disorders affecting the sister chromatic cohesion complex 
likely represent an underappreciated class of clinical disorders, it is necessary to 
screen for NIPBL and SMCIL1 mutation negative individuals with CdLS for the 
possibility of patient-specific mutations in other proteins associated with cohesin 
complexes. According to all the chromosome anomalies reported to be associated with 
CdLS, hSccIIRAD21 and APRIN seem to be the most possible disease causing genes. 
Nevertheless, the majority of the CdLS patients with chromosomal abnormalities 
showed no consistent regions involved. This may suggest that the multiple loci 
implicated in CdLS are just coincidental. Another possible explanation for the 
multiple chromosomal anomalies observed in CdLS cases is that the CdLS disease 
gene may play an important role in the repair of double strand DNA. Mutations in the 
CdLS gene(s) cause increased chromosome breakage at fragile sites and result in the 
multiple chromosome abnormalities associated in some CdLS patients. 
147 
3.6 REFERENCES 
Ben-Asher, E., and Lancet, D. (2004). NIPBL gene responsible for Cornelia de Lange 
syndrome, a severe developmental disorder. Isr Med Assoc J 6,571.572. 
Bhuiyan, Z, Mein, M., Hammond, P., Mannens, M. M., Van Haeringen, A., Van 
Bcrckclacr-Onnes, I., and Ilennekam, R. C. (2005). Genotype-Phenotype correlations 
of 39 patients with cornclia dc Lange syndrome: the Dutch experience. J Med Genet. 
Bhuiyan, Z. A., Klein, M., Hammond, P., van Hacringen, A., Mannens, M. M., Van 
Berckclacr-Onnes, I., and Iiennckam, R. C. (2006a). Genotype-phenotype correlations 
of 39 patients with Cornelia De Lange syndrome: the Dutch experience. J Med Genet 
43,568-575. 
Bhuiyan, Z. A., Zilfalil, B. A., and Hicnnekam, R. C. (2006b). A Malay boy with the 
Cornelia dc Lange syndrome: clinical and molecular findings. Singapore Med J 47, 
724-727. 
Borck, Q, Redon, It, Sanlaville, D., Rio, M., Pricur, M., Lyonnet, S., Vekemans, M., 
Carter, N. P., Munnich, A., Colleaux, L, and Cormier-Daire, V. (2004). NIPBL 
mutations and genetic heterogeneity in Cornelia dc Lange syndrome. J Med Genet 41, 
c128. 
Borck, G, Zarhratc, M., Cluzcau, G, Bal, E, Bonnefont, J. P., Munnich, A., 
Cormier-Daire, V., and Collcaux, L (2006). Father-to-daughter transmission of 
Cornelia de Lange syndrome caused by a mutation in the 5' untranslated region of the 
NIPBL Gene. Hum Mutat 27,731-735. 
Brudno, M., Do, C. B., Cooper, G M., Kim, M. F, Davydov, E., Green, E. D., Sidow, 
A., and Batzoglou, S. (2003). LAGAN and Multi-LAGAN: efficient tools for 
large-scale multiple alignment of gcnomic DNA. Genome Res 13,721-731. 
Cotton, R. Cx (1997). Slowly but surely towards better scanning for mutations. Trends 
Genet 13,43-46. 
Couronne, 0., Poliakov, A., Bray, N., Ishkhanov, T., Ryaboy, D., Rubin, E., Pachter, 
L, and Dubchak, I. (2003). Strategies and tools for whole-genome alignments. 
Genome Res 13,73-80. 
148 
Egcmen, A., Ulger, Z, Ozkinay, F., Gulen, F., and Cogulu, 0. (2005). A de novo t 
(X; 8)(p11.2; g243) demonstrating Cornelia de Lange syndrome phenotype. Genet 
Couns 16,27-30. 
Feingold, M., and Lin, A. E. (1993). Familial Brachmann-de Lange syndrome: further 
evidence for autosomal dominant inheritance and review of the literature. Am J Med 
Genet 47,1064-1067. 
Francois, J. (1981). [Dysmorphic idiopathic dwarfisms and their ocular 
manifestations]. J Fr Ophtalmol 4,511-524. 
Gardner, R. J. (2003). Another explanation for familial Cornelia de Lange syndrome. 
Am J hied Genet A 118,198. 
Gcck, P., Maffini, M. V., Szclci, J., Sonncnschein, C., and Soto, A. M. (2000). 
Androgen-induccd proliferative quiescence in prostate cancer cells: the role of AS3 as 
its mediator. Proc Natl Acad Sci USA 97,10185-10190. 
Gillis, L A., McCallum, J., Kaur, M., DeScipio, G, Yaeger, D., Mariani, A., Kline, A. 
D., Li, H. If, Devoto, M., Jackson, L CL, and Krantz, L D. (2004). NIPBL mutational 
analysis in 120 individuals with Cornelia de Lange syndrome and evaluation of 
genotype-phenotype correlations. Am J Hum Genet 75,610-623. 
Goodstadt, L, and Ponting, C. P. (2001). Sequence variation and disease in the wake 
of the draft human genomc. Hum Mot Genet 10,2209-2214. 
Gruber, S., Hiacring, C. H., and Nasmyth, K. (2003). Chromosomal cohesin forms a 
ring. Cell 112,765-777. 
Hakimi, M. A., Bochar, D. A., Schmiesing, J. A., Dong, Y., Barak, 0. (1, Speicher, D. 
W., Yokomori, K., and Shickhattar, R. (2002). A chromatin remodelling complex that 
loads cohcsin onto human chromosomes. Nature 418,994-998. 
Hayashi, K., and Yandell, D. W. (1993). How sensitive is PCR-SSCP? Hum Mutat 2, 
338-346. 
Howard, M. L, and Davidson, E. H. (2004). cis-Regulatory control circuits in 
development. Dcv Biol 271,109-118. 
149 
Hulinsky, It, Byrne, J. L, Lowichik, A., and Viskochil, D. H. (2005). Fetus with 
interstitial dcl(S)(p13.1p14.2) diagnosed postnatally with Cornelia de Lange 
syndrome. Am J Mcd Genct A. 
Krajewska-Walasck, M., Chrzanowska, K., Tylki-Szymanska, A., and Bialecka, M. 
(1995). A further report of Brachmann-de Lange syndrome in two sibs with normal 
parents. Clin Genet 47,324-327. 
Krantz, I. D., McCallum, J., DcScipio, G, Kaur, M., Gillis, L. A., Yaeger, D., 
Jukofsky, L, Wasserman, N., Bottani, A., Morris, C. A, et aL (2004). Cornelia de 
Lange syndrome is caused by mutations in NIPBL, the human homolog of Drosophila 
mclanogastcr Nipped-B. Nat Genet 36,631-635. 
liechti-Gallati, S., Schneider, V., Nccscr, D., and Kraemer, R. (1999). Two buffer 
PAGE system-based SSCP/HD analysis: a general protocol for rapid and sensitive 
mutation screening in cystic fibrosis and any other human genetic disease. Eur J Hum 
Gcnct 7,590-598. 
Matthews, If. R. (1995). Protein kinases and phosphatases that act on histidine, lysine, 
or arginine residues in eukaryotic proteins: a possible regulator of the 
mitogen-activated protein kinasc cascade. Pharmacol Ther 67,323-350. 
Miller, M. P., and Kumar, S. (2001). Understanding human disease mutations through 
the use of intcrspccific genetic variation. Hum Mol Genet 10,2319-2328. 
Miyake, N., Visser, It, Kinoshita, A., Yoshiura, K., Niikawa, N., Kondoh, T., 
Matsumoto, N., Harada, N., Okamoto, N., Sonoda, T, et aL (2005). Four novel 
NIPBL mutations in Japanese patients with Cornelia dc Lange syndrome. Am J Med 
GenetA 135,103.105. 
Musio, A., Sclic: orni, A., Focarclli, M. L, Gervasini, C., Milani, D., Russo, S., 
Vezzoni, P., and Larizza, L (2006). X"linked Cornelia de Lange syndrome owing to 
SMC1L1 mutations. Nat Genet 38,528-530. 
Niu, D. M., Huang, J. Y., Li, H. Y., Liu, K. M., Wang, S. T., Chen, Y. J., Udaka, T., 
Izumi, K, and Kosaki, K. (2006). Paternal gonadal mosaicism of NIPBL mutation in 
a father of siblings with Cornelia de Lange syndrome. Prenat Diagn. 
150 
Orita, M., Suzuki, Y., Sekiya, T., and Hayashi, K. (1989). Rapid and sensitive 
detection of point mutations and DNA polymorphisms using the polymerase chain 
reaction. Genomics S, 874-879. 
Partington, M. W. (1990). Rubinstein-Taybi syndrome: a follow-up study. Am J Med 
Genet Suppl 6,65-68. 
Petersen, I., Ohgaki, H., Ludeke, B., and Kleihues, P. (1994). Direct DNA sequencing 
following SSCP analysis. Anal Biochem 218,478-479. 
Pfeifer, D., Kist, R., Dewar, K., Devon, K., Lander, E. S., Birren, B., Korniszewski, L, 
Back, E., and Scherer, Q (1999). Campomelic dysplasia translocation breakpoints are 
scattered over 1 Mb proximal to SOX9: evidence for an extended control region. Am J 
Hum Genet 65,111-124. 
Prieto, I., Pezzi, N., Buesa, J. M., Kremer, L., Barthelemy, I., Carreiro, C., Roncal, F., 
Martinez, A., Gomez, L, Fernandez, R, et al. (2002). STAG2 and Rad2l mammalian 
mitotic cohesins are implicated in meiosis. EMBO Rep 3,543-550. 
Rao, V. B. (1994). Direct sequencing of polymerase chain reaction-amplified DNA. 
Anal Biochem 216,1-14. 
Rollins, R. A., Morcillo, P., and Dorsett, D. (1999). Nipped-B, a Drosophila 
homologue of chromosomal adherins, participates in activation by remote enhancers 
in the cut and Ultrabithorax genes. Genetics 152,577-593. 
Sunyaev, S., Lathe, W., 3rd, and Bork, P. (2001a). Integration of genome data and 
protein structures: prediction of protein folds, protein interactions and "molecular 
phenotypes" of single nucleotide polymorphisms. Curr Opin Struct Biol 11,125-130. 
Sunyaev, S., Ramensky, V., Koch, I., Lathe, W., 3rd, Kondrashov, A. S., and Bork, P. 
(2001b). Prediction of deleterious human alleles. Hum Mol Genet 10,591-597. 
Taylor, M. J., and Josifek, K. (1981). Multiple congenital anomalies, thymic dysplasia, 
severe congenital heart disease, and oligosyndactyly with a deletion of the short arm 
of chromosome 5. Am J Med Genet 9,5-11. 
Tonkin, E. T., Wang, T. J., Lisgo, S., Bamshad, M. J., and Strachan, T. (2004). NIPBL, 
151 
encoding a homolog of fungal Scc2-type sister chromatid cohesion proteins and fly 
Nipped-B, is mutated in Cornelia de Lange syndrome. Nat Genet 36,636-641. 
Williams, R. S., Chasman, D. I., Hau, D. D., Hui, B., Lau, A. Y., and Glover, J. N. 
(2003). Detection of protein folding defects caused by BRCA1-BRCT truncation and 
missense mutations. J Biol Chem 278,53007-53016. 
Yampolsky, L Y., and Stoltzfus, A. (2005). The exchangeability of amino acids in 
proteins. Genetics 170,1459-1472. 
152 
CHAPTER 4 EXPRESSION PATTERNS OF THE NIPBL GENE 
4.1 INTRODUCTION: 
Previously, we have identified a novel gene, NIPBL, as the major determinant for 
CdIS syndrome (Tonkin et al., 2004), however, the functions of this novel gene are 
not known. To determine if the expression patterns of this novel gene correlate well 
with CdIS phenotypes, riboprobes were designed to study the expression patterns of 
NIPBL. Northern blot analyses on both the adult and fetal tissues are examined first. 
When differentiatial tissue expression patterns are observed, ongoing tissue in situ 
hybridization by using riboprobes will be performed. Human embryos sections 
obtained from different Carnegie stages are chosen for the tissue in situ hybridisation 
studies. Carnegie stage (CS) 13-14 embryonic sections were chosen to study the 
expression patterns of NIPBL in early limb bud and CNS development to evaluate if 
NIPBL expressions are at sites of active proliferation. CS17-18 embryonic sections 
were chosen for the ongoing serial NIPBL expression studies in different organ 
systems. CS21-23 embryonic sections were used to study the more detailed CNS, 
craniofacial and limb expression. No human foetal tissues are available for us to study 
the expression patterns at later developmental stages due to ethical issues. 
4.2 APPROACHES TO EXPRESSION STUDIES OFNIPBL 
4.2.1 Northern blot analysis 
Northern blotting is the RNA counterpart of the Southern blot technique that was 
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developed for DNA analysis by E. M. Southern in 1975 (Southern, 1975). RNA 
samples are first separated by size via electrophoresis in an agarose gel under 
denaturing conditions. The RNA is then transferred to a membrane, crosslinked and 
hybridized with a labeled probe. RNA sequences of interest are detected on the blot by 
hybridization to a specific labeled probe. Probes for Northern blot detection generally 
contain full or partial cDNA sequences and - may be labeled by enzymatic 
incorporation of radiolabeled (usually 32P) nucleotides. After probe hybridization and 
washing to remove nonspecific label, the hybridization signal is generally detected by 
exposing blots to X-ray film. The resulting band identified by the probe indicates the 
size of the mRNA, and the intensity of the band corresponds to the relative abundance. 
Autoradiograph band intensities may be quantitated by densitometry, by direct 
measurement of hybridized radiolabeled probe via storage phosphor imaging or by 
scintillation counting of excised bands. 
As a result of the relative ease of Northern blotting, it has become the most 
widely used method for characterization of mRNA size, relative abundance and 
detection of alternative spliced transcript. Of the techniques discussed here, Northern 
blotting is the only one which allows mRNA size determination. Hence, it has been a 
key method for detecting mutations that result in abnormal mRNA size. In general, 
this technique should be considered semi-quantitative, and is most suitable for 
determining relative concentrations of mRNA species that occur in moderate to high 
abundance (Reue, 1998). 
Despite these advantages, there are limitations associated with Northern analysis. 
First, if RNA samples are even slightly degraded, the quality of the data and the 
ability to quantitate expression are severely compromised. Thus, RNase-free reagents 
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and techniques are essential. Second, a standard Northern procedure is, in general, 
less sensitive than nuclease protection assays and RT-PCR, although improvements in 
sensitivity can be achieved by using high specific activity antisense RNA probes, 
optimized hybridization buffers and positively charged nylon membranes. A third 
limitation of Northern blotting has been the difficulty associated with multiple probe 
analysis. To detect more than one message, it is usually necessary to strip the initial 
probe before hybridizing with a second probe. This process can be time consuming 
and problematic, since harsh treatment is required to strip conventional probes from 
blots. 
Previously, E. T. Tonkin performed Northern blot analysis and confirmed the 
predicted 9.8-kb transcript size by using probe designed across exons 10,11 and 12. 
NIPBL expression was strongly expressed in adult heart, muscle, thymus, kidney and 
placenta. NIPBL was also strongly expressed in fetal kidney, moderately expressed in 
fetal liver and mildly expressed. in fetal brain. The expression was nearly undetectable 
in adult and fetal lung, adult brain, colon, and small intestine. The result is shown in 
Fig. 4.1. 
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Fig. 4.1. Results of NIPBL expression by Northern blot. Figure on the left panels is the expression data 
from the commercially available membrane containing fetal RNA, while the figure on the right panels 
is the expression data of adult tissues. The probe used was corresponding to NIPBL exons 10-12. The 
NIPBL transcript was around 9.8kb in both fetus and adult tissues. The 2.0kb band was the actin 
transcript used as the control. Expression was strong in adult heart, muscle, thymus, kidney and 
placenta and fetal kidney. Expression was nearly undetectable in adult and fetal lung, adult brain, colon 
and small intestine. B: brain; H: heart; M: muscle; C: colon; T: thymus; Sp: spleen; K: kidney; Li: liver; 
SI: small intestine; P: placenta; Lu: lung; L: lymphocyte. 
(with permission from E. T. Tonkin) 
Differential tissue expression was observed in Northern blot. Thus, ongoing 
Tissue in situ hybridization can be performed. 
4.2.2 Tissue in situ hybridization 
The introduction in the late 1960s of in situ hybridization (ISH) techniques 
(Buongiorno-Nardelli and Amaldi, 1970) opened a new era in histology and cell 
biology. The immunocytochemical methods can demonstrate only the presence of 
synthesized protein molecules. They can not recognize specific DNA or RNA 
sequences in a tissue and in a cell to define the precise location of a potential or an 
effective synthesis of a given molecule. 
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Although Southern blot and Northern blot can identify different classes of DNA 
and RNA respectively by hybridization to membrane bound nucleic acids, ISH can fill 
the gap between the detection of a specific sequence and its precise location within 
the tissue or the cell. A major advantage of ISH is that it allows different 
hybridizations as it is often performed on thin or ultra thin sections of a piece of tissue 
(e. g., a single surgical biopsy), which, at times, is not sufficient to allow Northern or 
Southern blot analysis. It is also possible to make libraries of paraffin-embedded or 
frozen tissues. No significant loss of the hybridization signal was found in frozen 
sections kept at -70°C with desiccant for more than 6 years (Wilcox, 1993). 
The sensitivity and efficiency of ISH depend on several variables, for which 
optimal conditions must be determined: (1) the probe construction and hybridization 
conditions; (2) the type and efficiency of probe labeling; (3) the tissue preparation 
(fixation, embedding), which must permit the retention of the target of hybridization 
and/or the hybridized products; and (d) the method used for signal detection. 
ISH is a technique that allows the detection of specific nucleic acid sequences 
within the intact tissue and cellular architecture. It has the advantage of identifying the 
gene products from de novo synthesis rather than protein uptake or receptor-bound 
protein, which may result in false-positive immunostaining results. Conversely, 
because proteins may be rapidly secreted or destroyed, this may lead to false-negative 
immunostaining results. 
Complementary RNA probes or riboprobes are the probes of choice for ISH (Cox 
et al., 1984), because they are sensitive and specific and there is no competition 
between hybridization and probe re-annealing, as with double-stranded probes 
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(Melton et al., 1984). They can be efficiently transcribed from cDNA clones 
containing T7, SP6, or 13 RNA polymerase promoters (Jorgensen et al., 1991). 
However this depends on the availability of the cDNA of interest, which would have 
to be cloned into a suitable vector. Clones must also be linearized by enzyme 
restriction at opposite ends of the cDNA to allow transcription of sense and antisense 
probes from the appropriate promoter. The optimal size of the RNA probe is around 
500bp. For a probe size larger than 500bps, hydrolysis of the probe is often required 
to reduce it to a size that is capable of penetrating into tissue and hybridizing with the 
target (Angerer et al., 1992). Notably, some plasmid-generated probes have also been 
observed to hybridize nonspecifically due to the presence of sequences similar to 
human 28S rRNA in the plasmid multiple cloning site (Baumgart et al., 1997). To 
circumvent these problems, we can generate the probes by using simple PCR 
technology (Higuchi et al., 1988; Weier and Rosette, 1988). In 1991, Young et al. first 
produced a DNA fragment with both SP6 and '17 RNA polymerase promoters, 
enabling production of sense and antisense transcripts from a single template (Young 
et al., 1991). This technique obviated the need for cloning, screening, and large-scale 
plasmid culture and the difficulties associated with plasmid restriction digestion. 
Probe hydrolysis to facilitate ISH is also not required because the PCR-generated 
template can be designed to yield probe of optimal length. The distinct advantages of 
this technique are that the probe produced has a user-defined length and sequence 
without exogeneous vector sequences. 
4.2.3 Development of different organ systems during early human development 
4.2.3.1 The developing nervous system 
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The central nervous system (CNS) forms from the neural tube. The nervous 
system develops from the neural plate, a slipper-shaped area of embryonic ectoderm. 
The notochord causes the overlying ectoderm to differentiate into the neural plate, 
before the neural folds, neural tube and neural crest are formed from the neural plate. 
The neural tube differentiates into the brain and spinal cord. The neural crest gives 
rise to cells that form most of the peripheral nervous system (PNS) and autonomic 
nervous system (ANS), which consist of cranial, spinal and autonomic ganglia. 
Formation of the neural tube (neurulation) begins around Carnegie stage 11 
(22-23 days) in the region of the fourth to sixth somites. The cranial two-thirds of the 
neural plate and tube and the first 4 pairs of somites represent the future brain. The 
caudal one-third of the neural plate and tube represents the future spinal cord. 
The neural tube cranial to the fourth pair of somites develops into brain. Three 
primary brain vesicles are formed after fusion of the neural folds in the cranial region 
and closure of the rostral neuropore. These three primary brain vesicles develop into 
the future forebrain (prosencephalon), midbrain (mesencephalon) and hindbrain 
(rhomencephalon). During the fifth week the forebrain partly divides into two 
secondary brain vesicles, the telencephalon and diencephalons; the midbrain does not 
divide; the hindbrain partly divides into the metencephalon and myelencephalon 
(Moore, 2003). 
The neural tube caudal to the fourth pair of somites develops into the spinal cord. 
The lateral wall of the neural tube thickens, gradually reducing the size of the neural 
canal until only a small central canal of the spinal cord is present at 9-10 weeks 
(Moore, 2003). Initially the wall of the neural tube constitute the ventricular zone 
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(ependymal layer), the site for active neuronal cell proliferation. Soon a marginal zone 
composed of the outer parts of the neuroepithelial cells becomes recognizable. This 
zone gradually becomes the white matter. As these primitive cells continue to divide, 
subtle decisions begin to be made as to their fate. Some will become neurons while 
others are fated to become glial cells. The mechanisms controlling these processes 
still remain unknown. 
In early 1960, Fujita et al. noticed a very characteristic mitotic pattern in neural 
tube of human embryos, which he called it the "matrix cells" cytogenesis theory. In 
his proposed mechanism, there are three stages of cytogenesis of the multipotent 
neuroepithelial stem cells (matrix cells). In stage I, the matrix cells perform 
"elevator-like movements" during proliferation. The nuclei of the cells undergo a 
cyclic change of position in the neuroepithelial cell layer. That is, the nuclei of 
intermitotic cells lie deeply, and progressively approach ventricular lumen during G2 
and prophase. Nuclear division occurs exclusively at the luminal surface, upon which 
the daughter nuclei move back again to the deeper positions, as illustrated in Fig. 5.5. 
(Fujita, 2003). 
160 
M 
S 
Fig. 4.2 Elevator movement and the relationship with the cell-cycle of the by neuroepithelial cells. M: 
mitotic zone; I: intermediate zone; S: zone of DNA synthesis. (Adapted from S. Fujta, cell structure and 
function 28: 211) 
During stage II cytogenesis, neuroblasts are derived from matrix cells. The 
neuroblasts subsequently migrate peripherally to the mantle and marginal layers, and 
are characterized by an absolute lack of 3H-thymidine incorporation, which represent 
complete repression of DNA synthesis. The production of neuroblasts in various 
regions of the brain was found to follow a well-organized temporal and spatial pattern 
(Lyons et al., 2003). 
During stage III of cytogenesis (stage of filial ditýterentiation). 3H-thymidine 
autoradiography revealed that the matrix cells switch off to neuroglial differentiation, 
and change into ependymoglioblasts, which are committed glial progenitors. At this 
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time the ependymoglioblasts are morphologically indistinguishable from the matrix 
cells. The ependymoglioblasts are then rapidly differentiated into the ependymal cells 
and glioblasts. The glioblasts then differentiated into astrocytes, oligodendrocytes and 
finally the microglia (Fujita, 2003). 
There are marked regional differences in the progression of the stage from Ito II, 
and from II to III in various parts of the CNS. In some regions, neuronogenesis 
(stageIl) is prolonged and the transition between stage II and III takes place after birth 
(Johansson et al., 1999). The postnatal neuronogenesis is reduced as the animals grow 
older (Zitnik and Martin, 2002). However, modification of neuronal fate can occur 
only at early stages of matrix cell differentiation. When stage II neurogenesis starts, 
neuronal fate is irreversibly fixed. The basic mechanism this specification relies on 
the so called "major differentiation" hypothesis. That is, in the beginning of 
ontogenesis, the cell is at its maximum totipotent state, and the length of the S-phase 
is expected to be short. As the cell progresses by steps of differentiation, irreversibly 
inactivated replicons increased in number and the S-phase become longer. The type of 
cell differentiation is determined by a specific combination of irreversibly inactivated 
replicons. With repeat mitoses and entering into G1 phase, irreversibly inactivated 
replicons increase in number. Cells undergoing neuron-generating division have a 
longer cell cycle than those undergoing proliferating division and this cell-cycle 
lengthening mostly concerns Gi (Calegari et al., 2005). However, the molecular basis 
underlying this specification is still not well known. 
4.2.3.2 The developing limbs 
Basically, the limb consists of four segments: (1) the root (zonoskeleton); (2) a 
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proximal segment (stylopodium) consisting of a single bone (humerus, femur); (3) a 
middle segment (zeugopodium) consisting of two bones (radius and ulna, tibia and 
fibula); and (4) a distal, more complex part (autopodium) consisting of several bones 
(hand, foot) (Gurrieri et al., 2002). The limb arises from a group of mesodermal cells 
covered by surface ectoderm. The mesodermal cells contain progenitors of 
condrocytes and connective tissues that form tendons and muscle sheaths. The 
surrounding muscles and vessels are developed from cells that migrate into the early 
limb bud (Kardon et al., 2002). The establishment and outgrowth of the early limb 
bud depends on the number of cells that constitute it. Once established, the limb bud 
rapidly increases in size. Expansion of progenitors of proximal, middle and distal 
compartments is completed at different times, in a proximal to distal sequence 
(Dudley et al., 2002; Tickle, 2003). Little is known about how it is regulated. It may 
be a reflection of the timing of condensation (Janners and Searls, 1970). 
The key stages in limb skeletal development are initiated as a protrusion from the 
lateral mesodermal plate of the embryo. Substantial outgrowth and patterning occurs 
over the course of the next few days, culminating in the establishment of cartilage 
templates that will form future bones. During this time, chondrocyte progenitors 
aggregate and form prechonfrogenic condensations. Joint formations subsequently 
begin and the chondrocytes differentiate and secret cartilage extracellular matrix 
molecules (as illustrated in Fig. 4.3) (Mariani and Martin, 2003). 
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Fig. 4.3 Key stages in limb skeletal development. a, limb formation initiates in the chicken embryo at 
-3 days of development. b, substantial outgrowth and patterning of the limb bud that prefigure the 
bones. c, chondrocyte progenitors aggregate and form prechondrogenic condensations. d, joint 
formation begins and e, the condrocytes differentiate and begin secreting cartilage extracellular matrix 
molecules (Figure from F. V. Mariani & G. R. Martin. Nature, 423: p321). 
The formation of condensations of chondrocyte progenitors that outline the 
future limb skeleton patterning is possibly the most critical events in limb 
development. Prechondrogenic condensations are detectable morphologically as 
regions of increased cell density. Cell-cell interactions are important in initiating 
condensation, perhaps by establishing an "aggregation centre" that recruit cells from 
surrounding tissue (DeLise et al., 2000a; DeLise et al., 2000b). It seems that 
condensations form at specific stages of limb development, in a proximal to distal 
sequence. If timing for condensations is indeed fixed, alterations in cell number in the 
limb bud should affect skeletal patterning. If fewer condrocyte progenitors are present 
at the time of condensation, one might expect smaller elements to form. It has been 
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shown that when the limb bud cell number is reduced, the skeletal elements that form 
are smaller than normal and misshapen (Wolpert et al., 1979). Moreover, when the 
limb bud cell number drops below a certain threshold, condensations do not occur 
(Wolpert et al., 1979). The limb reduction defects in patients with CdLS range from 
amelia (absence of limb), meromelia (absence of part of the limb), and these are often 
asymmetric. Digital abnormalities seen in CdiS patients include acheiria, 
oligodactyly, hypoplasia of the thumb and first metacarpal, clinodactyly of the -fifth 
finger, and ectrodactyly. Long bone abnormalities include ulnar a/hypoplasia, 
dysplasia of the radial head, or fusion of the elbow. Fusion at the elbow and 
oligodactyly are often observed whenever a single long bone of the middle segment is 
present (Braddock et al., 1993). 
Joint formation is another process crucial for patterning. It occurs at several 
stages, either between the boundary of two adjacent condensations or within single 
condensation. Proper positioning of joints within condensations influences the number 
and the size of skeletal elements (Cohn et al., 2002; Francis-West et -al., 1999). 
Fusion of the elbow joint as described in CdIS phenotypes may result from 
inappropriate joint formation during limb patterning. 
4.2.3.3 The developing craniofacial system 
Although the neural crest received a significant amount of attention, it is not the 
only craniofacial tissue with patterning information. New studies have demonstrated 
the contribution of epithelia as a source of patterning information for the face. The 
epithelia can be of ectoderm covering the facial prominences (Hu et al., 2003), or are 
neural ectoderm (Cordero et al., 2004), or are of endodermal origin that line the 
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pharynx (Ruhin et al., 2003). In a growing number of cases, epithelial tissues are 
actually the instigators of morphological change (Tapadia et al., 2005). The 
craniofacial complexes initially have a more simple geometry, consisting of a series of 
swelling or prominences that undergo growth, fusion and expansion. These consist of 
the midline frontonasal prominence, and three paired structures, the lateral nasal, 
maxillary and mandibular prominences derived from the first pharyngeal (brachial) 
arch. The frontonasal prominence is derived from a midline primordium that forms on 
top of the forebrain. The frontonasal prominence contributes to the forehead, midline 
of the nose, philtrum of the upper lip and primary palate. Until recently, it was thought 
that the ventral region of the first pharyngeal arch gave rise to the mandibular 
prominence and therefore the lower jaw. Moreover it was thought that the dorsal 
region of the first arch gave rise to the maxillary prominences, which contribute to the 
sides of the middle and lower face, the lateral borders of the lips, and the secondary 
palate. Two new studies demonstrated that at least part of this fate map is incorrect. 
Both groups showed that the ventral region of the first arch actually gives rise to both 
maxillary and mandibular skeletal elements, rather than only to the mandibular 
elements as previously thought (Cerny et al., 2004; Lee et al., 2004). The cells 
comprising the face have undergone a massive relocation through both active neural 
crest cell migration and the passive displacement of tissue that is associated with 
neurulation and head flexure (Couly et al., 1996). 
One of the first crucial steps in craniofacial development occurs when head 
ectoderm is subdivided into non-neural and neural regions to establish the head 
epithelium. While the non-neural regions will lie outside of the cranial neural crest, 
the neural regions will lie inside it. A subset of epithelial cells located at this 
neural/non-neural boundary adopts a mesenchymal character and initiates the 
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epithelial cells' migration between these two epithelium layers. This 
epithelial-mesenchymal transition marks the birth date of the neural crests and has 
been shown to depend upon cells shifting from Gi to S phase. This shift is dependent 
upon, at least for trunk neural crest cells, - bone morphogenetic protein (Bmp) 
(Burstyn-Cohen et al., 2004). When Bmp signaling is inhibited by the overexpression 
of noggin, a Bmp antagonist, the Gl/S transition is blocked and neural crest cells are 
no longer generated from the margins of the neural folds (Burstyn-Cohen et al., 2004). 
Bmp exerts its effect, . in part, though the regulation of the 
Wnt I transcrition 
(Garcia-Castro et al., 2002). 
Debate still continues over verifying the correct tissue that controls facial 
patterning. Recent experiments have demonstrated that the pharyngeal endoderm has 
a profound influence on the morphogenesis of the middle and lower face (Crump et al., 
2004a; Crump et al., 2004b; Le Douarin et al., 2004). However, not all cartilages are 
equally affected. Mandibular cartilages derived from Hox-negative neural crest cells 
are less affected than are Hox-positive second arch cells. Removal of the endoderm 
completely blocked the formation of pharyngeal arch skeletons (Ruhin et al., 2003). 
Even so, the pharyngeal endoderm is not required for normal development of the 
middle and upper part of the face. As an alternative, the anterior (or forebrain) 
neuroectoderm and the facial ectoderm appear to have taken over this crucial role 
(Aoki et al., 2002). 
4.2.3.4 The developing heart 
The heart arises from cells in the anterior lateral plate mesoderm of the early 
embryo, where they are arranged in bilateral fields on either side of the prechordal 
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plate and rostral notochord. These fields include the precursors of both myocardial 
and endocardial cells, although there is apparently no common pool of bipotential 
precursors for these two heart cell lineages. The cells of the cardiogenic mesoderm are 
brought to these positions by gastrulation movements that occur in close association 
with cells of the rostral endoderm. In mammalians, the bilateral fields of the 
cardiogenic mesoderm merge at their anterior margins to form the so-called "cardiac 
crescent". More recent studies have identified a second type of heart field that is 
located more medially in the splanchnic mesoderm, directly adjacent to the cardiac 
crescent. The cells from this bilateral field, termed anterior heart-forming field, are 
fated to generate anterior heart structures of the outflow tracts (Kelly and Buckingham, 
2002) The earliest steps of assembly of the heart tube are initiated by the convergence 
and fusion of the bilateral heart primordia along the midline. The cells of the anterior 
heart-forming field, after having migrated anteriorly, are added to the anterior end of 
the linear tube during and after this period. The resulting beating tubular heart is 
composed of an external myocardial and an internal endocardial layer and also 
possesses a polarity along the anteroposterior axis, in which the prospective tissues of 
the aortic sac, outflow tract (conotruncus), right ventricle, left ventricle, and atria are 
present in an anterior to posterior order along the tube (Kelly and Buckingham, 2002). 
The tubular heart undergoes a process known as rightward looping. The 
morphogenetic steps required to achieve looping are guided by molecular 
asymmetries that are established in and around the heart by the embryonic left/right 
axial pathway. Furthermore, in higher vertebrates, septal division of the chambers and 
formation of the valves, which involves endothelial cells, are essential steps leading to 
the formation of an integrated 4-chambered heart with separate venous (or inflow) and 
arterial (or outflow) poles. During the growth process of the cardiac epithelium, 
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another distinct cell lineage, the migrating cardiac neural crest cells, populate the 
heart through the outflow channel and contribute to the formation of the great vessels 
and outflow septum (Christoffels et al., 2000). 
The spatial and temporal orchestration of these processes implies a complex 
program of genetic control. This program is exerted in large part through precisely 
controlled processes of cell-cell signaling - and regulators of gene expression. The 
major signaling mechanisms controlling early heart development, specification of 
myocardial cells and heart patterning will be discussed below. 
During the stage of early inductive processes in heart specification and 
determination, cells of the anterior endoderm and/or their precursors have a major role 
in inducing cardiogenesis. Ectodermal influences on cardiac induction have also been 
described and are thought to serve mainly in counteracting negative influences from 
the neural plate. Nevertheless, in vertebrates, the heart-inducing activity is 
predominantly of endodermal origin (Zaffran and Frasch, 2002). 
Genes encoding factors of the NK homeodomain, GATA, T -box, and other 
families were found to exert the functions of inductive signals during specification, 
patterning, and differentiation of the heart. Moreover, developmental signaling 
pathways are required to act in combination with tissue-specific transcriptional 
cofactors to elicit inductive responses. 
Signaling pathways involved during the induction of cardiogenic mesoderm 
include (1) BMP/Dpp signaling, (2) Wnt/Wingless signaling, (3) Fibroblast growth 
factor signaling, and (4) Notch signaling pathways (Zaffran and Frasch, 2002). 
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Complete disruption of any of the major pathways in early heart development 
results in embryonic lethality. More subtle disruptions by haploinsufficiencies and 
hypomorph or dominant-negative mutations can lead to malfunctioning of the heart at 
later stages during the lifespan of the organism (Chien, 2000). 
4.2.3.5 The developing lung, kidney and pancreas 
Branching morphogenesis, defined as growth and branching of epithelial tubules 
during embryogenesis, is elemental to the formation of several mammalian tissues 
including the kidney, lung, salivary gland, mammary gland, and pancreas. During 
branching morphogenesis, a tubular network is generated via mesenchymal-epithelial 
interactions that are coordinated by a complex network of several gene products. 
Signals derived from the mesenchyme instruct the epithelium to grow and branch. 
Although several classes of growth factors are involved, members of FGF family act 
in many tissues to positively regulate branching morphogenesis, while members of 
BMP family might act to limit branching in kidney and lung branching morphogenesis 
(Angle et al., 2003). 
Lung development begins with the appearance of the laryngotracheal groove, 
which is a small diverticulum that arises from the floor of the primitive pharynx 
during the fourth week of gestation in human embryos. The groove sepreates 
dorsoventrally from the primitive esophagus to form the tracheal rudiment that gives 
rise to two primary bronchial buds. This initial branching event is followed by 23 
generations of branches via invasion into the surrounding mesenchyme and bifid 
branching. Human diseases associated with the pulmonary branching defects include 
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tracheoesphageal fistula, pulmonary hypoplasia, bronchopulmonary dysplasia, and 
even asthma (Bartram and Speer, 2004; Chinoy, 2003). 
Formation of the kidney starts during the fifth week of gestation, in human 
embryos . (CS 14) when the ureteric duct is induced to undergo lateral outgrowth from 
the Wolffian duct and to invade the adjacent metanephric mesenchyme. Reciprocal 
induction between the ureteric bud and metanephric mesenchyme leads to multiple 
repetitive branching events and elongation of the ureteric bud to form the collecting 
system. The mesenchyme is induced to condense and epithelialise around the branch 
tips and eventually matures into the part of nephron responsible for regulation of iron 
and organic molecule transport (proximal and distal tubules), as well as the 
glomerular (filtering) components (Piscione and Rosenblum, 1999; Qiao et al., 
1999a). 
The pancreas is derived from endodermal cells of the upper duodenal region of 
the foregut. In the human embryo, the pancreatic primordial first appears during the 
fifth week of gestation in the form of epithelia buds from dorsal and ventral 
evaginations of the primitive foregut. The buds undergo lateral and iterative bifid 
branching to form a complex branched structure. 
4.2.3.6 The developing gastrointestinal system 
The gut is composed of two tissue types in a tubular arrangement. The outer 
layer(s) of the tube is primarily smooth muscle derived from lateral plate splanchnic 
mesoderm. The inner luminal lining is an epithelium derived from ectoderm in the 
most anterior region of the gut (the mouth) and the most posterior region (the anus). 
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The majority of the gut epithelium is endodermally derived. The endoderm of early 
gut tube stages is remarkably uniform in its morphology along the anterior-posterior 
length of the primitive gut tube. There are no morphologic differences between the 
portions of tube formed by elongation of the anterior intestinal portal (AIP) or by the 
caudal intestinal portal (CIP) poles of the embryo, and no distinctions in regions that 
will eventually form the AP portions of the gut: foregut, midgut, hindgut and their 
adult phenotypes of esophagus/stomach, intestine, and colon. As the mesoderm grows 
and differentiates into smooth muscle, the gut tube alters its gross morphology, 
resulting in clear demarcations among the foregut, midgut, and hindgut. When 
considering gut formation, it is necessary to pay attention to the interaction between 
the endoderm and mesoderm. Each of these layers probably contains positional 
information prior to the establishment of their topographical juxtaposition. Numerous 
cofactors, enhancers, and modifiers are involved in gut development. Basic events 
that control gastrointestinal tract development remain still poorly understood (Roberts, 
2000). 
4.2.3.7 The developing germ cells 
The initial stages of gonadal development occur during the fifth week when a 
thickened area of mesothelium develops on the medial side of the mesonephros. 
Proliferation of this epithelium and the underlying mesenchyme produce a bulge on 
the medial side of the mesonephros - the gonadal ridge. During the sixth week of 
gestation, the primordial germ cells enter the underlying mesenchyme and are 
incorporated in the gonadal cords (Moore, 2003). Primordial germ cells are migratory 
cells. They arise very early in embryogenesis and have a similar pattern of migration 
in Drosophila, Xenopus, chick and mouse. Germ cells proliferate mitotically from the 
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time they begin to migrate to the time they colonize the genital ridges (Gomperts et al., 
1994). 
The aim of this project is to use human embryos collected from different 
Carnegie stages to study the expression patterns of NIPBL in different major organ 
systems. The details will be shown in later sections. 
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43 MATERIALAND METHODS 
4.3.1 Tissue in situ Hybridization 
4.3.1.1 Collection of human embryos 
Collection of human embryos was carried out in accordance with National 
Ethical Guidelines (Polkinghorne, 1989) and Local Ethical Committee approval by 
Prof. S. Robson and Dr. P. Bullen (Department of Fetal Medicine, University of 
Newcastle upon Tyne). Most of the slides were prepared by staffs of Human 
developmental Genetics in the Institute of Human Genetics, University of Newcastle 
upon Tyne. Patients who had decided to undergo termination of pregnancy (TOP) 
were given an information sheet covering the use of embryonic material for research 
and written consent was gained from those agreeing. The procedure requires the 
fulfillment of two requirements in order to take place. It is necessary to make sure that 
(1) the termination of the pregnancy was not motivated by research needs (2) the 
obstetrician involved in the termination process did not use the embryonic material for 
research (Polkinghorne, 1989). Embryos from Carnegie stage 10 to 22 (21 to 53 days 
of development) were collected and staged based on classification of O'Rahilly and 
Muller (O'Rahilly R, 1999). Embryos were investigated for normal anatomy under 
stereomicroscope. 
4.3.1.2 Tissue fixation and embedding 
After dissection from the amniotic sacs, the embryos were placed in RNase free 
Duran bottles containing 4% PFA in PBS for 16 hours with gentle agitation. The 
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embryos were then dehydrated by passing through a series of 70%, 80%, 90% and 
100% ethanol solutions for 2 hours each at room temperature with gentle agitation. 
The embryos were treated with chloroform for 16 hours to remove the ethanol and 
then molten paraffin three times (2 hours each) at 60 °C with the last one being in 
vacuum. Embryos were orientated in paraffin at certain position and the paraffin 
blocks were allowed to solidify. The embedded embryos were kept at 4°C until 
required for sectioning. 
4.3.1.3 Tissue sectioning 
Paraffin blocks containing fixed embryos were oriented into the required plane to 
enable transverse or sagittal sectioning and mounted on a microtome stage, which was 
securely, fitted into the microtome (leica RM 2135, Leica Instruments, Germany). The 
microtome, the wooden trays and cutting accessories were cleaned with 0.1% DEPC 
in 96% ethanol to ensure that they are RNase free. Sections were cut at Sum and 
collected as continuously orientated ribbons on RNase free trays. Four sequential 
sections were mounted on a single slide and placed them on a meniscus of sterile 
water covering the coated slide. The sections were warmed up to 51°C to stretch the 
tissues. The water was removed from the slide by using a pipette tip attached to a 
suction tube. The slides were kept in a warm plate for a few hours before drying them 
overnight at 37°C in a drying cabinet. Dried sections were stored at 4°C in RNase 
free boxes. 
4.3.1.4 Tissue pre-treatment 
Tissue pre-treatment allows the accessibility of target RNA to the labelled probe 
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and reduces non specific binding during hybridization (Moorman et al., 1993). All the 
pre-treatment steps were completed in RNase free conditions by cleaning the surfaces 
thoroughly with 0.1 % DEPC in 96% ethanol. In addition, all the glassware used in 
the procedures was prebaked at 180 °C for at least 4 hours prior to use. All the 
solutions were made by using DEPC treated water or PBS. The slides were placed in a 
metal rack and de-waxed three times with xylene treatment for 5 minutes each. They 
were then set in a mixture of xylene/ethanol (1: 1), before being twice laid in 100% 
ethanol for 3 minutes each. Finally they were placed in a series of 90%, 70%, 50% 
ethanol (2 minutes each) and washed twice in PBS solution for 2 minutes each. The 
sections swell after this treatment, which help both the accessibility of proteins for 
digestion in the next step and the unfolding of target RNA. Protease treatment was 
performed using Proteinkinase K (20 ,u g/ml) dissolved in PBS solution (20 g I/ml) for 
8 minutes. The treatment time varied according to the type of tissue, the age of the 
embryo (no treatment for CS 13,8 minutes for embryo staged more than CS17). The 
tissues were washed twice in PBS solution for 2 minutes each, before being immersed 
in 4% PFA/PBS solution for 20 minutes to retain their morphology. To reduce the 
non-specific background staining, the slides were then immersed in a solution 
containing acetic anhydride (0.25% Acetic anhydride, O. 1M Triethanolamine pH 8.0) 
for 10 minutes and washed in PBS twice for 2 minutes each. Afterwards, the sections 
were dehydrated in a series of 50%, 70%, 90%, 100% and fresh 100% of ethanol. The 
slides were dried under filtered air stream and hybridized within 3 hours. 
4.3.1.5 Probes used for in situ hybridization 
Antisense and sense RNA probes were synthesised from cDNA clones, contained 
in plasmid vectors, which have two of the RNA polymerase promoter sites. The 
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cDNA clones used for this are described below: 
(1) The human NIPBL cDNA clone was generated by PCR amplifying a 424bp 
fragment extending exon 10,11 and 12 of the human NIPBL, which should hybridize 
to transcript encoding both the long and short isoforms. The PCR fragment was 
amplified from Homo sapiens IMAGE: 1952030 cDNA clone. No - overlapping 
sequences were found in the amplified fragment in the whole human genome. The 
primers used for the amplifying are: 5'GAAAGGAGAGCCGAAAGACA'3 and 
5'CGCTCTTCATATT000AAGC'3. The amplified 424-bp cDNA fragment was 
cloned into the pGEM-T Easy vector (Promega) containing Sp6 and T7 RNA 
polymerase promoter sites. For isoform A specific probe, cDNA was generated by 
using PCR primers designed to amplify a 348bp cDNA probe in the 3'end isoform A 
specific region. The sequences of the primers are: 
5'CTTGAAAATGTGTTTGGCACA 3' and 5' GAAAAGGGATCCCCAGGTAA 3'. 
For isoform B specific probe, cDNA was generated by primers designed to amplify a 
405bp cDNA probe in the 3'end isoform B specific region. The sequences of the 
primers are: 5'CAAAAGGATGTATAAACGGGTAA 3' and 5' 
CCAAAATCACAGAAGAAGAGGTGAA3'. 
(2) Mouse MLC 2V cDNA probe: This probe is a kind gift from Steve Lisgro 
(Department of Developmental Genetics). The cDNA was cloned into TA vector 
containing the Sp6 and T7 RNA polymerase sites. The purpose for using this probe is 
for positive control for in situ hybridization. Mouse MLC 2V is stably expressed in 
the embryonic mouse's heart. 
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4.3.1.6 Probe labeling 
4.3.1.6.1 Temperate linearilisation 
Single-stranded RNA was synthesised from the cDNA template within a plasmid 
vector containing Sp6, T7 or T3 RNA polymerase promoter sites (Mierendorf and 
Pfeffer 1987). The plasmid was linearised by a restriction enzyme which separates the 
rest of the vector from the insert. Complete digestion was checked by agarose gel 
electrophoresis. The linearised template was cleaned by phenol/chloroform extraction, 
precipitated in absolute ethanol and 0.3 M sodium acetate and resuspended in TE 
buffer to a concentration of 0.3-1, uglul (Ausubel, 2002). 
4.3.1.6.2 RNA transcription 
Single stranded labelled RNA probes were synthesised using non-radioactive 
DIG labelling (Roche Applied Science) from 0.5, ug of DNA template in a reaction 
mixture containing 2µl of 1OX transcription buffer, "2 µl NTP labelling mixture (10 
mM ATP, Cl?, GTP, 6.5 mM UTP and 3: 5 mM DIG-11-UTP, pH 7.510 x conc. ), 1 , UI 
RNase inhibitor, 2µl RNA polymerase and RNase-free water to a final volume of 
20µl. The reaction mixtures were incubated at 37°C in a water bath for 2-3 hours 
followed by adding 1 u1 DNase and incubated for further one hour at 37`C. The 
quality and quantity of the labelling was determined by gel electrophoresis with 
Hind III as marker and also by ND-1000 Spectrophotometer (NanoDrop 
Technology). The labelled RNA probes were purified by adding 30µl of RNase-free 
water to a total of 50 µl volume. The unincorperated labelling mix was removed by 
adding the final reaction mixture to the centre of a column and centrifuged at 
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2500rpm for 2 minutes. The purified probes were collected into new microcentrifuge 
tubes. The purified probes can be stored at -80°C for up to 6 months. 
4.3.1.6.3 Control Riboprobes 
To assess the efficiency of transcription from the plasmid-generated template, the 
sense and pSTP18-neo (provided with the labeling kit) riboprobes were used as 
negative control probes. Mouse MLC2V cDNA was used as positive control. 
4.3.1.7 Probe hybridization 
300, ug of riboprobes was used for each slide for hybridisation. Briefly, the 
riboprobe was mixed with DIG Easy Hyb (Roche Applied Science) to a total volume 
of 100µl for each slide to be hybridized. The hybridization mixture was then carefully 
added to the slide and the slide was covered with a clean RNase-free coverslip. The 
slides were kept horizontal in RNase free plastic trays and put in moist Hybridisation 
chamber (50% formamide/2xSSC). The hybridization was carried out in an oven at 65 
°C overnight. 
4.3.1.8 Post-hybridisation washes 
The slides were rinsed in 5xSSC (pre-warmed to 65°C) and coverslips were 
removed from the slides carefully by gentle agitation and placed in a slide rack. The 
slides were then rinsed in 200m1 of 50% fonmamide/2xSSC at 65°C for 20 minutes in 
a fume hood. Afterwards, the slides were washed in a series of 2xSSC (30minutes at 
50°C, twice), 0.2xSSC (30 minutes at 50°C, once) and 0.2xSSC (30 minutes at room 
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temperature, once) solution in a shaking water bath to remove the non-hybridized 
riboprobes. 
4.3.1.9 Antibody Detection 
The slides were rinsed in wash Buffer 1 (0.1M Tris pH7.6,0.15M NaCl, 1mM of 
levamisole) for 5 minutes (twice) and- blocked in a blocking solution (10% heat 
inactivated fetal calf serum/Buffer I) for 1 hour. 100µl of anti-DIG mix (anti-DIG Ab: 
2% fetal calf serum/Buffer I=1: 1000) was then carefully applied to each slide and the 
slide was covered with a strip of parafilm to prevent from drying out. The slides were 
then put in a large moistened tray at 4°C overnight. The slides were subsequently 
washed in Buffer I for 30 minutes (6 times), and equilibrated in Buffer II (0.1M Tris 
pH9.5,0.1M NaCl, 50mM MgC12,1mM of levamisole) for 5 minutes. The slides were 
subsequently placed in a light proof coplin jar containing NBT/BCIP (4-Nitro blue 
tetrazolium chloride/5-Bromo-4-chloro-3-indolyl-phosphate 4-toluidine) solution 
(20µ1/m1 stock solution in Buffer II). The slides were then left to develop for several 
hours. The degree of the tissue staining was periodically checked under a light 
microscope. The staining was stopped by placing the slides into Buffer II and rinsed 
in water. To reduce background staining, the slides were quickly rinsed in 
1%HC1/methol solution and washed in several changes of water. The sections were 
mounted in Antifade Mounting Solution (Aquamount) with coverslips. 
43.2 Immunohistochemical (IHC) staining of the slides 
The embryos' collection, sectioning were as previously described. As the 
expression patterns of NIPBL (see results) prompted us to examine the possibility that 
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the gene product of NIPBL might be associated with active proliferation, we 
examined the expression of the proliferating marker-PCNA and compared the 
expression with the NIPBL in situ staining. Due to the lack of feasible RNA probes 
available for PCNA, we used IHC staining of the PCNA antibody (abCam) instead. 
4.3.2.1 Dewaxing and Antigen retrieval 
Formalin fixed tissue requires an antigen retrieval step before 
immunohistochemical staining can proceed. This is due to the formation of methylene 
bridges during fixation, which cross link proteins and therefore mask antigenic sites. 
The two methods of antigen retrieval are (1) enzymatic and (2) heat mediated. Both 
serve to break the methylene bridges and so expose the antigenic sites in order to 
allow the antibodies to bind. 
Briefly, slides were dewaxed by immersing them in 3 changes of Xylene, for 5 
minutes each and rehydrated in a series of 100%, 100%, 90%, 70%, and 50% of 
ethanol solution for 2 minutes each. The slides were then rinsed in PBS twice for 5 
minutes each. 
For antigen retrieval, the slides were placed in a microwavable vessel containing 
retrieving solution (0.1M Tri-sodium citrate, 0.2MHCl pH6.0) and heated in a full 
powered microwave for 30 minutes. To prevent drying out of the solution, more 
retrieving solution was added after 15 minutes in the microwave. In order for the 
slides to cool down, the slides were placed under running water. 
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4.3.2.2 Staining of mouse monoclonal primary PCNA antibody 
The slides were rinsed in TBS (6.06g TrisHCl, 1.39gTrisBase, 8.77g NaCI make 
up to 1 liter with ultra pure -water) twice for 5 minutes each. To inactivate the 
endogenous peroxidase activity, the slides were placed in 1.6% of hydrogen peroxide 
in TBS for 30 minutes and then washed in 2 changes of TBS0.025%Triton for 5 
minutes each. The slides were subsequently blocked in 10% normal saline/1% BSA 
(Bovine serum albumin) in TBS for 2 hours at room temperature. PCNA mouse 
monoclonal antibody was applied (1: 1000 dilution with 1%BSA in TBS) and 
incubated at 4°C overnight on an orbital shaker. 
4.3.2.3 Secondary Antibody staining and antibody detection 
After overnight incubation with primary antibody, the slides were rinsed in TBS 
0.025% Triton-X twice for 5 minutes each. Secondary biotinylated antibodies (Goat 
anti-mouse) made up in 1%BSA/TBS were applied to slides at room temperature and 
incubated for 2 hours. Meanwhile, the ABC complex (0.1% Streptavidin, 0.1% HRP 
(or AP)-Biotin) in TBS was made. After 2 hours of incubation, the slides were rinsed 
twice with TBS 0.025% Triton for 5 minutes each followed by the application of ABC 
complex in TBS for 30 minutes and developed with chromogen (DAB, 
Diaminobenzidine) for variable time and checked periodically. The slides were then 
counterstained in 2% methyl green solution (2% (w/v) methyl green in 0.1 M nodium 
acetate, pH 4.2) and followed by a series of 50%, 70%, 90%, and 100% of ethanol 
dehydration and cleared in 2 changes of xylene. The slides were mounted histomount 
(Invitrogen). 
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43.3 Image analysis 
The mounted slides were allowed to dry for at 24 hours and then the sections 
were visualised using a Zeiss Axiophot microscope under daylight. Images were 
captured with the Image Axioversion Rel 4.1 version software and photographed "" 
using cooled CCD camera. 
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4.4 RESULTS 
The expression in different tissues showed different intensities by the result of 
Northern blot. However, precise location of expression can not be detected by 
Northern analysis alone. Thus, I decided to perform tissue in situ hybridization by 
using riboprobes on parafilm embedded human embryos section and tried to correlate 
the expression pattern and the phenotypes associated with CdLS. 
The expression of NIPBL was studied in human embryos ranging from 28-60 
post ovulation days, which corresponds to Carnegie Stages 13-23 (see Appendix B for 
an approximate equivalence of Carnegie stages and postovulatory days). The 
expression of the human NIPBL gene during all these stages was seen in many 
different organ systems. The expression patterns by using riboprobes in different 
organ systems are described in detail below: 
4.4.1 Expression of NIPBL in human embryonic nervous system 
At stage 13 (28-30 postovulatory days), NIPBL transcripts were detected in the 
spinal cord and primordium spinal ganglion (see Fig. 4.4). At Carnegie stage 20 and 
21 (52-53 postovulatory days), the expression was widely detected on cerebral 
hemisphere, midbrain, cerebellum, thalamus, hypothalamus and brain stem. The 
expression was mainly seen in the inner most ventricular zone (see Fig. 4.5) where 
active proliferation of matrix cells (multipotential stem cells) occurs. To test whether 
NIPBL expression involved the active proliferating cell zone, I used proliferating cell 
nuclear antigen (PCNA) antibody as a probe for immunohistochemistry staining near 
the embryo section that we used for RNA tissue in situ hybridization and compared 
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the pattern of expression. The sites of tissue expression were very similar in the brain 
for both NIPBL and PCNA (see Fig. 4.6). Initially, I also intended to compare the 
expression pattern of PCNA- and - NIPBL on CS 13 embryo paraffin sections.. 
Unfortunately, lack of CS13 embryo sections hindered me for further investigation. 
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Fig. 4.4 Expression pattern of NIPBL transcript on CS l3 (A) and CS20 (B) embryo sections. The 
expression of NIPBL transcript was seen on pseudostraified cylindrical epithelium of the developing 
spinal cord and spinal ganglion. Sp: spinal cord and Ga: spinal ganglion 
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Fig 4.6 NIPBL expression on the developing brain of CS23 human embryonic section. Expression 
patterns of , VJPBL transcript using riboprobes and PCNA antibody on CS23 embryo sections showed 
(A) CS23,1.25X. The NIPBL expression was seen on ventricular zone of the developing brain tissue. 
(B) CS23,5X of section (A); the expression of NIPBL transcript was mainly observed in the innermost 
ventricular zone. (C) Expression of NIPBL transcript is parallel to that of the expression pattern of 
PCNA using immunohistochemistry which indicate zone of active proliferation. Bst: brain stem: Cb: 
cerebellum, D: diencephalon; H: hindbrain: Hy: hypothalamus, M: midbrain: T: telencephalon ; Th: 
thalamus; Ton: tongue 
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4.4.2 Expression of NIPBL in human embryonic limbs 
The expression of NIPBL in early limb buds (CS13, Fig. 4.7) was found mainly 
in the multilayered epithelial structure. As the limbs elongate, the expression on CS21 
embryo is mainly traced in the chondroblasts in diaphyseal ossification centres and 
the surrounding developing muscles (Fig. 4.7 & 4.8). 
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Fig. 4.7 17PBL expression the early limb bud (CS 13). The expression was observed mainly in the 
surface layers, the limb placode (arrow head). Lb: limb bud; LbP: limb placode. 
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4.43 Craniofacial and ophthalmic expressions of NIPBL in human embryos 
4.4.3.1 Craniofacial expression of NIPBL 
NIPBL expression was only observed in glabella/the nasal root area, certain 
facial musculatures and musculature of the tongue (see Fig. 4.10). The expressions of 
NIPBL in the developing craniofacial skeleton, however, are not obvious. I have tried 
several experiments, which resulted in similar expression patterns. NIPBL expression 
was seen in glabellas near the frontonasal prominence. NIPBL expression was also 
seen in the nasal septum, olfactory epithelium and pharyngeal endoderm (see Fig. 
4.10 & 4.11). 
193 
A 
Le 
C 
ExO 
Mi Pal 
B 
NuRe 
*Ns 
ý*'Olfe 
Ton Mu 
Mes 
Olfe 
Ns 
Olfe 
Mi Pal ýý 
Fig. 4.10. NIPBL expression in developing face. A: NIPBL expression (CS20) was seen on nural retina 
and lens epithelium. B: expression of NIPBL (CS20) was seen on mesenchyme of glabellas and 
olfactory epithelium. C: expression of NIPBL (CS22-23) was seen on nasal septum, extraocular 
muscles, olfactory epithelium, midline of palate, and musculature of developing tongue. ExO: 
extraocular muscle; Le: lens epithelium; Mes: mesenchyme; Mi Pal: midline of palate; Ns: nasal 
septum; NuRe: neural retina; Olfe: olfactory epithelium; Ton: tongue; Ton Mu: tongue musculature. 
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4.43.2 Expression of NIPBL in developing eyes 
The expression of the NIPBL transcript in the developing eyes was mainly seen 
on the retina and lens epithelia, sees (Fig. 4.10A). 
4.4.3.3 Expression of NIPBL in developing ears 
The expression of NIPBL transcript is mainly seen on the surrounding otic 
mesenchyme, which will form the future otic canal (see Fig. 4.12). 
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4.4.4 Expression of NIPBL in developing heart 
After finishing the preparation of the manuscript published in Nature Genetics 
(Tonkin et al., 2004), I decided to perform more detailed, serial expression data on 
human embryos of different stages. After several experiments, I accidentally found 
out that my gene expression pattern is very similar to that of genes such as Wnt 8B 
where heart expression should not exist. This prompted me to examine whether the 
expression data that I used in the published Journal were correct or not. I then 
performed radioactive labeled tissue in situ hybridization, which showed similar 
expression data as compared to the previous data except that the NIPBL expressions 
are stronger in the liver and weaker in the heart (data not shown). However, due to 
high cellularity and the presence of a large amount of red blood cells in the liver, I did 
not consider it significant. I also considered the use of NIPBL antibodies for 
histoimmunocytostaining. Unfortunately, no feasible antibodies were present until 
recently. After several months of trying, with the help from staffs in the 
developmental genetics group, the optimal protocol for tissue in situ hybridization that 
will yield the least background and tissue specific staining was determined. The major 
difference between the new protocol and old protocol include: (1) acetylation of the 
slide sections, for which I incubated slides with 0.1M triethanolamine (TEA) buffer, 
pH 8.0, containing 0.25% (v/v) acetic anhydride to acetylate the slides first; (2) 
quantification of the DIG-labeled probes by using direct blotting procedures with the 
test strip provided by the manufacturer (Roche), spectrometry quantification by using 
nanodrop spectrometer, and by direct electrophoresis of the probes. 300 77 g of labeled 
probes was used per slide instead of 500 i g. (3) use of the hybridization buffer 
directly purchased from Roche Lab. (with the concentration of salmon sperm being 
5X more, Denhardt's solution is 50% less, and SSC are twice more than previously 
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used. (4) more postbybridization washes than previously used (10X compared to 3X). 
In comparison to the previously used protocol, the tropism to myocardium was 
diminished. The new protocol yielded less background and less myocardium tropism 
in several different probes we used. The expression result of NIPBL by using the new 
protocol is still pretty similar to that of previous protocol except in the myocardium. 
No NIPBL expression was observed in myocardium by using the modified protocol. I 
also suspected that if the new protocol will lead to the decreased myocardium staining. 
I used mouse myocardium light chain 2V (MLC2k) antisense and sense strands as 
controls since MLC2V is exclusively expressed in embryonic mouse myocardium. 
Expression on myocardium was seen in MLC2V antisense probe but not with sense 
probe in mouse myocardium. Thus I excluded the possibility of non-staining of the 
myocardium by the modified protocol (see Fig. 4.13). 
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4.4.5 Expression of NIPBL in developing lung, kidney and pancreas 
4.4.5.1 Expression of NIPBL in developing lung 
In my experiments, NIPBL expression was seen on tubule epithelium of the 
developing lung (see Fig. 5.14), which initiates branching morphogenesis. 
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4.45.2 Expression of NIPBL in developing kidney 
In my expression studies, NIPBL expression was seen in metanephric vesicles 
of CS 14 (around 35 postovulartory days) human embryo and in both epithelia and 
surrounding mesenchyme of CS18 mesonephros and metanephros tubules (see 
Fig. 4.15. ). 
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Fig. 4. l5 
_`I»BL expression 
in de%eloping embryonic kidney. (A) expression was seen on mesonephros 
of CS 14 embryonic section. (B) Expression was seen in mesonephric duct, tubules and the developing 
mesonephric glomerulus at Carnegie stage 18 embryo. (C) Expression was seen in metanephric tubules 
and the surrounding mesench}me of the same embryonic section as (B). Glo: developing glomerulus; 
Gon: gonad; Kid: developing kidney (mesonephro); \leC: mesenchyme: N4nD: mesonephric duct; 
Mntu: mesonephric tubule; Ms: mesonephron; Tu: metanephric tubule. 
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4.4.5.3 Expression of NIPBL in developing pancreas 
In my studies, NIPBL expression was seen in developing pancreatic ductal 
epithelium and foregut endoderm (Fig. 4.16). 
4.4.6 Expression of NIPBL in developing gastrointestinal tract 
In my experiment, NIPBL was seen both in the endoderm and mesenchyme of 
the developing foregut and midgut (see Fig. 4.16). 
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Fig. 4.16 NIPBL expression in the developing stomach and pancreas. Expression was seen on stomach 
epithelium and mesenchyme and pancreatic ductal epithelium in CS 18 human embryo. 
206 
4.4.7 Expression of NIPBL in developing gonads. 
NIPBL expression was seen on the premodium germ cells of the urogenital ridge 
in CS 13 embryonic sections. No expression was seen on control slide by using sense 
RNA as control probe. 
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4.5 DISCUSSION 
4.5.1 Expression of NIPBL in nervous system 
In my experiments, I used PCNA as a proliferating marker instead 3H-thymidine 
incorporation. Homogeneous staining was seen exclusively on the ventricular zone of 
the developing brain (Fig. 4.6). The expression of the NIPBL transcript is parallel to 
that of PCNA. Thus, the NIPBL expression should also exist on matrix cells that are in 
their active proliferation state at stage I of cytogenesis. Defects in matrix cells 
proliferation will result in defective neuronogenesis and defective production of glial 
progenitors. Microcephaly, decreased cognitive function and behavior problems may 
result, as seen in patients with CdIS. 
The yeast homologue of human NIPBL, Scc2, is found to be involved in 
cohesion loading which is important for cell replication (Ciosk et al., 2000; Neuwald 
and Hirano, 2000) and postreplicative double strand DNA repair (Sjogren and 
Nasmyth, 2001). By interacting with Scc4, Scc2/Scc4 complexes help in the 
establishing and loading of cohesin onto chromatin during the G1/S phase (Ciosk et 
al., 2000). Thus, it is plausible that defects in Human Scc2, NIPBL, will result in 
aberrant proliferation of the matrix cells and differentiation and thus affect the size 
and function of the developing brain. However, most of the cells undergoing stage II 
or III of cytogenesis may only appear later in the fetal or even postnatal stage. To 
examine the effect of NIPBL protein on neuronogenesis and glial progenitors 
differentiation, further investigation by using mouse or rat at the later developmental 
stage, such as the fetal and postnatal stage, is necessary. 
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4.5.2 Expression of NIPBL in developing limb 
In mild CdIS patients with minimal limb defects, proportionately small long 
bones, hands and feet are observed in 90% of patients with CdIS (Jackson et al., 
1993). My expression data showed that the NIPBL expressions were seen in the limb 
placode close to apical ectodermal ridge in CS 13 (28-32 postovulatory days) early 
limb bud where rapid cell proliferation occurs, as seen in Fig. 4.7. At the later stage, 
expression was seen in regions of increased cell density in the CS 18 embryo (44-48 
postovulatory days) when ossification commences. Multiple foci of mesenchymal cell 
aggregations (arrow heads) and some areas of chondrogenic ossification centre (arrow) 
can be observed (see Fig. 4.8). The expression pattern seen in Fig. 4.8 was similar to 
that seen in PCNA immunocytostaining (data not shown). This suggests that NIPBL 
expression was mainly involved in cells under active proliferation. If NIPBL gene 
product, delangin, is involved in cell proliferation as suggested by my finding, it is 
plausible to suspect that the mutations that lead to truncation of delangin found in 
severe CdIS patients with limb defects may result from a decrease in chondrogenic 
progenitors at the early stage of limb development. If the mutations lead to severe 
reduction in progenitor cells under certain thresholds, amelia and severe limb 
reduction defects may occur. 
However, the patterning process is complex and involves lots of regulating genes 
(Tickle, 2003). Thus, it is not clear to us whether the minor limb defects such as 
syndactyly observed in CdIS patients result from direct impaired joint formation or 
from the impaired apoptosis of the interdigital mesenchyme. In CS 23 embryo 
sections, expression was seen in mesenchyme surrounding the developing finger 
skeletons (data not shown). Whether this expression is associated with 
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cutaneous/skeletal syndactyly observed in patients with CdLS (Jackson et al., 1993) is 
not known. It has been reported that drosophila homologue, nipped-B, might facilitate 
the communication between the remote enhacer and the cut promoter (Dorsett et al., 
2005; Rollins et al., 1999). Moreover, I do not know the level of NIPBL expression in 
the chondrocyte at the time when the condensations differentiated into cartilage 
templates. At that stage, the chondrocytes proliferation was decreased with low 
mitotic indexes. To investigate whether the level of NIPBL expression shows an 
inverse relationship as the chondrocyte enter a more differentiated stage, further serial 
studies under a more stringent quantitative control are mandatory. They would involve 
the use of a stringent amount of labeled riboprobes and hybridization to sections from 
the embryos/fetuses of mice/rats at different stages of development in one experiment. 
Although observed with minor statistical significance, mutations that lead to 
truncation of the NIPBL gene product were more likely to be seen in patients with 
severe CdLS. Thus, it is reasonable to speculate that truncation mutations of NIPBL 
might result in a severe reduction of the gene dosage. Such a reduction would lead to 
a decreased progenitor cells population during early embryogenesis. These events will 
consequently lead to the severe limb reduction defect and misshaped limbs. For 
mutations that lead to altered protein quality rather than quantity, milder forms of limb 
defects such as small hands and feet may result. Whether this is via the direct effect of 
the change in delangin function or through the indirect effect by interaction with other 
interacting proteins is not known. In vivo and in vitro studies using the site-directed 
mutagenesis of the full length cDNA containing NIPBL (homologues) sequences in 
other animal models are necessary to clarify the role of NIPBL protein during limb 
development. 
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4.53 Expression of NIPBL in developing craniofacial skeletons, eye and ear 
In addition to microcephaly, long, bushy and neat pencil like eyebrows as well as 
a peculiar face with a long philtrum and a short and anteverted nose are facial 
hallmarks for patients with CdLS (Ireland and Burn, 1993; Ireland et al., 1993). To 
our surprise, NIPBL expression is not obvious in craniofacial skeletons. Although 
NIPBL expression was not directly seen in the neural crest cells of the developing 
craniofacial skeletons, the NIPBL gene product may exert its influence on craniofacial 
patterning through the interaction of pharyngeal endoderm and neural ectoderm. 
Factors that lengthen the developmental window related to neural crest induction may 
lead to facial dysmorphism. Defects in NIPBL protein may lead to the decreased 
number of cyclindrical epithelium cells overlying/underlying neural crests, and thus 
affect the epithelial-mesenchyme interactions. This will result in hypoplasia of the 
facial skeleton seen in patients with de Lange syndrome. 
A cleft palate was also observed in patients with CdIS (Kim et al., 2005; 
Kousseff et al., 1994). As seen in Fig. 5.10. NIPBL expression was seen in the midline 
where the two sides of the palate meet. Failure of the unification of two palatal halves 
might lead to the clefting seen in patients with CdIS. 
Furthermore, the NIPBL expression was also seen in the musculature of the 
developing tongue and pharyngeal endoderm. As described above, the pharyngeal 
endoderm may play a role in lower face and neck skeleton patterning, while 
involvement of the developing tongue musculature might have an impact on speech 
delay and feeding difficulties as seen in patients. Though mental retardation is a 
characteristic in classic CdLS patients, we do not know whether the existence of 
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difficulty in communication due to tongue muscle weakness will further impair the 
I. Q. score in patients with CdLS. NIPBL protein may also exert its effect through 
interaction with other molecules such as Wnt, Bmp, Fgfs and Hedgedog proteins 
during early craniofacial development. However, to clarify this, gene knock down in 
feasible animal models is necessary and such experiments are underway now. 
As described in Chapter 1, the ophthalmic findings associated with CdLS 
include synophrys, long accurate eyelashes, hypertelorism, telecanthus, myopia, any 
degree of nasal lacrimal duct obstruction, ptosis, strabismus and nystagmus (Levin et 
al., 1990). The expression of NIPBL was seen in the nasal root area. If the defective 
expression of NIPBL results in the flat nasal root as observed in patients with CdLS, 
then obstruction of the nasal lacrimal duct may occur since most obstructions appear 
where the nasolacrimal duct enters the nasal cavity (Robb, 2001). Ptosis of the eye is 
due to failure of normal development of the levator palpebrae superioris muscle or 
abnormal development of the superior division of oculomotor nerve, which supplies 
this muscle. Moreover, extraocular muscle involvement defects are also associated 
with strabismus. The retina and optic nerve fibers are derived from neuroectoderm of 
the forebrain. Up to now, only one CdLS patient with idiopathic retinal telangiectasia 
has been reported to be associated with retinopathy (Folk et al., 1981). However, this 
finding is not compatible with the finding we have. Nevertheless, the vertebrate retina 
is derived from paired evaginations from the neural tube in embryonic development 
and is initially produced by progenitor cells similar to those that generate the neurons 
and glia of other areas of the central nervous system (Reh and Levine, 1998). 
Furthermore, the central nervous system, which is consistent with that NIPBL 
expression, is mainly on sites with active proliferation. 
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In patients with CdIS, hearing defects may be present in 60-100% of children 
(Jackson et al., 1993). Comprehensive studies of the ear and hearing examinations in 
45 children revealed stenosis of the external auditory canals in 80% and hearing loss 
from a mild to a severe form in all patients with CdLS (Sataloff et al., 1990). Thus, 
defects in otic mesenchymal progenitors might lead to conductive hearing 
impairment. 
4.5.4 Expression of NIPBL in developing heart 
Expression of NIPBL was not seen by using the modified protocols for tissue in 
situ hybridization. However, congenital heart disease was reported to be observed in 
one fourth of patients with CdLS. (Greenwood et al., 1977; Tsukahara et al., 1998) 
Right-sided obstruction is most common. Recently, a 32-year-old woman with CdLS 
and a severe calcified aortic valve was described. Inactivation of the Notch signaling 
causing differentiation of the valvular cells into osteoblast-like cells was presumed to 
be the cause of calcified aortic valve seen in this patient (Oudit et al., 2006). 
In Drosophila, Notch signaling pathway was suggested to have a genetic 
association with Drosophila Nipped-B (Dorsett et al., 2005; Rollins et al., 2004). 
Notch, which is involved in a wide range of developmental contexts, but is best 
known for its role in lateral inhibition, is activated by its transmembrane ligands Delta 
(Drosophila and vertebrates) as well as Serrate (Drosophila) and its vertebrate 
homologue Jagged. The glycosyl transferase Fringe differentially modulates the 
responsiveness of Notch to Delta versus Serrate/Jagged ligands. In addition, the 
transmission of the signal to target genes involves the nuclear factor Su(H)/RBP-J and 
its co-repressor(Bray and Furriols, 2001; Mumm and Kopan, 2000). In Drosophila, 
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the Su(H) insulator protein encoded by the suppressor of the Hairy-wing [su(H)] gene 
interferes with enhancer-promoter communication. Su(H) binds a DNA sequence in 
the gypsy transposon. When gypsy inserts into a gene, enhancer-promoter interactions 
are blocked in a Su(H)-dependent manner (Rollins et al., 1999). During Drosophila 
cardiogenesis, Notch functions throughout two distinct developmental events, namely 
the process of lateral inhibition and the control of lineage decisions during 
asymmetric cell divisions of heart progenitors. Activation of Notch signaling will 
prevent the cells from differentiating into cardiac progenitors. On the contrary, 
inactivation of the pathway causes ectopic expression of heart markers and expansion 
of the heart (Zaffran et al., 1995). After specification of the cardiac progenitor cells, 
differentiatial activity is responsible for the acquisition of asymmetric cardiac cell 
fates in the two daughter cells. Drosophila Nipped-B has been suggested to facilitate 
promoter-enhancer communication through antagonistic to insulation by 
Su(H)(Rollins et al., 1999). 
The occurrence of congenital heart defect in patients with CdIS may be through 
interaction of NIPBL with other signaling pathways, such as Notch signaling, that 
affect cardiac development. We can not exclude the possibility that locations of 
NIPBL transcripts are in locations outside of the developing heart and secrete its 
protein product to interact with other major signaling pathways involved in cardiac 
development. It is also possible that the expression of NIPBL in the developing heart 
is a very early event (earlier than CS 17) such as in the early induction phase of 
cardiac progenitors. Thus, it is important to for us to perform immunohistochemistry 
staining to verify the expression pattern of NIPBL in developing embryonic heart 
from very early stage of development to late embryonic stages when feasible delangin 
antibodies are available. 
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4.5.5 Expression of NIPBL in developing lung, kidney and pancreas 
Considering that the most frequent cause of death in patients with CdIS is 
recurrent pulmonary infections due to chronic lung disease (Beck and Fenger, 1985; 
Gupta and Goyal, 2005), it is reasonable that the NIPBL gene product might play a 
crucial role in lung morphogenesis. 
Anomalies of the kidney and urinary tract occur in approximately 40% of the 
patients with de lange syndrome. Renal manifestation of patients with CdIS includes: 
absent or poor corticomedullary differentiation, pelvic dilatation, small kidneys, 
isolated renal cyst, vesicourethral reflux, decreased glomerular filtration rate and renal 
ectopia. All is associated with branching defects as described in section 4.2.3.5. Renal 
function impairment was found in approximately one third of CdIS patients with 
structural anomalies. Anomalies of the kidney and urinary tract and renal functional 
impairment more frequently occur in patients with the classic rather than the mild 
clinical phenotype (Selicorni et al., 2005). 
Aside from complete renal agenesis, very few knockout mutations of genes that 
operate during early branching result in moderate to severe branching defects. On the 
contrary, these phenotypes tend to be slight or undetectable (Qiao et al., 1999b). The 
lack of moderate to severe branching defects may arise from a requirement for an 
essential number of nephrons for organ survival. In addition, mechanisms such as 
redundancy may allow for activation of compensatory processes that are able to buffer 
the effects of genetic mutations (Wagner, 2000a; Wagner, 2000b). Furthermore, gene 
dose may also play a role in the lack of moderate to severe branching defects. For 
example, although Gdnf null mice lack kidneys and die, heterozygotes show an array 
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of renal phenotypes ranging from small kidneys to unilateral agenesis with no 
intermediate phenotypes (Cullen-McEwen et al., 2001). 
Defects during early or late branching may predispose to disorders of reduced 
nephron number and results in reduced filtration surface area (Cullen-McEwen et al., 
2003). Finally, in the developing kidney, branching must cease and the caliber of the 
tubule lumen must be regulated. Defects in branching termination may result in 
generation of cysts with corresponding clinical manifestations ranging from 
asymptomatic simple cysts to end-stage polycystic kidney disease (Selicorni et al., 
2005). Defects during initial ureteric bud outgrowth may result in renal agenesis, as 
ureteric budding requires the presence of GDNF as a primary inducer. Collecting 
system duplication which may result in bifid ureter and duplex kidney is another 
common renal malformation during the initial ureteric bud outgrowth stage (Pohl et 
al., 2002). 
Annular pancreas, a malformation in which a band of pancreatic tissue 
completely encircles the duodenum associated with formation of a second ventral bud, 
has been reported in patients with CdLS (Lagunas Flores et al., 1981; Wick et al., 
1982). 
In conclusion, it seems that NIPBL is expressed on sites that are associated with 
the branching morphogenesis in human embryos. However, in more than 50% of 
patients with CdLS phenotypic presentation shows no defects associated with 
branching morphogenesis. It is possible that NIPBL gene haploinsufficiency may not 
be sufficient to cause the urinary abnormality due to variable penetrance and/or a 
dose-dependent genotype-phenotype relationship. In total, that NIPBL functional 
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redundancy and/or dose effect might exist during early branching morphogenesis. 
Finally, the number of human disorders involving defective branching morphogenesis, 
for which a molecular basis has been identified, is far smaller than the number 
predicted by the number and diversity of identified phenotypes. Thus, from the 
expression data and the associated phenotypes observed in patients with CdLS, I 
believe that NIPBL gene product might play an important role during early branching 
morphogenesis in a dosage-dependent manner. To verify this, establishing an animal 
model by using conditional knockout of NIPBL gene in mouse is crucial and is now 
underway. 
4.5.6 Expression of NIPBL in developing gut 
Few gastrointestinal malformations were reported to be associated with CdLS 
except for cecal volvulus, hiatal hernia and gastroesophgeal reflux (Holthusen and 
Rottingen, 1998; Husain et at., 1994; Jackson et at., 1993; Lachman et at., 1981; 
Masumoto et al., 2001; Pei et at., 2000). The cecal vovulus is associated with 
non-fixation of the cecum and ascending colon (Husain et al., 1994; Masumoto et al., 
2001). The gastroesophageal reflux is observed in around 65% of CdIS patients 
(Luzzani et al., 2003). The main cause of gastroesophageal reflux disease (GERD) is 
incompetence of the antireflux barriers at the esophagogastric junction. The antireflux 
barriers include two sphincters: the lower esophageal sphincter, and the crural 
diaphragm that functions as an external sphincter. 
The NIPBL expression was seen in most the developing skeletal muscles 
including the developing diaphragmatic musculature during human embryogenesis 
(data not shown). This may contribute to the high prevalence of gastroesophageal 
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reflux disease (GERD) seen in CdLS patients. Furthermore, congenital diaphragmatic 
hernia has also been reported in CdIS patients (Cunniff et al., 1993; Jelsema et al., 
1993; Pankau and Janig, 1993). Thus, the external sphincter malfunctions might 
contribute, at least partly, to the pathogenesis of GERD seen in patients with CdIS. 
Also, a set of Hoxd genes contributes to the formation of a major anatomical and 
physiological subdivision of the gut, the ileocaecal sphincter, which forms the 
boundary between the small intestine and the large bowel. Inactivation of several 
Hoxd genes results in abnormal ileocecal sphincters. Is it possible that NIPBL gene 
product may influence the sphincter architect in the gastrointestinal tract though direct 
or indirect pathway? Is NIPBL involved in foregut positional patterning and does it 
lead to the posterior homeotic shift in which esophageal epithelium has the character 
of the more caudal gastric phenotypes? Why are no severe gut phenotypes reported in 
patients with CdIS if NIPBL expression was seen both in endodermal epithelium and 
mesenchyme? It is possible that haploinsufficiency of the NIPBL product alone is not 
enough to cause the phenotypes. Moreover, genetic redundancy makes it necessary for 
several functionally similar genes to be inactivated to generate a recognizable gut 
phenotype (Beck, 2002). 
4.5.7 Expression of NIPBL in developing gonads 
Patients with a severe form of CdIS seldom reproduce and genital abnormality 
such as hypospadia has been reported in CdIS patients (Elhassani and Moyd, 1987). 
My expression study in the early human embryo revealed the expression of NIPBL 
transcript in the gonadal ridge. Thus, it is plausible that mutations in NIPBL lead to 
severe phenotypes of patients with CdIS and result in infertility in these patients. 
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4.6 CONCLUSION: 
In this study, I found that the expression pattern in tissue in situ hybridisation is 
similar with that of northern blot except that (1) Expression was not visible in adult 
brain and weak in foetal brain. However, this is not surprising if the NIPBL expression 
only involves cells under active proliferation during early development. (2) The 
expression on heart is strong. However, more experiments need to evaluate this. (3) 
Weak expression of adult and foetal lung seen in Northern blot may reflect that NIPBL 
expressions are only restricted to early generation of branching tubules. 
During human development, similar mitotic pattern as seen in neuroepithelium 
was observed in a wide variety of proliferating tissues. Specifically, the so-called 
germinal cells are rounded and always lie directly (1) beneath the luminal surface 
showing mitotic chromosomes; (2) between the mitotic zone (M) and the deep nuclear 
zone, an intermediate zone with sparse nuclei which are at the latter half of telophase 
and early prophase. The proliferating tissues with these characteristics include: Adult: 
the epithelium of the efferent duct of the epididymis; the gastric mucosa; the intestinal 
mucosa; the epithelium of the endometrial gland. Embryo: the epithelium of the 
branchial clefts; the tracheal and lung tubular epithelium; the gastric mucosa; the 
intestinal epithelium; the epithelium of the bile duct system including the gall-bladder; 
the epithelium of the pancreas (the above six embryonic tissues are of endodermal 
origin); the mesonephric tubules; the mesonephric duct; the metanephric tubule; the 
thickened part of the mesothelium (these four tissues are of mesodermal origin); the 
epithelium of the nasal pit; Rathke's cleft; the anlange of the retina; the neural tube 
(these four tissues are of ectodermal origin) (Fujita, 2003). The sites of NIPBL 
expression are parallel to the embryonic tissues described above. What is common 
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to these tissues is the fact that they consist of a single layer of cylindrical epithelium. 
Thus, it is quite possible that the NIPBL expression is mainly on tissues undergoing 
active proliferation. Defect in NIPBL gene products will lead to decrease in these 
totipotent progenitors. Generalized proportionate growth deficiency may result as 
seen in patients with CdIS. 
In most proliferating somatic tissues, growth is tightly coupled to the cell cycle, 
which makes the increase in the cell number a reliable indicator of tissue growth and 
size during development. There are several ways in which cell numbers in a tissue can 
be modulated. These include alterations in patterning which determines the initial size 
of the stem or founder cell population, the rate and mode of proliferation of founder 
and progenitor cells, cell death and cell migration. In plants, cell proliferation and 
growth primarily contribute to organ size; the removal of overproliferated cells and 
cell migration does not occur (Shpak et al., 2004). 
In Drosophila, the coordination of cell proliferation and cell death is essential for 
determining the correct numbers of cells in a tissue. In mammals, the contributions of 
proliferation, migration and death to the regulation of cell number vary greatly 
between tissues. One example of this is retina, in which proliferation has a significant 
effect on cell number during development and slowing down of the cell cycle causes a 
major deficit in the cell number (Green et al., 2003). 
Cell growth is tightly coupled to cell cycle progression. However, it is not clear 
how coupling occurs. Several mechanisms may be involved, which include nutritional 
availability, protein synthesis and RNA transcription (Britton et al., 2002; Orian et al., 
2003). In mammals, cell size at cell division appears to depend on the speed of the 
221 
cells progress through the cell cycle and the speed of the growing process, which in 
turn depends on extracellular signals that control cell cycle progression, cell growth, 
or both. 
In addition to cell cycle regulation, patterning and morphogenesis may be 
directly regulated by cell-cycle related events in early embryogenesis. In Xenopus, 
progression through a limited number of cell cycles in the midblastula transition stage 
is necessary for HoxB gene cluster activation in neuroectoderm. More cell cycles are 
required for the correct spatial expression of HoxB genes along the AP axis (Fisher 
and Mechali, 2003). 
In my experiments, NIPBL expression patterns are similar to that of the 
proliferating marker, PCNA. Their expressions are mainly on sites of active 
proliferation such as early limb bud, gonads and ventricular zone of developing 
nervous system, and most of the cylindrical epithelium as described above. If 
mutations occuring in NIPBL lead to the prolongation for each cell cycle and result in 
a decreased cell number during organogenesis, growth deficiency may occur as seen 
in patients with CdLS. Although severe patterning defects (except in limbs) seldom 
reported to be associated with CdIS, NIPBL mutations seen in patients with CdIS are 
due to hemizygous rather than homozygous defects and thus lead to less severe 
phenotypes. It is possible that homozygous mutation of NIPBL will severely impair 
cell cycle progression and is non-viable for the developing early human embryos. 
Thus, it is important to establish a gene knockout model to understand the effect of 
NIPBL gene product and the impact they have in embryonic development. Such an 
experiment is underway now. 
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CHAPTER 5 THE EXPRESSION PATTERNS AND MUTATION 
SCREENING OF HUMAN MAU-2 
5.1 INTRODUCTION 
The proper transmission of genetic material is crucial for the growth and survival 
of all organisms. Each time a eukaryotic cell divides; it must faithfully produce two 
copies of each chromosome, known as sister chromatids, and accurately distribute 
them between two daughter cells. Missegregation produces cells bearing too few or 
too many chromosomes, with often fetal consequences. Sister chromatids are moved 
to opposite poles of the cells by forces generated by microtubules, which attach to 
specialized structures at centromeric regions of the chromatids called kinetochores. 
The process can only deliver a complete set of cell's chromosomes to each daughter 
cell if the kinetochore of each chromatid is attached to microtubules with opposite 
orientations to those attached to its sister, which is known as amphitelic attachment. 
Amphitelic attachments result in a competition between microtubules attempting to 
pull sister chromatids apart, and cohesion complexes between sisters glue them 
together to resist the splitting force. It is sister chromatid cohesin complex that make it 
possible for cells to segregate their chromosomes long after duplication. Only when 
all chromosomes are bi-oriented on the metaphase plate, do cells start to destroy the 
connection between sisters and triggers their segregation to opposite poles during 
anaphase. The discovery of two multiprotein complexes, cohesin and condesin, has 
provided insight s into the molecular mechanisms of chromosome segregation (Ciosk 
et al., 2000; Toyoda et al., 2002) 
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Cohesin is a four-subunit protein complex, in which a heterodimer of SMC 
proteins (SMC1/SMC3) associates with two other non-SMC subunits, the 
Scc1/RAD21/Mcd1 and Scc3 proteins. In vertebrates there are two variants of Scc3, 
called SA1 and SA2. The cohesin forms a tripartite ring in which the open-V structure 
of the SMC heterodimer is closed by the binding of Sccl, a member of kleisins 
superfmaily proteins, to the head domains of SMC1 and SMC3 (Gruber et al., 2003; 
Haering and Nasmyth, 2003). It is proposed that the cohesin complex may hold sister 
chromatids together by embracing two DNA duplexes within its coiled-coil arms 
(Gruber et al., 2003). Proteolytic cleavages of the Sccl subunit of the complex might 
open the ring and thereby trigger sister chromatid separation at the onset of anaphase 
(Uhlmann et al., 1999). 
Loading of cohesin onto chromatin requires Scc2/Scc4 complexes during G1 
phase (Ciosk et al., 2000). Scc2 are HEAT repeat proteins that physically interact with 
cohesin. It has been suggested that Scc2 may promote hydrolysis of ATP bound to 
SMC's heads and thereby stimulate the opening of the ring to allow loading onto 
chromatin (Arumugam et al., 2003). In Xenopus egg extracts, loading of Scc2 on 
chromatin depends on the assembly of prereplication licensing complex but not on the 
initiation of DNA replication (Gillespie and Hirano, 2004). Cytological studies 
suggested that cohesin does not colocalize with Scc2/Scc4 on chromosome. However, 
Scc2 and Scc4 showed an identical pattern of localization and were distinct from the 
site occupied by cohesin (Ciosk et al., 2000; Lengronne et al., 2004) and their binding 
to chromatin coincided with strong transcription (Lengronne et al., 2004). 
High-resolution mapping of cohesion-binding sites in yeast revealed a preference of 
cohesin for sites of convergent transcription (Lengronne et al., 2004). It is proposed 
that after DNA is transported into cohesion ring, cohesin may be able to slide along 
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chromatin, responding to steric requirements of transcription. Cohesin is loaded onto 
chromosomes next to its loading factor Scc2/Scc4, from where it relocates to places of 
convergent transcription. Once loaded, prevention of further Scc2/Scc4 action on 
cohesin would be important to secure stability of the ring (Arumugam et al., 2003). 
Pushing cohesin away from its loadings sites by the transcriptional machinery until 
they reach the sites where RNA polymerase traveling in opposite direction meet 
(Lengronne et al., 2004). In vertebrate, most cohesin dissociates from chromatin at 
prophase, and only a small population in pericentrimeric region remains on 
chromosome by metaphase (Waizenegger et al., 2000). This step is regulated by two 
mitotic kinases, polo and aurora B (Haering and Nasmyth, 2003). 
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chromatids. 
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Aside from their canonical role for the proper segregation in yeast chromosomes, 
recent studies have shown that cohesin might also contribute to gene regulation by 
regulating enhancer-promoter communication (Rollins et al., 2004; Rollins et al., 
1999). It is proposed that the mechanism used by cohesin to attach two sister 
chromatids in trans might also be used in cis on the same sister chromatid to help 
enhancer contact promoters over long distance (Rollins et al., 2004). gypsy, a 
Drosophila transposon, functions as an insulator to block enhancer-promoter 
communication. Insertion of gypsy causes loss-of-function "cut wing" phenotypes in 
Drosophila when located between a wing enhancer and the cut promoter. In a genetic 
screen for mutations that exacerbate the gypsy induced cut wing phenotype identified 
Nipped-B, a drosophila homologue of yeast cohesin regulatory factor Scc2 (Rollins et 
al., 1999). It was suggested that Nipped-B normally facilitates long-range 
enhancer-promoter communication and thus, mutation of Nipped-B would reduce 
their ability to overcome the gypsy insulator. Also, Nipped-B mutations cause weak 
cut-wing phenotypes even in the absence of gypsy, which supports a normal role in 
gene regulation at the cut locus. They also observed that Nipped-B protein and 
cohesin have opposite effects on this long-range regulation supports the model that 
Scc2/Nipped-B acts both as a loader and unloader of cohesin and certain 
developmental genes could be particularly sensitive to the silencing effect of cohesin. 
Reduction levels of Scc2 will result in the unopenable cohesin ring and cause 
transcriptional silencing during development. This might also explain that mutation of 
one copy of human Nipped-B like (NIPBL) gene cause Cornelia de Lange syndrome, a 
developmental defects characterized by growth deficiency, limb defects and mental 
retardation (Krantz et al., 2004; Tonkin et al., 2004). However, it remains unclear 
whether these developmental defects are derived from misregulation of cohesin or 
whether Scc2/Nipped-B/NIPBL may have a cohesin-independent functions that affects 
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the dynamics of other transcriptional regulators. 
The amino acids sequences of the Human Nipped-B like (NIPBL) gene product, 
delangin, are well conserved among different species ranging from Scc2 of S. 
cerevisiae, Mis4 of S. pombe and Rad9 of C. cinereus, and Nipped-B of D. 
melanogaster. In many cases, the ortholog proteins are known to have a major role in 
sister chromatid cohesin. The C-terminal domain, spanning around 1300-1500 amino 
acids that is especially evolutionary strongly converved, contains at least 5 HEAT 
repeats. HEAT repeats are tandomly arranged bihelical structure and appear to 
function as flexible joints to wrap target substrate and as scaffolding on which other 
molecular components may assemble (Groves and Barford, 1999). Repeat proteins 
contain strings of tandem repeats of a basic structural element. Their construction is 
quite different from that of globular proteins, in which sequentially distant elements 
coalesce to form the protein. The different families of repeat proteins use their diverse 
scaffolds to present highly specific binding surfaces through which protein-protein 
interactions are mediated. HEAT repeats have been found in a variety of 
chromosome-associated proteins such as cohesin and condensing (Neuwald and 
Hirano, 2000) and may function as flexible scaffolding that recognizes and binds 
target substrates. 
On the contrary, the N-terminal region of Scc2 orthologs is comparatively poor 
conserved. Notably, a consensus PXVXL motif was found to be located within the 
relatively poor conserved N-terminal. PXVXL motif binds directly to the 
chromoshadow domain of HP1 proteins. The HP1 proteins function as adaptors, bring 
together different proteins in multiprotein complexes through protein-protein 
interactions with the chromo and shadow domains. When shadow domain binds to 
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PXVXL consensus motif and with the recognition of Lys-9-methylated histone H3 by 
the chromo domain, the HP! family proteins can mediate chromatin packaging and 
gene silencing (Lechner et al., 2005; Thiru et al., 2004). Thus, it is believed that 
delangin might also play a role in developmental regulation through the interaction 
with the heterochromatin proteins. 
In order to elucidate the function of delangin as developmental regulators, we 
tried to find the proteins that interact with it. As described above, yeast Scc2 interacts 
with Scc4 to help in the loading of cohesin onto chromatin. In contrast to Scc2, Scc4 
appeared to be poorly conserved during evolution (Ciosk et al., 2000). Standard 
BLAST analyses by using Scc4 protein query to screen for the protein and translated 
nucleotide sequence databases identify significant sequence matches in a limited 
group of organism such as Candida glabrata, Kluyveromyces lactis and 
Eremothecium gosspii. To identify the human homolog of yeast Scc4, we used 
PSI-BLAST to search the databases (http: //www. ncbi. nlm. nih. govBLAST/). After 5 
rounds of search identify the human KIAA 0982 as the most possible ortholog with the 
highest value (the analysis was performed by Prof. Tom Strachen). 
As described above, ortholgues of yeast Scc4 were not readily identified in other 
species. In order to search for the interacting patemer for the Drosophila Nipped-B, 
one group identified a 71-kDa Drosophila Nipped-B interacting protein which is 
co-immunoprecipitated with the FLAG-Nipped-B extract in a genetic screen (personal 
communication by Dale Dorsett). After query protein databases with selected value 
mass values, the 71-kDa protein was identified as the Drosophila CG4203 gene 
(Seitan et al., 2006) and subsequent global yeast two-hybrid screen and the reciprocal 
yeast two-hybrid experiments in Drosophila confirmed that the CG4203 protein was 
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bound to Nipped-B protein (Seitan et al., 2006). 
Recently, it has become clear that CG4203 and KIAA0892 are ortholgs of C. 
elegans mau-2, a gene broadly required for the proper guidance of cells and axons that 
undergo long-range migrations during development of worm (Benard et al., 2004; 
Takagi et al., 1997). Expression of Mau-2 in C. elegans was reported to be 
cytoplasmic (Takagi et al., 1997). 
In order to determine whether KIAA 0892 protein is the human ortholog of 
Drosophila CG4203 and as the interacting protein of delangin, Northern blot analysis 
and tissue in situ hybridization were used for the expression studies of human Mau-2 
(hMau-2) 
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5.2. MATERIALAND METHODS: 
5.2.1. Northern blot analysis 
5.2.1.1 Probe used for Northern blot analysis and Tissue in situ hybridization 
The human Mau-2 cDNA probe was generated by PCR amplifying a 400bp 
fragment corresponding to exon 19 (3' UTR) of human Mau-2 (KL4A0892). The 
primers used for the amplifying are: 5' TGTCTCTCCAGAGCCATCCT 3' and 5' 
AGGTGCAGATGTTTGGAAGC 3'. The cDNA fragment was cloned into the 
pGEM-T Easy Vector (Promega) as described previously. All the procedures are the 
same as described in Chapter 4. 
5.2.2.2 Probe labelling-random priming 
The purified PCR amplified fragment was used as probe. Briefly, 25ng of the 
purified probe with distilled water to a total of 20 jt I was denatured at 100°C for 5 
minutes in hot block and snapped cool on ice for 2 minutes. Then, 3 ,u1 of 10x 
labelling buffer, 3 ,uI of mixed oligonucleotides, 3 It 1 of [a 
32 P] and 1 /u 1 of Klenow 
were added to the probe mixture the reaction mixture was placed in oven at 37°C for 1 
hour. After one hour of labelling procedure, the unincorporated nucleotides was 
removed by applying the reaction mixture into the nick column (Amersham) as 
described in chapter 2. The purified labelled probe was denatured at 95°C for 5 
minutes and snapped cool on ice for 2 minutes before hybridization. 
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5.2.23 Prehybridization of the RNA blots 
Preheat the hybridization buffer (ULTRAhyb, Ambion) at 65°C for warming up. 
Then, prehybridization the blots of human adult and fetal RNA containing -2, u g of 
mRNA per lane (Clontech) with 10ml of hybridization buffer (ULTRAhyb, Ambion) 
in the oven at 42°C for 30minutes. 
5.2.2.4 Hybridization 
The purified and denatured labelled probe was added to the prehybridized blots 
and hybridized at 42°C for overnight. 
5.2.2.5 Post-hybridization wash and film development 
After overnight hybridization, the blots were washed with 2xSSC/0.1% SDS 
twice, 15 minutes each. Then the membranes were washed on 1xSSC/0.1%SDS twice, 
15 minutes each followed by 0.5xSSC/0.1%SDS, if necessary. Washes generally 
started at room temperature, but higher temperature, lower concentration of SSC and 
higher concentration of SDS have been used for more stringent washings. After 
washing, the blots were placed between two sheets of polyethylene wrap in a cassette 
and X-ray film (Kodak) was placed on top of the blots. The cassette were kept 
overnight at -70°C. The autoradiography was performed by passing the X-ray film 
through Amidol developer which converts the Ag+ ions to Ag atoms and thiol which 
removes the unexposed silver halide crystals (Buongiomo-Nardelli and Amaldi, 
1970). 
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5.2.2 Tissue in situ hybridization: 
The probe we used for tissue in situ hybridization is same as that of Northern blotting. 
All the procedures are same as those described in Chapter 4. 
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:. 3 RESULTS 
5.3.1 Northern blot analysis 
BL Li K 
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Fig. 5.2 Northern analysis of KIAA 0892 transcript. B: brain; C: colon; H: heart; K: kidney; L: lung; Li: 
liver; Ly: peripheral lymphocyte; PI: placenta; Sk: skeletal muscle; SI: small intestine; Sp: spleen; Th: 
thymus. 
The expression of hNfau-2 transcript was seen on multiple organ system with 
unequal intensity. There are two isoforms and the transcript sizes are around 4.0 Kb 
and 6.0Kb respectively. The expression was strongest on fetal brain, lung, and kidney 
and also on adult brain, heart, skeletal muscle, kidney, placenta; expression was only 
moderate on fetal and adult liver and lymphocytes; weak expression was seen on adult 
colon, small intestine, thymus and lung. 
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5.3.2 Tissue in situ hybridization by using riboprobes 
The expression of hMau-2 on human embryonic sections showed similar pattern 
to that of NIPBL. The expression was strong in the proliferation zone of the 
developing embryonic brain and muscles on CS18 and CS23 embryos. 
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Fig. 5.3 hAlau-2 expression on CS23 embryo. The expression was seen on (A) ventricular zone of the 
developing brain, retina of the developing eye and mesenchyme of the developing ear. (B) no 
expressison was seen on control slide by using sense strand as the riboprobe. F: forebrain; Ey: 
developing eye; Ot: otic placode. Vz: ventricular zone of the developing brain. 
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Generally speaking, the expression pattern of hMau-2 in developing human 
embryo is less tissue specific in sagital sections (Fig. 5.4) as compared to NIPBL 
and is more similar to the expression pattern of PCNA. However, expression 
pattern of hMau-2, NIPBL and PCNA in human embryonic brain are very similar. 
Thus, it is also expressed on the active proliferative zone of the developing brain. 
533 Mutation screening 
The similar expression pattern seen in NIPBL and hMau-2 transcripts 
prompted us to further investigate if hMau-2 is a Human Scc4 homologue, the 
interactor protein of delangin. Human delangin was found to be 
co-immunoprecipitated with hMau-2 gene product (Seitan et al. 2006) in human hela 
cells. Thus, it is highly likely that hMau-2 is the interacting partner of the human 
delangin. Therefore, we decided to perform mutation screens in NIPBL 
mutation-negative CdIS patients. The hMau-2 contains 4161 bps, 218 amino acids 
and 19exons. Primers were designed on exon-intron flanking regions (see appendix C) 
for the primer information and amplification conditions). 
No mutation was found in patients with CdLS up to now. This is compatible with 
the phenotypes observed in worms with Mau-2 mutation (homologue of hMau-2). 
Heterozygous worms produced by the homologous mutant mother appear completely 
wild type which suggested autosomal recessive inheritance. As autosomal dominant 
inheritance is suggested as mode of transmission for CdLD, this makes Wau-2 an 
unlikely candidate for CdIS. 
However, considering that Roberts syndrome, an autosomal recessive disorder 
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characterized by craniofacial anomalies, tetraphocomelia and loss of cohesion at 
heterochromatic regions of centromeres and the Y chromosome, is caused by 
mutations in a novel human gene, ESCO2. The ESCO2 gene product is required for 
the establishment of sister chromatid cohesion during S phase (Vega et al., 2005). 
Moreover, the highest mutation detection rate of CdLS patients in NIPBL gene was 
around 50%. Thus, it is possible that other gene products involved in the 
establishment of cohesin complexes might be candidates for CdLS. 
Recently, another gene, SMC1, was found to be mutated in X-linked CdIS 
patients (Musio et al., 2006). SMC1 constitutes part of the cohesin complexes. Thus, 
it is necessary for us to perform mutation screening of the human SMCJ gene in 
NIPBL mutation negative CdIS patients, especially for patients with suspected 
X-linked inheritance within families. Other genes involved in the establishment of 
cohesin may need further investigation for the possibility of being other CdIS disease 
causing genes. 
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5.4 DISCUSSION: 
In comparison of NIPBL, the expression of hMau-2 transcript on northern blot 
analysis revealed that the intensity of expression of hMau-2 is higher in both fetal and 
adult brain and fetal lung than those of NIPBL. The expression of hMau-2 is also 
higher in adult lymphocyte than that of NIPBL. In a serial of experiments in tissue 
hybridization studies, hMau-2 tends to has more background and less tissue specific 
expression than NIPBL (Tonkin et al., 2004). To elucidate this, more serial expression 
studies by using fetal and postnatal mouse sections may be necessary. 
In metazoan, Mau-2 was found to be associated with cellular and axonal 
migration (Benard et al., 2004; Takagi et al., 1997). Defects in Mau-2 will lead to 
uncoordinated movements, early demise in worms. However, the larval lethality can 
be rescued by the maternal effects. That is, homozygous mutants derive from 
heterozygous mothers; the uncoordinated phenotypes could be fully rescued. However, 
phenotype which develops post-embryonically such as egg-laying can not be rescued. 
Thus, mau-2 is necessary for C. elegans both in early developmental and 
post-embryonic stages (Takagi et al., 1997). Up to now, no vertebrate phenotypes are 
reported to be associated with defects in vertebrate mau-2 (KIAA0892) proteins. 
However, this may be due to the fact that vertebrate has just recently been recognized 
(Seitan et al., 2006; Watrin et al., 2006) and thus not much is known about it. Or 
according to the phenotypes observed in worm may suggest that the phenotypes in 
vertebrate null mutants of vertebrate Mau-2 may be rescued by the wild-type maternal 
Mau-2 existed on the cytoplasm of the fertilized ovum and the surviving null mutants 
may not reproduce. Heterozygous mutant may not result in any defective phenotypes. 
Nevertheless, to further elucidate the development regulatory role of vertebrate Scc4 
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and Scc2 during different developmental stages even after birth, knock out 
experiments using animal models such as mouse is necessary for our future work. 
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CHAPTER 6: CONCLUSION & FUTURE WORKS 
In 2004, we identified a novel gene, NIPBL, which is found to be mutated in 
around 45% of CdIS patients (Tonkin et al., 2004). Standard point mutational 
screening of the NIPBL exons and sequences flanking the exon-intron boundaries 
revealed a wide variety of pathogenic mutations. More than half of the mutations 
resulted in premature termination. Loss of function causing haploinsufficiency is 
supported by patients with heterozygous deletion involving the whole NIPBL gene. 
No genotype-phenotype correlation was observed. 
Our preliminary data obtained from tissue in situ hybridisation on early human 
embryos by using riboprobes suggest that the expression patterns of NIPBL are 
similar to that of the proliferating marker, PCNA. Thus, it is plausible that defects in 
Human Scc2, NIPBL, will result in aberrant proliferation of the matrix cells and 
differentiation and thus affect the size and function of the developing brain. However, 
most of the cells undergoing stage II or III of cytogenesis may only appear later in the 
fetal or even postnatal stage. To examine the effect of NIPBL on neuronogenesis, glial 
progenitors differentiation and axonal migration, further investigation by using mouse 
or rat at the later developmental stage, such as the fetal and even the postnatal stage, is 
necessary. 
The major role of Scc2 in yeast and Xenopus is to interact with Scc4 to help in 
loading the cohesin ring onto chromatin in the early S phase during cell replication. 
We also identified the sequence of the human Scc4 homologue, which we call human 
Mau-2. The cohesin ring can help to hold the sister chromatids together during cell 
replication. Defects occurring in the cohesion can cause premature sister chromatids 
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separation (PSCS). However, no significant PSCS in CdLS patients' chromosomes 
was observed in our series (personal communication by Tom Strachan). We speculated 
that haploinsufficiency of delangin is not enough to cause PSCS. Thus, it is necessary 
to test if homozygous defects in NIPBL will cause PSCS. 
In Drosophila, Nipped-B was also found to participate in remote activation of the 
cut and Ultrabithorax genes. Reducing the Nipped-B dosage reduces activation of the 
wild-type cut gene by the remote wing margin enhancer and causes the wing margin 
defect in Drosophila. Thus, to test if mouse delangin and Mau-2 help in cohesion 
loading onto the chromatin and participate in the remote control of the mammalian cut 
and ultrabithorax homologues, we need to examine the levels of gene expression in 
NIPBL/hMau-21hSMC11or hSCC1 by siRNA knockdown in selected cell lines and try 
to elucidate the relationship between these genes. Moreover, to overcome the 
possibility of cell death after siRNA knockdown, conditional siRNA knockdown 
technology and phenotypic rescue by cDNA transfection need to be used. 
Furthermore, to examine if the highly conserved sequence within intron 1 
contains a cis-regulatory element, experiments need to be designed to test the 
transactivating ability of this sequence. 
As mutations in NIPBL may lead to the prolongation for each cell cycle and result 
in a decreased cell number during organogenesis, growth deficiency may occur as 
seen in patients with CdIS. Although severe patterning defects (except in limbs) are 
seldom reported to be associated with CdLS, NIPBL mutations seen in patients with 
CdIS are due to hemizygous rather than homozygous defects and thus lead to less 
severe phenotypes. It is possible that homozygous mutation of NIPBL will severely 
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impair cell cycle progression and is non-viable for the developing early human 
embryos. Thus, it is important to establish an animal gene knockout model to 
understand the effect of NIPBL gene product and the impact it has on embryonic 
development. This work is now underway. 
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Appendix A: NIPBL specific primers 
Exon Forward primer Reverse primer Size 
2 AGGTTGAACAAACCAAAGCAG AAAGGGCAGTTTCAGTTGCT 383 
3 GGAAGAGGAGGAATGCCTTT TGAAATAAAACCAGGAATACGG 383 
4 TTGGCCATACCAGTGTGATT GCTTGTTAAAGAAGACACCTGGA 299 
5 AAAATCTCTGGMTGTTrGAAAGAA TCCACCATTACCTAAATGTATGAAC 291 
6 GAGGACTTTGTGACAGTCAGATTT GCCATATCTTFAAAAAGGTTTACTGAC 377 
7 GGCAGAGTGTTAAGATTTGATGA CAAATTTTGAAATGGAAATACTAGG 400 
8 GAAAACAGGAMGTGCAGAAGAA CATGATCCAGACCTGCTTGT 394 
9A GTGAAACCACCACAACTG TGAGCAGCATTTAGTGGGC 429 
9B CAGGACAGACTTCAAAAACACC CCAAATCTCATATAGTTGTTTCAG 512 
1OA TTGCATTTGCATTrTACTCCA GTGTCTCAGGATGGTTTTCTGG 428 
lOB TACGGGAAATGGGGTCAAGGC AGGCTCAACTATGGTGCTCTCG 424 
1OC TGAGAGCAGAACAACTGAATGC TGGCTTTCCAGGAATCCCTCC 352 
1OD AGGTGAGAGCCGCCCTGAAACTC CACGAGGACTGTCAGGTCTTGA 467 
10E TGAATCAGGGGACTCAAGGG AGGGAACTTCTTGATTTGTCCTC 468 
1OF AGGAGCTAAGCCTGTAGTTGTG CTTGAGTAGTGGGTGGGGAAGA 349 
11 ATTGTCACTTTAGGGTTAAGAGTATT AAGGTGACTGTGCTTTTGCT 446 
12 TTCCCCATGTGATTCATTTGT CGATAATCACTGCACATAGAAACT 432 
13-14 AGMCTATGTGCAGTGATTATCG TGATTTCAAGGTAGGACACATCA 485 
15 TGTCCT=CATTCAGGGTTT TCTCAGAAGTCAACAATGAGTTTTC 400 
16 CCTCCATAGCTCAAAGGGAAT TGAGAAAATGGAAAATGAAACAA 279 
17 TCCACCAGTGAAMTCAAATCA GGTGCCATTTTAAGTCCTATTTTG 400 
18 GCTTTATCTTCCAGGTTCTGTAGC GGAAAAATTCTTGATAATATAGTGCTG 388 
19 CCAGTAAGCTTATGAATGTATTGGAA TTGAAATGAATGTACTGAAAACCA 292 
20 CATTTTCATTCTAAATGGCAGGTA AAATCAGACAGAAATGAAGAATAAATG 293 
21 TGGCAAACACAGTATCGTGAA AGCGAGACTCCGTCTCAAAA 357 
22 CCCCTCTTCAGTAATAACATGACAAT GAAACCAAGTGTCAGGAAGATG 299 
23 GCTAACAATTTCAATCATGTTGGT GCACATGCAAAAAGAGATGC 352 
24 TGGGACAATATCACAGGAAAAA TTGAATCCACACAAAATGAAATG 375 
25 CAGTTTTTCCTTCAGATTTGTGTTT TGAAAATCAATATTCCAAACAACTT 300 
26-27 TTTGTATTCCTGTAATGTGAGCA GATTACAGGCGTGAGCCACT 682 
IntFl CACACCTTCTCAGTTrAGCACA GATTACAGGCGTGAGCCACT 400 
IntF2 TTTGTATTCCTGTAATGTGAGCA GGGAAATAGATATCAAGGAGATAAATG 362 
28-29 TTGTTTTCTTTTGCATGTTTTCA TTGTTrAGAAAGTGGCAATAGTTCA 576 
30 GCAGAAAGCATGTAAAAAGCAA CGATTCATTGTAAAGTGTTTGGA 392 
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31 TCCTGGCAGTTTGTGTTTTG GGCAGCAGTACGAMTGTCA 345 
32 TMWrrGAGAAAATTGAAACAT TCCCTACCAAAAGAACTAAAAAGG 283 
33 ACCTTAGGTCTTACACAGCAA TGTGCTCAACTAGGTTATCAAC 362 
34 TTGAGGCCTATACTGGACCTATTT GTGGTTGACGCATGTGAACT 335 
35-26 TATTTCTGCCCCCAMTACG GAGAGGACCACGGTGGATAA 598 
37 TGGTGGCACACGACTGTAATCC TCATCCTGGGTCACTACTGTCAT 467 
38 CACACAAATTCTCATTGTTTTAAGG TGACAAGAATGCAACCCAGT 362 
39 CTAGGTAAGGCCACCAGCAT CCCAGCTATAGACCTCAGCA 472 
40 TGTAACGT MGTGATTTTGGTT AGAAGAGTAAGAGGAACGAAGAACT 400 
41 AGGAAGGCCTATAAGGTTAAATTC AACTTAGTTGCATGTTTAGAAGATAGG 364 
42 GCTAGCCTCAGAATGTAATGCTC TCCCCTTCACTTCTGACTGTG 459 
43 TGAGGTGAAAGTGCCCTGTA CCAAGTCAAGTATTGCCCAGA 398 
44 CAAGCTGTTGAATGGAGCATAC CATGAGCCACCACACCCAGC 434 
45 TGAAGCTGTCCTAGGATCACAA TGCAATGGGAAAGACAAGC 500 
46 CACCCACACCAMCTACTGC CTTGGTGTACAMAATAGACTGACAT 382 
47 GCGTCAAGGGATTAAAAGCA CCTGTAAATTTGGCTGCATGT 488 
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Appendix B 
Carnegie stage Days (approx) Size (mm) Events 
1 1 0.1-0.15 fertilized oocyte, pronuclci 
2 2-3 0.1-0.2 cell division with reduction in 
cytoplasmic volume, formation 
of inner and outer cell mass 
3 4-5 0.1-0.2 loss of zona pellucida, free 
blastocyst 
4 5-6 0.1-0.2 attaching blastocyst 
5 7-12 0.1-0.2 implantation 
6 13-15 0.2 extraembryonic mesoderm, 
primitive streak 
7 15-17 0.4 gastrulation, notochordal 
process 
8 17-19 1.0-15 primitive pit, notochordal canal 
9 19-21 1.5-2.5 Somite Number 1- 3 
neural folds, cardiac 
primordium, head fold 
10 22-23 2.0-35 Somite Number 4 -12 
neural fold fuses 
11 23-26 2.5-45 Somite Number 13 - 20 
rostral neuropore closes 
12 26-30 3.0-5.0 Somite Number 21- 29 
caudal neuropore closes 
13 28-32 4.0-6.0 Somite Number 30 
leg buds, lens placode, 
pharyngeal arches 
14 31-35 5.0-7.0 lens pit, optic cup 
15 35-38 7.0-9.0 lens vesicle, nasal pit, hand plate 
16 37-42 8.0-11 nasal pits moved ventrally, 
auricular hillocks, foot plate 
17 42-44 11-14 finger rays 
18 44-48 13-17 ossification commences 
19 48-51 16-18 straightening of trunk 
20 51-53 18-22 upper limbs longer and bent at 
elbow 
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21 53-54 22-24 hands and feet turned inward 
22 54-56 23-28 eyelids, external ears 
23 56-60 27-31 rounded head, body and limbs 
Following this stage Fetal Development occurs until birth (approx 40 weeks) 
Sources: UNSW Embryology, Version 5.3. -An educational resource for learning 
concepts in embryological development (http: //emblyolojzy. med. unsw. edu. aiI 
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Appendix C 
hMau-2 specific primers 
Exon Forward primer Reverse primer Size 
1 AGC CTATCA GCG ATG CCTAA GCT TTC GTG TCC CTT GAG AG 679 
2 AGT AAG CCT ACC CTC TCA 
GGC 
GGA CAC TCC AGG TGC TCT GTG 312 
3 GCT GTG CTC CTC TTT GTG CT ATT CCA ACT CCC GGA ACC 384 
4 ACT TTT AAT AAA GTA AAT TGG 
CAA CC 
TGT CCC CAC CTA CTC CAT GT 389 
5 GCC AAC TGG AGC TGT GTA CC TGC CAT TTC TGT TAT TTG TCC T 371 
6 GCA GTC TTG TAA GGG GAC 
TGT T 
GCT CTT GCC TCA GCA TGA AT 396 
7 CAC CCT ATG GGA TTC ATG CT GAC CCT GTT CCC AGA TAC CA 539 
8-9 TGG CTG ATT CAT GGG AGT 
GCG 
TCT GAC GTT GGA CAC CAG CAT 670 
10 CAC TGT GGG AAC CAA CCT CT GAT CAG TGG TGC CCA TGC 483 
11 CCT CAT GGT GGA CGT GTC T ATC GTG CCT GGG AAG GTT AT 392 
12 GCT CCC AGT GAG CAT CTT GT GCC CCA TAG CTG TCC CTT AT 472 
13 CCG TAA CGC AGA TGA TGG TT CAT AGC CCG ATT CAC CTC TG 466 
14 CGG CCC TTC TCA CCA GAG GGT TTA CAA AAC GGC AGT GG 385 
15 CTC CCC GTG CTC TTT GGT CGG TTC AGG TCC TCA GCA T 399 
16 TCC AGG GAC GCT ACA ACG 
AGG 
TCA GGG CAT CCA CCT AGA CGT 368 
17 GAT GGG CTC TGA GGT AAG CA TCG CAG CCT CTG TGT CCT AT 493 
18 GAC AGG GCT CAG GTC CAG T CCG GGA CTC TGT TCT CCA T 739 
19 CTC AGG TGA TCC CTT GAT GG CAC CTG TGA GCC TCT GCA C 493 
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NIPBL, encoding a homolog of fungal Scc2-type sister 
chromatid cohesion proteins and fly Nipped-B, is mutated 
in Cornelia de Lange syndrome 
Emma T Tonkin'', Tzu-Jou Wang1'3, Steven Lisgo 1, Michael J Bamshad2 & Tom Strachan I 
Cornelia de Lange syndrome (CdLS) is a multiple 
malformation disorder characterized by dysmorphic facial 
features, mental retardation, growth delay and limb 
reduction defects'-Z. We indentified and characterized a new 
gene, NIPBL, that is mutated in individuals with CdLS and 
determined its structure and the structures of mouse, rat and 
zebrafish homologs. We named its protein product delangin. 
Vertebrate delangins have substantial homology to orthologs 
in flies, worms, plants and fungi, including Scc2-type sister 
chromatid cohesion proteins, and D. melanogaster Nipped- 
B. We propose that perturbed delangin function may 
inappropriately activate DLX genes, thereby contributing to 
the proximodistal limb patterning defects in CdLS. Genome 
analyses typically identify individual delangin or Nipped-B- 
like orthologs in diploid animal and plant genomes. The 
evolution of an ancestral sister chromatid cohesion protein 
to acquire an additional role in developmental gene 
regulation suggests that there are parallels between CdLS 
and Roberts syndrome. 
Figure 1 FISH mapping of a 5p13 translocation breakpoint in an 
individual with classical CdLS. (a) Individual with classical CdLS with 
characteristic limb and facial abnormalities (including an upturned 
triangular nose, long philtrum, thin upper lip, downtumed corners of the 
mouth; see fuller description for individual P46 in Table 1). (b) Giemsa 
chromosome banding showing a balanced de novo t(5; 13)(p13.1; g12.1) 
translocation. (c-e) Metaphase chromosome FISH with the breakpoint- 
spanning BAC clone CTD-2653m23 (c) and overlapping fosmid clones 
G248P8426284 (d) and G248P8840C 10 (e), all labeled with Spectrum 
Red. Labeled in green is a chromosome 5q telomere-specific probe. 
Arrows indicate the normal chromosome 5 and the der(5) 
t(5; 13)(p13.1; q 12.1) and der(13) t(5; 13)(p 13.1; q 12.1) chromosomes. In 
occasional metaphases a weak G248P84262B4 signal can be detected on 
the der(5) chromosome as well as a strong signal on the der(13). The 
combined data suggest that the most likely location for the breakpoint is 
close to the proximal end of the region of overlap for inserts of 
G248P84262B4 and G248P8840C10 (Fig. 2a). 
The multisystem nature of the CdLS phenotype suggests that it is 
caused by a microdeletion or microduplication affecting several genes 
or by a single gene that regulates various target genes. A high-density 
BAC microarray comparative genome hybridization screen found no 
evidence for a consistent pattern of microdeletion or microduplica- 
tion3. Because CdLS is rare and most cases are sporadic, genome-wide 
linkage screens are problematic. As an alternative, we analyzed chro- 
mosomal breakpoints associated with CdLS, focusing first on three 
classical cases with de novo balanced translocations, including the 
previously described translocations t(3; 17)(g26.3; q23.1)4 and 
t(14; 21)(g32; q11)5. We first analyzed the 3q26.3 breakpoint because of 
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Table 1 Phenotypes of selected individuals with CdLS with identified mutations 
Individual Category° Nature of mutation Location of mutationb Inherited or de novo Amino acid change Phenotype 
P2 Classical 1-bp insertion 7306_7307insG, De novo S2462X Growth retardation, 
exon 43 microbrachycephaly, flat facial 
profile, long philtrum, thin lips, 
crescent-shaped mouth, low-set 
ears, synophrys, bushy eyebrows, 
general hirsutism, hearing 
impairment, myopia, micromelia, 
clindactyly, proximally placed 
thumbs, fixed flexion of the elbows, 
syndactyly of the feet, recurrent 
pulmonary infection, hypoplastic 
umbilicus, bilateral inguinal 
hernias, undescended testes 
P3 Classical Missense 7289A-aG, exon 43 De novo Y2430Cc Severe growth retardation, lobster 
limb defect, characteristic face, 
feeding difficulty, gastroesophageal 
reflux 
P11 Classical Splice acceptor 5575-2A-G, De novo Undetermined Growth retardation, characteristic 
AG dinucleotide intron 29 facial features including long 
philtrum, anteverted nostrils, thin 
lips, crescent-shaped mouth, left 
postaxial polydactyly, bilateral 
hearing impairment, heart murmur 
P13 Mild 3-bp deletion 3616-3618 Change absent 11206dell Growth retardation, small hands, 
deIATA, exon 14 in maternal DNA; microcephaly, speech delay, 
no paternal DNA available inguinal hernia 
P16 Classical Missense 40437-, G, exon 17 De novo L1348RC Growth retardation, synophrys, 
long philtrum, thin upper lip, 
speech delay, high arched palate, 
congenital heart defect, short digits, 
feeding difficulty with 
gastroesophageal reflux 
P18 Mild Missense 3931T-*C, exon 17 De novo C1311Rc Small for gestational age, growth 
retardation, microcephaly, mild 
synophrys, neat arched eyebrows, 
depressed nasal bridge, smooth 
philtrum, thin lips, micromelia with 
short first and fifth digits of hands 
P27 Classical Nonsense 7903G-+T, exon46 No parental DNA E2635X Severe growth retardation, 
samples available microcephaly, flat facial 
profile, synophrys, bushy eyelashes, 
short nose, anteverted nostrils, thin 
lips, downturned corners of mouth, 
micrognathia, small hands, 
hypoplastic and overlapping toes, 
bilateral syndactyly of second and 
third toes, delayed speech 
P29 Classical 1-bp insertion 347_348insA, No parental Y116X Severe growth retardation, 
exon 4 DNA samples available microcephaly, micromelia of the 
hands, feeding difficulty, atrioseptal 
defect type II, cryptochidism 
P37 Classical Splice acceptor 7686-2A-G, No parental Undetermined Growth retardation, characteristic 
AG dinucleotide intron 44 DNA samples available facial features including long 
philtrum, anteverted nostrils, thin 
lips, crescent-shaped mouth, 
bilateral upper limb 
reduction defect 
P46 Classical t(5; 13) intron 1 De novo N/A Severe growth retardation, 
(see Fig. 2a) characteristic facial abnormalities 
and bilateral transverse upper limb 
reduction defects (see Fig. I a), 
ventricular septal defect, cleft 
palate. sacral myelomeningocele 
'Classical and mild CdLS are primarily distinguished according to the severity of growth retardation and the extent of developmental delay29,3O. "Nucleotide numbering refers to the cDNA 
sequence specifying the 2,804ami no acid isoform and commencing at the +1 position of the initiation codon. 'Known amino acid conservation data are as follows: Ie1206 is conserved in 
mouse, rat and zebrahsh, changed to methionine in fly and valine in C. elegans; Cys1311 is conserved in mouse, rat, zebrafish, fly and C. elegans; Leu1348 is conserved in mouse, rat and 
zebrafish, changed to isoleucine in fly and C. elegans; Tyr2430 is conserved in mouse, rat, zebrafish and fly, changed to phenylalanine in C. elegans. 
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perceived phenotypic overlap between duplication 3q syndrome and 
mild CdLSI, '. The 3q breakpoint disrupts a large gene undergoing 
unusual alternative splicing, but we found no additional mutations 
specific to any individuals with CdLS3. Molecular analyses of regions 
spanning the 17q23,14q32 and 21g11 breakpoint regions also did not 
identify a gene likely to underlie CdLS (data not shown). 
We localized the breakpoints in a third translocation case to 5p13.1 
and 13g12.1 (Fig. la, b and Table 1). Fluorescent in situ hybridization 
(FISH) mapping identified BACs crossing the 5p breakpoint (Fig. 10 
and the 13q breakpoint. CdLS was recently reported to be associated 
with a 5p13.1-5p14.2 deletion (D. Viskochil, personal communication), 
and so we focused on the 5p breakpoint. We continued FISH mapping 
with fosmids until we identified two clones with overlapping inserts that 
mapped to either side of the 5p13 breakpoint. G248P84262B4 gave a 
clear hybridization signal on the normal chromosome 5 and the 
der( 13), indicating preferential binding to the region telomeric to the 5p 
breakpoint (Fig. Id). In contrast, G248P88840C10 hybridized clearly to 
the der(5) chromosome but was not visible on the der(13) chromosome 
(Fig. le). 
The 5p breakpoint mapped close to a previously predicted gene- 
like sequence of unknown function, called IDN3. Using in silico 
analyses and in-house cDNA sequencing, we determined that IDN3 
was a gene fragment and that it comprises 90 kb of a new 190-kb gene, 
which we named NIPBL (Nipped-B-like; Fig. 2a, b). NIPBL contains 
47 exons and is predicted to generate isoforms of 2,804 or 2,697 
amino acids (Fig. 2c). Northern-blot analysis confirmed the pre- 
dicted 9.8-kb transcript size and showed that NIPBL was strongly 
expressed in fetal and adult kidney, fetal liver, 
adult placenta, heart, skeletal muscle and 
thymus, but weakly or almost undetectably a 
expressed in fetal and adult brain and lung 
and in adult liver, colon, small intestine and 
leukocytes (Supplementary Fig. 1 online). 
We screened other individuals with CdLS 
for mutations in NIPBL and identified nine 
plausible point mutations, at least five of which 
arose de novo (Table 1 and Supplementary Fig. b 
2 online). As we found NIPBL mutations in 
individuals with severe and mild CdLS, pheno- 
type variation can be explained, at least in part, 
by allelic heterogeneity. The spectrum and dis- F 
tribution of mutations imply that pathogenesis 
arises from loss or altered function of a single 
NIPBL allele. Our mutation detection rate was 
-50%6. Locus heterogeneity could be a factor, 
but limitations of the screening methods is a 
plausible explanation for the comparatively 
low mutation detection rate. Considerable Figure 2 Normal exon-inl 
intrafamilial variation in phenotype, even 5p13 breakpoint. (a) Gei 
between siblings with CdLS8, has been organization of NIPBL is 
reported, suggesting that additional factors clones spanning 
and extf 
clones that immediately 
maybe important. shown in blue. (b) Cogna 
Using BLAST and BLAT analyses we cDNAs used to determin, 
determined the full-length sequence of the and overlapping clones tl 
mouse, rat and zebrafish NIPBL homologs sequence defines the sta 
(data not shown). The exon structure is very the short isoform. (c) Prc 
well conserved in vertebrates and specifies a 
to exon 47, generating a 
shorter isoform. The opei protein of -2,800 amino acids. Sequence striped box representing identities between human delangin and ver- fungal Scc2-type protein 
tebrate orthologs are 96% (for mouse and are identical to those of I 
rat) and 63% (for zebrafish; data not the 121-amino acid C-t¬ 
shown). TBLASTN searches against expressed-sequence tag data- 
bases showed that the two C-terminal isoforms are conserved in 
cow, pig, mouse, rat and chick (data not shown). 
We also identified delangin homologs in flies (Drosophila 
melanogaster Nipped-B, Anopheles gambiae X141_320088), worms 
(Caenorhabditis elegans PQN-85, C. briggsae CBG0727), plants 
(Arabidopsis thaliana NM_121558, Oryza sativa NM_I86173) and fungi 
(Scc2 family of sister chromatid cohesion proteins). In each case, 
homology is largely confined to a segment of -1,500 amino acids span- 
ning most of the delangin C-terminal half (Fig. 2c). Discounting small 
polyglutamine- and lysine-rich segments, most of the homologs do not 
share significant homology with any other protein sequence predicted 
from the relevant genome sequence. Because they are expected to be 
essential and most of their sequence shows homology to delangins, they 
may be viewed as orthologs. The pufferfish may be an exception: BLAT 
analyses suggest that there are two related NYKPBL-like gene sequences. 
Many of the fungal homologs have crucial chromosomal roles: 
Saccharomyces cerevisiae Scc2 and Schizosaccharomyces pombe Mis4 in 
sister chromatid cohesion"° and Coprinus cinereus Rad9 in meiotic 
chromosome pairing and DNA repair". Some metazoan orthologs, 
however, are known or likely to be developmental regulators. By facili- 
tating activation of remote enhancers, the D. melanogaster Nipped-B 
protein regulates the Ultrabithorax (Ubx) and Cut homeobox genes'-"1 3. 
RNA-interference knock-down of the gene encoding C. elegans PQN-85 
results in a high level of embryonic lethality; survivors have a paralyzed 
uncoordinated phenotype, body morphology defects and sometimes a 
vulval defect U. Ahringer, personal communication). 
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flank the breakpoint (marked by the vertical arrow; see also fig. td, e) are 
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e the full exon complement, including the original IDN3 A and IDN3 B clones 
hat defined new 5' exons (in red). The 5' end of the IMAGE 5784375 clone 
rt of exon 1. The asterisk denotes alternative 3' end truncation distinguishing 
tein product. The coding sequence commences in exon 2 and continues either 
long isoform, or to an expanded variant of exon 46, generating a slightly 
n bar represents the long (2,804 amino acids) isoform, with the internal 
a region that is highly conserved during evolution and significantly related to 
s. The short isoform contains 2,697 amino acids, of which residues 1-2,683 
the long isoform, leaving a 14-amino acid C-terminal end that is unrelated to 
ýrminal end of the long isoform. 
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Because embryonic expression can differ substantially between 
some human-mouse orthologs14, we carried out NIPBL in situ 
hybridization analyses on human embryonic tissue sections. The 
observed expression pattern was largely consistent with the CdLS 
phenotype (Figs. 3 and 4). NIPBL was expressed in developing limbs 
(Fig. 3a, b) and later in cartilage primordia of the ulna and of various 
hand bones (Fig. 4c). Sites of craniofacial expression included the 
cartilage primordium of the basioccipital and basisphenoid skull 
bones (Figs. 3a and 4f) and elsewhere in the head and face, including 
a region encompassing the mesenchyme adjacent to the cochlear 
canal (Fig. 4e, f). 
NIPBL was also expressed in the spinal column, notochord and sur- 
face ectoderm (Figs. 3a, b and 4b), sclerotome and what seem to be 
migrating myoblasts (Fig. 3b). Expression in the developing heart was 
pronounced in the atrial and ventricular myocardium and in the ven- 
tricular tubeculae but absent in the endocardial cushions (Fig. 3a, b). 
NIPBL was also expressed in the developing esophagus, trachea and 
midgut loops (Fig. 3a), in the bronchi of the lung (Figs. 3b and 4d) 
and in the tubules of the metanephros (Fig. 4a). 
Expression in organs and tissues not typically affected in CdLS (e. g., 
the developing trachea, bronchi, esophagus, heart and kidney) may 
reflect a bias towards underreporting of more subtle aspects of the 
phenotype or problems that typically present later in life. Respiratory 
and feeding difficulties and gastroesophageal reflux are known CdLS 
complications'. 15, individuals with CdLS have a greater incidence of 
congenital heart abnormalities 1.16 and renal abnormalities can be 
found in >50% of classical cases (A. Selicorni, personal communica- 
tion). Expression in the mesenchyme surrounding the cochlear canal 
(Fig. 4e) may be related to the hearing impairment commonly found 
in CdLS'7. Expression of NIPBL in embryonic brain was not evident, 
but the main neurodevelopmental deficits in CdLS are thought to 
occur during late gestation'8"9. 
Figure 4 Detail of NIPBL expression in human embryonic development. 
Expression of NIPBL transcripts in specific structures of the metanephros 
(a), spinal column (b) and lung (d) of a single Carnegie stage 18 embryo, and 
in the hand plate of a Carnegie stage 21 embryo (c). Lower panels illustrate 
head and craniofacial structures in sagittal (e) and transverse (f) sections of a 
Carnegie stage 18 embryo. TU, metanephric tubule; GL, metanephric 
glomerulus; CPN, cartilage primordium of the neural arch; DRG, dorsal root 
ganglia; CU, cartilage primordium of the ulna; CC, cartilage primordium of 
the carpal bones; CM5, cartilage primordium of the metacarpal of the fifth 
digit; CP3, cartilage primordium of the phalangeal of the third digit; BR, 
bronchi of the lung; E, eye; 0V, otic vesicle; 80, cartilage primordium of the 
basioccipital bone; MP, maxillary process; TO, tongue. 
Figure 3 Specific embryonic expression of NIPBL transcripts shown by in 
situ hybridization. Bright-field microscopy images after hybridization to 
embryonic sections of a 424-bp antisense riboprobe corresponding to 
sequences in exons 10-12 of NIPBL. Images represent a midline section 
through a sagittally sectioned Carnegie stage 18 embryo (a) and a transverse 
section of a Carnegie stage 17 embryo W. BP, cartilage primordium of the 
basisphenoid bone; BO, cartilage primordium of the basioccipital bone; NO, 
notochord; ES, esophagus; HT, heart; TR, trachea; LU, lung; ML, midgut 
loop; LL, lower limb; MC, heart myocardium; AVC, A-V cushion; BR, 
bronchus; PPH, precartilage primordium of the humerus; CE, centrum 
(vertebral body); MY, migrating myoblasts. 
The involvement of Nipped-B in activating the Ubx and Cut 
homeobox geneset may provide insights into the molecular basis of 
CdLS pathogenesis. Ubx suppresses limb formation in the fly 
abdomen by repressing Distalless (Del), a gene required for distal 
limb development20. The Dlx family of mammalian DII homologs 
are involved in multiple developmental processes, including limb 
and branchial arch patterning, neurogenesis and hematopoiesis2l. 
They are expressed in the apical ectodermal ridge of the developing 
limb bud, which partly coordinates limb outgrowth, and also in 
facial primordia. Therefore, the proximodistal limb patterning 
defect that underlies limb reduction in CdLS and possibly the associ- 
ated facial abnormalities could largely be explained by inappropriate 
activation of DLX genes. Mutations in fly Cut cause leg and wing 
abnormalities. The mouse homolog Cut12 (Cux2) is dynamically 
expressed in branchial arch and limb bud progress zones22, and so 
reduced expression of a human homolog in CdLS could also con- 
tribute to facial and limb abnormalities. The other mouse homolog, 
Cutll, is widely expressed but important in lung development23. 
A dual role for Nipped-B in sister chromatid cohesion and devel- 
opmental regulation was recently confirmed24. Similar dual roles 
e 
ov 
I 80 
mp --TO 
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can be expected for vertebrate delangins, suggesting a possible par- 
allel between CdLS and Roberts syndrome (OMIM 268300), which 
is characterized by growth retardation, limb reduction defects, 
craniofacial abnormalities and premature centromere separation. 
We assayed C-banded samples from individuals with CdLS for pre- 
mature centromere separation but, perhaps unsurprisingly, 
detected no abnormalities; targeted knock-down of both alleles 
might be more informative. If delangin does have a dual functional 
role, the housekeeping role in facilitating trans interactions between 
sequences on sister chromatids could be satisfied with a basal level 
of expression. An additional role in enabling long-distance cis inter- 
actions (between promoter plus remote enhancer) for select target 
genes could require strong expression in tissues and organs where 
the target genes are active. The Scc2-Nipped-B-delangin family 
provides a model system for investigating evolutionary diversifica- 
tion of protein function. 
METHODS 
Chromosome analyses. We used thymidine to synchronize phytohemagglu- 
tinin-stimulated blood cultures and carried out G-banding according to stan- 
dard protocols25. For premature centromere separation assays, we carried out 
standard C-banding25 on fresh slides of samples from 12 individuals with 
CdLS. We scored 25 cells from each individual sample for premature cen- 
tromere separation. We carried out chromosome FISH analysis by nick transla- 
tion labeling of assorted genomic clones with SpectrumRed (Vysis) according 
to the manufacturer's instructions. Genomic clones included YAC, BAC and 
fosmid clones. We hybridized labeled probes along with a prelabeled chromo- 
some 5p telomere-specific probe (Qbiogene) to metaphase chromosomes using 
standard methodology. 
DNA sequencing and mutation screening. We obtained Image cDNA clones 
from the MRC Geneservice (see URL below). We sequenced all inserts using a 
combination of vector-specific and insert-specific primers and the MegaBACE 
ET system (Amersham). We screened mutations by direct sequencing and, 
when exons were suitably small, by SSCP-heteroduplex analysis using standard 
protocols. In the latter case, we denatured PCR products, size-fractionated 
them in Ix MDE gels (BioWhittaker) containing 5% glycerol and 0.6x TBE 
buffer at 300 V for -20 h (depending on fragment size) and visualized them by 
silver staining. Any samples that had band differences relative to an unaffected 
control were sequenced using the MegaBACE ET system (Amersham). If the 
primary chromatogram suggested the presence of a deletion or insertion, we 
cloned the PCR product and sequenced a number of transformants to confirm 
the change. We reamplified and resequenced all mutations to confirm that the 
change observed was not the result of base misincorporation by the DNA poly- 
merase. We used a panel of genomic DNA samples from 45 individuals of 
European descent (mostly from the UK, some from Poland and Ireland) with 
CdLS. For each mutation, we also screened 200 normal chromosomes. We 
screened parental DNA (when available) to confirm that the observed mutation 
had occurred de novo. 
Because of the very long coding sequence (8,412 nucleotides), our mutation 
screening protocol surveyed a subset (26) of the 46 coding exons, namely exons 
2-8,13-20,23,24,30,34-36,38,40,43,45 and 46. The coding sequence sam- 
pled in these 26 exons corresponds to -31% of the total. This means that 
approximately one-third of the coding sequence was sampled in 45 individuals 
and more than one-half of the proximal intronic sequence was also sampled for 
splicing mutations. On the basis of observed relative frequencies of splice site 
mutations and other mutations in large multiexon genes, and assuming that all 
affected individuals are heterozygotes (as expected from the strong evidence for 
autosomal dominant transmission26) and that there are no strong mutational 
hot spots in the coding sequence, the identification of 9 mutations in a panel of 
45 individuals with CdLS (Table 1) equates roughly to a detection rate >50%. 
The relatively low mutation detection rate could reflect limitations of the muta- 
tion screening protocol: only coding sequences and proximal intronic 
sequences were analyzed, and the gene is large and possibly prone to undetected 
large-scale mutations. 
Gene expression analyses. We designed PCR primers to amplify a 424-bp 
cDNA probe spanning exons 10-12 of NIPBL, which should hybridize to tran- 
scripts encoding both the long and short isoforms (primer sequences are avail- 
able on our website; see URL below). For northern-blot analyses, we labeled the 
probe to high specific activity with [a3-PI-dCTP by random priming. After 
removing unincorporated nucleotides (NICK column, Amersham), we 
hybridized the probe against blots of human adult and fetal RNA (Clontech) 
containing -2 . tg of mRNA per lane at 42 °C overnight in ULTRAhyb 
(Ambion). We washed the blots in 0. lx SSC in 0. ISDS at 65 °C before exposing 
them to film. After removing the test probe, we rehybridized the blots with ran- 
dom-primed labeled control cDNA for human ß-actin. 
For tissue in situ hybridization, we cloned the 424-bp cDNA fragment into 
the pGEM-T Easy vector (Promega) and transcribed it with T7 and SP6 RNA 
polymerases incorporating DIG-I I-UTP to generate labeled sense and anti- 
sense riboprobes, respectively. We generated additional isoform-specific 
probes to correspond to the long isoform of 2,804 amino acids and the short 
isoform of 2,697 amino acids (primer sequences are available on our website; 
see URL below). We hybridized the probes to sections of human embryonic 
tissue as described27. The isoform-specific probes generated similar expression 
patterns as the non-isoform-specific probe. We collected and used human 
embryonic tissue samples with ethical permission from the joint Ethics 
Committee of the Newcastle Health Authority and with appropriate signed 
consents. Samples were staged by microscopic examination. We fixed and 
processed tissue samples as previously described's. We selected the material 
we studied to have normal karyotypes and to be unrelated to disease. 
URLs. Sequences of primers used for expression are available at our Newcastle 
CdLS research website at http: //www. ncl. ac. uk/inglcdls. Servers used for 
nucleotide sequence analysis were the US National Center for Biotechnology 
Information's BLAST server (http: //www. ncbi. nih. gov/BLAST/), the University 
of California at Santa Cruz's BLAT genome search server (http: //genome. ucsc. 
edu/cgi-bin/hgBlat), the Ensembl genome browser (http: //www. ensembl. org/), 
the University of California at Santa Cruz genome browser (http: //genome. ucsc. 
edu/cgi-bin/hgGateway), the NIX suite of nucleotide sequence analysis pro- 
grams (http: //www. hgmp. mrc. ac. uk/Registered/Webapp/nixl) and Baylor 
College of Medicine's sequence utilities programs (http: //searchlauncher. bcm. 
tmc. edu/seq-util/seq-util. html). Servers for protein sequence analysis included 
PSORTII (http: //psort. nibb. ac. jp) and the DomPred program for predicting 
protein domains (http: //bioinf. cs. ucl. ac. uk/dompred/). The Rep program 
(http: //www. embl-heidelberg. de/-andrade/papers/rep/search. html) allowed us to 
identify five HEAT repeats in the conserved C-terminal domain. Alignment of 
multiple orthologous sequences was aided by using the ClustalW program at 
httpl/searchlauncher. bcm. tmc. edu/multi-align/multi -align . html. IMAGE cDNA 
clones were obtained from the MRC Genservice, available at http: //www. 
hgm p. nvc. ac. uk/ genese rvice/i ndex. sh tml. 
GenBank accession numbers. Human NIPBL mRNA encoding the long delan- 
gin isoform, A1627032; homologous mouse mRNA encoding the long delangin 
isoform, AJ627033; human NIPBL mRNA encoding the short delangin iso- 
form, AJ640137; homologous mouse mRNA encoding the short delangin iso- 
form, AJ640138; Image clone 5784375, AJ627564. 
Note: Supplementary information is available on the Nature Genetics website 
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